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Abstract
O steoporosis is a degenerative d isorder characterised b y  a reduction  in  bone strength 
m an ifestin g  its e lf  in  fra g ility  fractures. Current d iagn o sis re lie s on the m easurem ent 
o f  bone m ineral density  ( B M D )  generated b y  dual X - r a y  absorptiom etry ( D X A )  
scanners. Se ro lo g ica l m arkers o f  d isease or b io m arkers, present them selves as a 
u sefu l and p o ten tia lly  in exp ensive  m ethodology o f  assessin g  d isease status. 
Pro teom ic technologies u tilise d  on b io flu id s  have proven them selves as capable o f  
id e n tify in g  candidate b io m arkers o f  disease. T h e  a im  o f  the w o rk  in  this thesis w as 
to u tilise  proteom ic p latform s 2 D  D I G E  and antibody array tech n o lo g y  to id e n tify  
candidate m arkers o f  osteopenia and osteoporosis.
2 D  D I G E  w as u tilised  to analyse  serum  from  36 postm enopausal w om en w ith  a 
decline  in  B M D . P r io r  to a n a lys is , a serum  depletion strategy w as developed 
u tilis in g  the Seppro® Ig Y 1 4  S p in  C o lu m n  w ith  an altered protoco l resu ltin g  serum  
b e in g  produced depleted o f  14 abundant proteins. 16 unique protein  identifications 
resulted from  the 2 D  D I G E  study. L e v e ls  o f  both g lia l f ib r il la r y  a c id ic  protein 
( G F A P )  and vitronectin , were elevated in  postm enopausal w om en w ith  osteopenia 
and osteoporosis com pared w ith  norm al b y  E L I S A  (p < 0 .0 5 ). A n a ly s is  o f  the area 
under the curve ( A U C )  generated b y  rece iver operating characteristic  ( R O C )  curves, 
ascertained that the co m bination  o f  m easurem ent o f  G F A P  and v itronectin  produced 
the optim um  sp e c ific ity  and se n sitiv ity  le ve ls  (0 .825).
A n tib o d y  array a n a lys is  o f  w h o le  serum  taken from  101 postm enopausal w om en 
identified  156 s ig n if ic a n tly  d iffe re n tia lly  expressed proteins (p < 0 .0 0 0 1 ). L e v e ls  o f  
D ic k k o p f-1  ( D k k l )  w ere s ig n if ic a n tly  in v e rse ly  correlated w ith  B M D  param eters 
(p < 0 .0 5 ) and W n t in h ib ito ry  factor 1 ( W I F I )  w as elevated in  the osteoporosis group 
com pared w ith  both norm al and osteopenia (p < 0 .0 5 ). D k k l  and W I F I  com bined 
produced the best A U C  va lu e s fo r id e n tify in g  in d iv id u a ls  w ith  osteopenia from  
those w ith  osteoporosis (0 .736).
M e asu rin g  c ircu latin g  le ve ls  o f  D k k l ,  W I F I ,  G F A P  and v itro n ectin  both alone and 
in  com bination, is a p ro m is in g  m ethodology fo r assessing B M D .
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Chapter 1 Introduction
T h e  w ord osteoporosis is  derived  from  the G re ek language; ‘osteo’ m eaning bone, and 
‘poros’ m eaning porous. T h is  ve ry  descriptive  term in o lo gy  g iv e s  one an instant 
im pression  o f  the d isorder and a llo w s one to envisage  its im p licatio n s. A  healthy 
skeletal system  is essential to o vera ll good health and w e ll b e ing. T h e  deterioration o f  
one’s bones due to a reduction in  bone m ineral density ( B M D )  has a s ign ifica n t im pact 
on one’s q u a lity  o f  life  and indeed, m o rb id ity  and m ortality. H o w e ver, bones and the 
skeletal system  are an often overlo oked  aspect o f  health, until a fracture occurs. 
O steoporotic fractures are com m on, co stly  and represent a s ig n if ic a n t burden on 
in d iv id u a ls  and society.
T h e  term ‘osteoporosis’ w as co ined b y  the Fren ch  patho logist Jean  G eorges Chrétien  
Fréd éric  M artin  Lo b ste in  ‘the Y o u n g e r ’ (177 7-18 35). M u c h  has been learned since 
about the disorder, its pathogenesis, ep id em io lo gy, and treatment, p a rticu la rly  in  the 
last few  decades. H o w e ver, the current population  w orld w id e  is  set to age over the 
co m in g  years p o sin g  m an y ch allenges fo r society. O steoporosis is  a ch ro n ic disease 
that d isproportionately affects the e lderly, and as such, its prevalence is  projected to 
increase m arkedly. I f  these predictions m anifest, osteoporosis and osteoporotic 
fractures w il l  have a substantial negative im pact on  society. C o nsequently, there is a 
pressing need to p rio ritise  the d iagn o sis and m anagem ent o f  the d isorder in  order to 
attenuate its effects. A  W o rld  H ealth  O rgan isatio n  (W H O ) T e c h n ic a l Series Report on 
the prevention and m anagem ent o f  osteoporosis in  2003 h ig h ligh te d  the need for 
inexpensive  d iagnostics fo r osteoporosis (W o o lf  and P fleg er, 2003). B io m a rk e rs offer 
the potential for in exp ensive  assessm ent o f  disease, m o n ito rin g  o f  progression, and 
treatment evaluation in  a num ber o f  disorders.
1.1 Osteoporosis
O steoporosis is  a reduction in  bone strength w h ich  increases the lik e lih o o d  o f  fracture. 
S p e c if ic a lly , the N atio n a l Institutes o f  H ealth  ( N IH )  defines it as ‘a skeletal d isorder 
characterized b y  co m pro m ised  bone strength p red isp o sin g  an in d iv id u a l to an 
increased r is k  o f  fracture. B o n e  strength p r im a rily  reflects the integration o f  bone 
density and bone q u a lity ’ (N a tio n a l Institute o f  H ealth  C o nsen su s D eve lo pm ent Panel
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on O steoporosis Prevention, 2001). A  fra g ility  fracture, the c lin ic a l m anifestation o f  
osteoporosis, is  one that occurs as a result o f  low  or no trauma. C o m m o n  fra g ility  
fractures are those o f  the distal forearm  (C o lle s ’), vertebrae, or p ro x im a l fem ur (hip). 
O ther fra g ility  fractures include those o f  the p ro x im a l hum erus, p e lv is , ribs and tib ia  
(A v io l i ,  1983). A  num ber o f  types o f  osteoporosis have been described:
• Postm enopausal osteoporosis
T h is  is a form  o f  p rim ary  osteoporosis, that is , osteoporosis that cannot be attributed to 
one sp e c ific  cause, and the m ost com m on form  o f  the disorder. T h e  reduction in  the 
le ve l o f  c ircu la tin g  oestrogen experienced b y  w om en after m enopause results in a 
dram atic rise  in  bone turnover, that is , the rate o f  bone resorption and bone form ation. 
T h e  end result is a tip p in g o f  the balance o f  bone turnover in  the direction o f  bone 
resorption, w ith  an o vera ll reduction in  the amount o f  bone present. Osteoporosis is 
three tim es m ore com m on in  w om en than in men, p artly  because w om en have a low er 
peak bone m ass and p artly  because o f  the reduction in  the level o f  oestrogen in  w om en 
after m enopause (N ew to n -Jo h n  and M organ, 1970). Oestrogen has an im portant role 
in  p re serv in g  bone density in  adulthood, so bone loss w il l  o ccur as oestrogen levels 
d eclin e  w ith  ageing. Further, w om en live  longer than m en and w il l  therefore have 
greater reductions in  bone density; increasin g  life  expectancy in  m an y parts o f  the 
w o rld  m eans that m any w om en liv e  m ore than one-third o f  their liv e s  after menopause 
(U N , 2004).
A s  the focus o f  this thesis is  w ith  postm enopausal osteoporosis, other form s o f  the 
d isorder are b r ie fly  sum m arised here:
• O steoporosis in  m en
O steoporosis is less com m on in men than it is  in w om en and is less w e ll studied as is 
evident from  the bone densiom etric defin ition  o f  osteoporosis in  m en being less w ell 
characterised than in w om en (G ennari and B ile z ik ia n , 2007). A s  in w om en, the r isk  o f  
h ip  fracture in men increases dram atica lly  w ith age, how ever, the increase begins
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approxim ate ly  10 years later (Farm er et al., 1984). T h e  W H O  recom m ends u s in g  the 
same B M D  criteria  to categorise osteoporosis in  m en as in  w om en (K a n is  et al., 2008).
• Secondary osteoporosis
O steoporosis for w h ich  a sp e c ific  cause can be identified  is  referred to as secondary 
osteoporosis. T h is  form  o f  osteoporosis occurs in  both m en and w om en and can o ccur 
at a re la tive ly  yo u n g  age. C au ses o f  secondary osteoporosis inc lu d e  an orexia  nervosa, 
g lu co co rtico id  therapies, k id n e y  fa ilure , m alabsorption  syndrom es, an tico nvu lsive  
therapies, h yp erca lc iu ria , and hypo go n ad ism  (A a ro n  et al., 1989; K lib a n s k i, 2001; 
B o lin g , 2004; La n e  et al., 2006).
1.2 Bone
1 . 2 . 1  S t r u c t u r e  o f  B o n e
Bone is a co m p lex tissue co m p ris in g  o f  a protein based m atrix , predom inantly type I  
co llagen  but also co nta in in g  osteocalcin , osteonectin and phosphoproteins, w h ich  has 
been m ineralised, m a in ly  w ith  hydroxyapatite  C a io (P 0 4 )6 (O H )2  (A erssen s et a l. ,
1994). T h is  confers upon bone the opposing qualities o f  b e in g  r ig id  w h ilst  h a v in g  
some degree o f  e lasticity. There  are two types o f  bone; co rtica l and cancellous. 
C a n ce llo u s bone has a re lative  density o f  < 0 .7g/cm 2 and co rtica l bone has a relative 
density  o f  > 0 .7g/cm 2 (G ib so n  and A sh b y , 1997) (F ig u re  1.1).
C o rtica l bone com prises 8 0 %  o f  bone in  the hum an skeleton, and is  found in  the shafts 
o f  lo n g bones such as the fem ur, and in  a thin  layer co ve rin g  other bones such  as short 
bones, e.g. at the w rist, flat bones, e.g. ca lv a ria l bones, and irre gu lar bones e.g. 
vertebrae and p e lv ic  bones. M ature co rtica l bone is lam ellar, or layered in  its 
structure. It is  permeated b y  interconnecting canals fa c ilita tin g  vascu larisatio n ; the 
H aversian  system s. C o rtic a l bone is arranged in  concentric lam ellae  around these 
system s, thus fo rm in g structural units ca lled  osteons. C o rtica l bone is denser than 
cancellous bone w ith  a p o ro sity  o f  5 -1 0 % . Im m ature co rtica l bone, found p rim a rily  in 
d eve lo p in g foetuses and seco n d ly fo llo w in g  fracture, is referred to as w oven bone as it
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is  irregu lar in  structure and does not contain osteons. It  is  even tu a lly  replaced b y  
m ature co rtica l bone.
C a n ce llo u s bone com prises 2 0 %  o f  bone in  the hum an skeleton, and is  found 
sandw iched between co rtica l bone layers such as the interio r o f  vertebrae and in  the 
fem oral head. Its structure resem bles that o f  a honeycom b in  that it  is  made up o f  a 
netw ork o f  struts or trabeculae and thus has a greater surface area than cortical bone. 
C a n ce llo u s bone is  m ore porous than cortical, ran g in g  from  5 0 -9 0 %  porosity  (F ig u re  
1.2).
Figure 1.1: Section of the proximal femur in the frontal section.
(D o w n e y  and S ie g e l, 20 06)
B o n e  section o f  the p ro x im a l fem ur in  the frontal plane illu stratin g  co rtica l and 
can ce llo u s bone. D o u b le  arrow s indicate arch in g  pattern o f  trabeculae.
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Figure 1.2: The structure of bone.
(T a y lo r  et al., 2007)
Schem atic o f  bone co n sistin g  o f  the b asic  functional unit o f  co rtica l bone co ntain ing 
H a ve rsia n  system s (osteons): a H a ve rsia n  canal w ith  lam ellae  and osteocytes 
surrounding it. C a n ce llo u s bone is also depicted. B la c k  and w hite m icro sco p e  im age 
inset (sca le  bar in  pm ) show s osteocytes (w hite  dots) lin k e d  b y  processes (fin e  w hite 
lin es) fo rm in g  the syncytium .
1 . 2 . 2  B o n e  c e l l s
There are four ce ll types found in  bone: osteoblasts, osteocytes and bone lin in g  ce lls  
w h ich  are m esenchym al in  their lineage and osteoclasts w h ich  are hem atopoietic 
(F ig u re  1.3 and F ig u re  1.4). In  addition, due to the close anatom ical lo ca lisa tio n  o f  
bone w ith  bone m arrow , im m une ce lls  p la y  a role in  bone dyn am ics. T h is  ro le  has 
been o verlo oked  to som e degree until recently  w ith  the em ergence o f  new  reports
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h ig h lig h tin g , for exam ple, the role o f  B -  and T -  ce lls  in  bone form ation ( L i  et a i,  
20 0 7 ), and the identification  o f  osteom acs; m onocytes that reside in  the periosteum , 
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Figure 1.3: Bone ceil types and their lineage.
(R o sen , 2008)
IG F :  In su lin - lik e  grow th factor, M - C S F :  M acrophage co lo n y-stim ulatin g  factor, I L :  
In terleukin , O P G : O steoprotegerin, R A N K :  R ecepto r activator o f  nuclear factor k -B , 
R A N K L :  R eceptor activator o f  nuclear factor k -B  ligand, D lx 5 : D ista l-le ss  hom eobox 
5, M s x l :  M sh  hom eobox 1, C / E P B : C C A A T /e n h a n c e r  core b in d in g  protein, p P A R y : 
Pero xiso m e proliferator-activated  receptor y, R u n x 2 : R u n t related transcription factor 
2, O blast: O steoblast.
B o n e  re m o d ellin g  requires recruitm ent o f  osteoblasts and osteoclasts in  a fin e ly  
orchestrated m anner. IG F -1  is im portant in  the d ifferentiative function o f  the 
osteoblast as w e ll as b e in g  synthesized b y  these ce lls. IG F -1  is also im portant in  
osteoclastogenesis and m ay be a critica l factor in  early  adipogenesis. T h e  stem ce ll 
stage is  depicted in  the left co lum n, the pre-osteoclast, -osteoblast, and -a d ip o cy te  
stage in  the m iddle  co lum n, and the differentiated ce ll in the right colum n.
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Figure 1.4: Histological section of bone showing osteoblasts, osteoclasts and osteocytcs.
www.cvtochemistrv.net
Sectio n  o f  bone dem ineralised and stained w ith  H e m o to xin  and E o s in  sh o w in g  a 
region  u n dergo ing resorption o f  o ld  bone b y  an osteoclast and form ation o f  new  bone 
b y  osteoblasts. A d d it io n a lly , a num ber o f  osteocytes are show n.
1 . 2 . 2 . 1  O s t e o b l a s t s
Osteoblasts are the bone fo rm in g ce lls , secreting a co llagen  based m a trix  w h ich  is  then 
m ineralised  w ith  hydroxyapatite. O steoblasts arise w hen m esenchym al stem  ce lls  
express the transcription factor R u n x 2  responsib le  for osteogenesis, fo rm in g  
osteoprogenitor ce lls  or pre-osteoblasts (C o h en , 20 06). O steoblasts are found 
adjacent to new  bone surfaces at areas o f  active  bone m atrix  synthesis. B o n e  
form ation occurs in  response to the rem oval o f  bone. O n  com pletion  o f  bone 
form ation, m ost osteoblasts undergo apoptosis; approxim ate ly  10 %  becom e either 
osteocytes or bone lin in g  ce lls. O steoblasts produce a u n id irectio n al e p ith e lia l-lik e  
structure at the surface o f  the o rgan ic m atrix ; osteoid com prised  m a in ly  o f  T y p e  I  
co llagen; osteoid then becom es m ineralised . M in era lisatio n  occurs w hen ca lc iu m  and 
phosphate ions are transported from  the e xtrace llu lar space o f  the bone m arrow  to the 
osteoid layer b y  transport system s in  the p lasm a m em brane o f  osteoblasts.
1 . 2 . 2 . 2  O s t e o c y t e s
T h e  m ost abundant ce ll type in  bone is the osteocyte, a p ost-pro liferative  ce ll, m a k in g  
up - 9 0 %  o f  the total ce lls  in  bone (M arotti et al., 1985). O steocytes are form ed w hen
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osteoblasts becom e embedded in  the bone m atrix. E a ch  osteocyte has 60-90 processes 
extending outwards from  it a llo w in g  com m unication  w ith  other osteocytes in  a 
m ineralised  m atrix. C e ll processes are contained w ith in  can a licu li. O steocytes are 
m echanosensitive, that is , they are responsive to m echan ica l forces, thus gu id in g  the 
m odulation  o f  bone (A ard en  et al., 1994). Further, an osteocyte’s a b ility  to resorb 
bone surrounding it enables its role in  ca lc iu m  hom eostasis (S h im iz u  et al., 1990; 
T a lm a ge  and T a lm age , 2007).
1 . 2 . 2 . 3  B o n e  l i n i n g  c e l l s
B o n e  lin in g  ce lls  are located at the border between bone and the periosteum , w h ich  is 
a m em brane co ve rin g  the outer surface o f  bones, and are form ed from  osteoblasts 
(M ille r  et al., 1989). B o n e  lin in g  ce lls  have an im portant role in  bone rem odelling in  
p ro v id in g  a l in k  between bone resorption and the form ation o f  new  bone; bone lin in g  
ce lls  are required to retract for resorption to com m ence (Za m b o n in  Z a llo n e  et al., 
1984). Further, w hen osteoclasts w ithdraw  from a resorption pit, bone lin in g  ce lls  
enter this p it and rem ove any rem ain ing bone m atrix  w h ich  is necessary before new 
bone can be form ed b y  osteoblasts (Eve rts et al., 2002).
1 . 2 . 2 . 4  O s t e o c l a s t s
O steoclasts are m ultinucleate ce lls  form ed b y  the m erging o f  a num ber o f  
m ononucleate osteoclast precursors. O steoclasts are responsible for bone resorption. 
T h e y  differentiate from  a m ononuclear p h ago cytic  precursor ce ll com m on w ith  
m acrophages. D ifferen tiatio n  from  haem atopoietic stem ce lls  to a com m on precursor 
ce ll is  induced b y  Interleukin  1 ( IL - 1 ) ,  granulocyte  m acrophage co lo n y-stim ulatin g  
factor ( G M - C S F )  and granulocyte co lo n y-stim u latin g  factor ( G - C S F )  (A ka tsu  et al., 
1991). O steoclast precursor ce lls  are form ed b y  stim ulation from  IL - 1 ,  IL -6 ,  tum our 
necrosis factor a  (T N F a ) ,  and epithelial grow th factor ( E G F )  (Su d a  et al., 1992). 
M ature osteoclasts form  b y  the fusion  o f  a num ber o f  osteoclast precursors, occurring 
in  the presence o f  prostaglandins (Q u in n  et al., 1997). O steoclast activation  occurs on 
b in d in g  o f  osteoblast m em brane-bound receptor activator for nuclear factor k  B  ligand  
( R A N K L )  to receptor activator for nuclear factor k  B  ( R A N K )  on the surface o f  
osteoclasts (L a c e y  et al., 1998). O steoprotegerin (O P G )  is a so luble m em ber o f  the
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T N F  receptor su p erfam ily  that is produced b y  osteoblast lineage  ce lls  and acts as a 
decoy receptor in h ib it in g  the form ation o f  m ature osteoclasts (Su d a  et al., 1999). T h e  
b in d in g  o f  R A N K L  to its cognate receptor R A N K  activates the transcription  factor 
co m p lex activator protein 1 ( A P I )  through the ind uction  o f  its com ponent c -F o s  
(W agn er and E fe r l, 2005). R A N K L  induces n u clea r factor o f  activated T  ce lls  
cyto p lasm ic 1 ( N F A T c l ) ,  w h ich  is the m aster regu lator o f  osteoclast d ifferentiation, 
this induction  b e in g  dependent on both T N F  receptor-associated factor 6 ( T R A F 6 )  and 
c -F o s  pathw ays (T a k a y a n a g i et al., 2002). N F A T c l  regulates a num ber o f  osteoclast- 
sp e c ific  genes, such as cathepsin  K ,  tartrate-resistant a c id  phosphatase ( T R A P ) ,  
ca lc ito n in  receptor, osteoclast associated receptor ( O S C A R )  and a vp3 integrin , in  
tandem w ith  other transcription  factors su ch  as A P I ,  P U . l ,  m icrophthalm ia-associated  
transcription factor ( M IT F )  and c A M P  response elem ent b in d in g  protein ( C R E B )  
(F ig u re  1.5) (T a k a y a n a g i, 2007).
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Figure 1.5: Osteoclastogenic signal transduction.
(T a k a y a n a g i, 20 10)
R A N K  activates the nu clear factor k -B  ( N F - k B )  and F B J  m urine osteosarcom a v ira l 
oncogene h o m o lo g (c -F o s) pathw ays that stim ulate the induction  o f  N F A T c l . 
Im m u n o g lo b u lin -lik e  receptors associate w ith  im m unoreceptor tyrosine-based 
activ iatio n  m o t if  ( IT A M )-h a rb o r in g  adaptors, F c  receptor com m on y  subunit (F c R y ) , 
and D N  A X -a c t iv a t in g  protein 12 ( D A P  12). R A N K  and IT A M  s ig n a llin g  cooperate to 
phosphorylate phospholipase C  y  ( P L C y )  and activate ca lc iu m  s ig n a llin g , cr it ica l for 
the activation  and auto am plification  o f  N F A T c l .  T e c  tyrosine kin ases (T e c  and B tk )  
activated b y  R A N K  are im portant fo r the form ation o f  the osteoclastogenic s ig n a llin g  
co m p lex com posed o f  T e c  kinases, B -c e ll  lin ke r ( B L N K ) / S H 2  dom ain  containing 
leu ko cyte  protein o f  76 k D a  (S L P -7 6 )  (activated b y  IT A M -S p le e n  tyrokine  kinase 
(S y k ) ) , and P L C y ,  w h ich  are essential fo r the e ffic ient phosphorylation  o f  P L C y .
1 . 2 . 3  B o n e  r e m o d e l l i n g
B o n e  is  a d yn am ic tissue in  that it  is  co nstantly undergoing renew al throughout a 
person’s life . B o ne  rem o d ellin g is  the process o f  rem o vin g  dam aged bone b y  
resorption fo llo w e d  b y  the form ation o f  new  bone to replace that w h ich  w as rem oved.
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O f  the total am ount o f  re m o d ellin g  that occurs in  bone, 8 0 %  o ccu rs in  cancellous bone 
and 2 0 %  in  co rtica l bone (F ilv a r o f f  and D e ry n ck , 1998). A  num ber o f  factors have an 
influence on bone hom eostasis and determ ine w hether bone undergoes form ation or 
resorption. P h a rm a co lo g ica l interventions can induce bone form ation  e.g. parathyroid  
horm one (P T H ) ,  or inh ib it bone resorption e.g. b isphosphonate drugs. L ik e w ise , 
p h ysio lo g ica l entities can exert in flu en ce  over bone hom eostasis w ith  im m o b iliza tio n  
h a v in g  the effect o f  both in h ib it in g  bone form ation and p rom oting bone resorption. 
Further p h y sio lo g ica l in fluences inc lu d e  age ing, m echan ica l lo a d in g  and oestrogen 
d efic ien cy  (F ig u re  1.6), (Fro st, 2001).
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Figure 1.6: Determinants of skeletal homeostasis and bone mass.
(H arada and Rodan, 2003)
B M P : B o n e  m orphogenetic protein, S O S T :  Sc lero stin , L R P 5 :  Lo w -d e n s ity  lipoprotein  
(LD L)-re ce p to r-re la te d  protein 5, P T H :  Parathyro id  horm one, S E R M : Se le ctive  
oestrogen-receptor m odulator.
Schem atic o f  the system  that m aintains bone m ass at a steady-state levels. 
P h y s io lo g ica l (b la ck ) and p h arm aco lo gica l (p in k ) stim ulators and inh ib itors o f  bone 
form ation and resorption are listed. T h e  re lative  im pact, w here know n is represented 
b y  the th ickness o f  the arrow s. S o lid  lines are current therapies and dotted lines are 
putative one.
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B o ne  rem o d ellin g is carried  out in sm all groups o f  ce ils  called  a b asic  m u ltice llu lar 
unit (B M U ). T h e  B M U  is covered by a canopy o f  ce lls , the phenotype o f  w h ich  is 
under debate, but m ay be osteom acs, creating a bone rem odelling compartment 
(H a u g e  et al., 2001). T h e  process is t igh tly  regulated fo llo w in g  a progressive series o f  
steps; activation, resorption, reversal, form ation and term ination (F ig u re  1.7) (Raggatt 
and Partridge, 2010).
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Figure 1.7: The remodelling cycle on a trabecula.
(R a g g a tt and Partridge, 20 10)
C S F -1 :  C o lo n y  stim ulating factor-1, M C P -1 : M o no cyte  chem oattractant protein 1.
Schem atic representation o f  a B M U  and the associated bo n e-rem o d e llin g  process. 
P rio r to activation, the resting bone surface is covered w ith  b o n e -lin in g  ce lls , 
in c lu d in g  preosteoblasts intercalated w ith  osteom acs. B -c e lls  are present in  the bone 
m arrow  and secrete O P G , w h ich  suppresses osteoclastogenesis. A ctiva tio n ; the 
endocrine b one-rem odelling s ig n a l P T H  b in d s to the P T H  receptor on preosteoblasts. 
D am age to the m in e ra lize d  bone m atrix  results in  lo ca lize d  osteocyte apoptosis, 
reducing the lo ca l T G F p  concentration and its in h ib itio n  o f  osteoclastogenesis. 
Resorption; in  response to P T H  s ig n a llin g , M C P -1  is released from  osteoblasts and 
recruits preosteoclasts to the bone surface. A d d it io n a lly , osteoblast expression  o f  O P G  
is decreased, and production  o f  C S F -1  and R A N K L  is  increased to prom ote 
pro liferation  o f  osteoclast precursors and d ifferentiation  o f  m ature osteoclasts. M ature 
osteoclasts anchor to R G D -b in d in g  sites, creating a lo ca lize d  m icroenvironm ent 
(sealed zone) that facilitates degradation o f  the m in e ra lize d  bone m atrix. R eversa l; 
reversal ce lls  e n g u lf and rem ove dem ineralised undigested co llage n  from  the bone 
surface. Tran sitio n  s ign a ls are generated that halt bone resorption and stim ulate the 
bone form ation process. Form ation; form ation s ig n a ls  and m o lecu les arise from  the 
degraded bone m atrix, mature osteoclasts, and poten tia lly  reversal ce lls . P T H  and 
m echan ica l activation  o f  osteocytes reduce sclerostin  expression, a llo w in g  for 
w in g le ss-typ e  M M T V  integration site fa m ily  (W nt)-d irected  bone form ation to occur. 
Term ination ; sclerostin  expression  l ik e ly  returns, and bone form ation ceases. The  
n ew ly  deposited osteoid is m in era lized , the bone surfaces return to a resting state w ith  
b o n e-lin in g  ce lls  intercalated w ith  osteom acs, and the re m o d ellin g  cy c le  concludes.
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*  A c t iv a t io n
A c tiv a tio n  o f  bone rem o d ellin g can occur as a result o f  a num ber o f  stim uli; 
m echan ica l lo ad in g on bone or horm onal changes. M ech an ica l strain due to d a ily  
activ itie s is  sensed b y  osteocytes w h ich  then initiate bone re m o d ellin g  (B o n ew ald , 
2007; T a y lo r  et a l., 2007). D am age  to the bone m atrix  or lo n g periods o f  
im m o b ilisa tio n  result in  osteocyte apoptosis and increased osteoclastogenesis 
(V e rb o rgt et al., 2002; A g u irre  et al., 2006). O steocytes secrete transform ing grow th 
factor p (T G F P )  w h ich  inh ib its osteoclastogenesis; w hen osteocytes undergo 
apoptosis, the leve ls o f  lo ca l T G F p  fa ll, a llo w in g  osteoclast form ation to proceed (de 
G orter et al., 2010). P T H  is a horm one in vo lve d  in  ca lc iu m  hom eostasis. Secreted in  
response to reduced serum  ca lc iu m  levels, P T H  b inds to its receptor, P T H R , on the 
surface o f  osteoblasts. B in d in g  activates protein k inase  A ,  protein kinase  C  and 
ca lc iu m  intracellu lar s ig n a llin g  pathw ays in  these ce lls , resu lting in  the secretion o f  
osteoclast precursor recruitm ent m olecules, in d u cin g  mature osteoclast form ation and 
thus in itia tin g  bone resorption (Juppner et al., 1991; Sw arthout et al., 2002).
• R esorption
O steoclast precursors are recruited to the rem o d ellin g site; osteoblasts produce the 
chemoattractant chem okine m onocyte chemoattractant protein 1 (M C P 1 )  in response 
to P T H  sign a llin g , M C P 1  enhances R A N K L  induced osteoclastogenesis ( L i  et al.,
2007). Further, ostoblasts express osteoclastogenic regulatory cytokines co lo n y 
stim ulato ry factor 1 ( C S F -1 ) ,  R A N K L  and O P G . T h e  expression  o f  O P G  is reduced, 
and C S F -1  and R A N K L  expression  are increased resu lting in  the form ation o f  mature 
osteoclasts and osteoclast a ctiv ity  (M a et al., 2001). M a trix  m etalloproteinases 
(M M P s), in c lu d in g  M M P -1 3 , are secreted b y  osteoblasts in  response to m echanical 
and endocrine rem odelling sign a ls (Partridge et al., 1987; Y a n g  et al., 2004). M M P s 
are responsib le  for rem oving unm ineralised osteoid lin in g  the bone surface exposing 
R G D  (A rg in in e -G ly c in e -A sp a rta te ) adhesion sites w ith in  m ineralised  bone necessary 
fo r osteoclast attachment ach ieved v ia  a vp3 integrins creating a sealed zone. H ydro gen  
ions are pum ped into the sealed zone resu lting in  the breakdow n o f  the m ineralised 
m atrix , producing H o w sh ip ’ s resorption lacunae (M cH u g h  et a l,  2000; Teite lbaum ,
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2000). R e m a in in g  organ ic  m atrix  is  degraded b y  co llagenases such  as cathepsin K  
(S a ft ig  et ah, 1998).
• R e versa l
F o llo w in g  osteoclast m ediated resorption, the reso iption  p it rem ains covered w ith  a 
p a rtia lly  m ineralised  co llagen  m atrix  (S a ft ig  et al., 1998). A  m ononuclear ce ll, the 
precise lineage o f  w h ich  is under debate, rem oves this re m ain ing  co llage n  preparing 
the surface for osteoblast m ediated bone form ation. It is  l ik e ly  that osteom acs and 
bone lin in g  ce lls  cooperate fa c ilita tin g  the reversal phase. T h e  fin a l event o f  the 
reversal phase is the receipt or production, to or from  the reversal ce lls  o f  co u p lin g  
sign a ls that a llo w  the transition  o f  bone resorption to bone form ation  in  the B M U  
(Eve rts et a l., 2002; T a ka h a sh i et al., 2004; N ew b y, 2008).
• Form ation
A  num ber o f  co u p lin g  m echan ism s have been proposed, the m ost p ro m isin g  b eing 
that o f  the ephB 4*ephrin -B 2 b id ire ctio n a l s ig n a llin g  co m plex. E p h B 4  receptors are 
expressed on the surface o f  osteoblasts; osteoclasts express the lig a n d  eph rin -B 2 . 
Forw ard  s ig n a llin g  through E p h B 4  into osteoblasts stim ulates osteogenesis, whereas 
reverse s ig n a llin g  through e p h rin -B 2  stim ulates osteoclastogenesis (Z h a o  et al., 2006). 
H ow ever, as the B M U  is re la tive ly  sm a ll and bone form ation continues after 
osteoclasts have left, other m echanism s other than co u p lin g  s ig n a llin g  m ust be in  p lay  
in  order fo r bone form ation to proceed. M e ch an ica l stim ulation  and P T H  can stim ulate 
bone form ation v ia  osteocytes. W h ils t  resting, osteocytes secrete sclerostin , w h ich  
binds low  density lipoprotein  receptor related protein 5/6 (L R P 5 / 6 )  preventing w nt 
s ig n a llin g , an inducer o f  bone form ation ( L i  et al., 2005). O n ce  m esenchym al stem 
ce lls  or osteoblast progenitor ce lls  return to the reso ip tio n  lacunae they differentiate 
into mature osteoblasts and secrete proteins, m a in ly  type I co llagen , fo rm in g osteoid. 
O steoid  then becom es m ineralised  in  order to form  mature bone. T h e  exact 
m echanism  o f  the in c lu s io n  o f  hydroxyapatite  into osteoid is  cu rrently  unknow n; 
how ever, tissue n o n sp e cific  a lka lin e  phosphatase, nucleotide pyrophosphatase 
phosphodiesterase and p rogressive  a n k y lo s is  ( A N K )  are in v o lv e d  in  generating the
1 6
optim um  extrace llu lar concentration o f  ino rgan ic  phosphate a llo w in g  m ineralisation  to 
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Figure 1.8: Signalling pathways involved in bone formation.
A .  In d ian  hedgehog (Ih h ) pathw ay B . B M P  pathw ay C . C a n o n ica l wnt-|3-catenin D . 
M itogen-activated protein kinase  ( M A P K )  pathw ay (D esch aseau x et al., 2009).
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(A )  Patched (P tch ) is an Ih h  receptor that in h ib its the receptor sm oothened (S m o ).
T h is  suppressive  a ctiv ity  leads to degradation o f  the G l i  activator and repressor ( G l iA  
and G l iR  resp ective ly) through p h osphorylation  b y  g lyco ge n  synthase k in ase  
P (G S K 3 P ) , protein k inase  A  (P IC A ) and case in  k inase  ( C S K ) .  Sm o  activatio n  inh ib its 
degradation o f  both G l iA  and G liR .  G l iR  is thus inactivated, w hereas G l iA  transloctes 
into the nucleus for in d u c in g  transcription  o f  target genes. ( B )  B M P s  in itiate s ig n a llin g  
from  the ce ll surface b y  b in d in g  tw o different types o f  receptors ( I  and I I )  that can 
activate the Sm ad  cyto p lasm ic proteins. T h e  heterodim eric form ation  o f  type I R  and 
type I I  R  (a lso  nam ed A L K  and B M P - R I I  re sp ective ly ) can o ccu r before or after B M P  
b in d in g, w h ich  induces signa l transduction through Sm ad s or m itogen-activated  
protein k in ase  ( M A P K ) .  Three classes o f  Sm a d  proteins include  receptor-regulated 
Sm ads (R -S m a d s), such as S m a d l, 5 and 8: the com m on m ediator Sm ad  (C o -S m a d ), 
Sm ad4; and in h ib ito ry  Sm ads (I-S m a d s), Sm ad 6 and 7. W hen activated b y  B M P - R I ,  
S m a d l, 5 and 8 associate w ith  Sm ad4 fo r translocation into the nucleus, w here they 
regulate the expression  o f  target genes. Sm ad6 and 7 can  suppress s ign a ls b y  
preventing association  o f  R -S m a d  w ith  C o -S m a d  or R -S m a d  phosphorylation. B M P s  
can act in  an autocrine and paracrine m anner. Furtherm ore, the sp e c ific  antagonist 
N o g g in  is  also expressed. ( C )  C a n o n ica l W n t s ig n a llin g  is transduced through the co­
receptors fr iz z le d  (F z d ) receptor and lo w -d en sity  lipoprotein  receptor-related protein 
(L r p )  5/6. In  the absence o f  W nt interaction, intracyto p lasm ic protein D ish e ve le d  
(D sh ) is  not activated, so (3-catenin can create a co m p lex w ith  proteins co ntain ing 
adenom atous p o lyp o sis  c o li ( A P C ) ,  a x in  and G S K 3 p . T h is  process induces subsequent 
degradation o f  P-catenin. W nt b in d in g  to F z d  and L rp  receptors induces 
phosphorylation o f  D sh , w h ich  in  turn leads to degradation o f  a x in  and suppression  o f  
G S K 3 P  a ctiv itie s and subsequent accum ulation  o f  P-catenin  w ith in  the nucleus. Then, 
P-catenin d isp laces inh ib itors from  the target gene prom oter and interacts w ith  the 
transcription inducer factors C B P /p 3 0 0  and lym p h o id  enhancer-b inding fa cto r/T -ce ll- 
sp e cific  transcription  factor ( L E F / T C F ) .  (D )  M A P K  can in h ib it  the a ctiv ity  o f  G S K 3 p  
and Sm ad  proteins b y  phosphorylation. C o n ve rse ly , M A P K  co uld  p o s it iv e ly  regulate 
the function o f  R u n x 2  and D lx 5 , thus fa c ilita tin g  m aturation o f  osteoblastic 
progenitors. T h e  M A P K  pathw ay can be triggered b y  several grow th factors such as 
epiderm al grow th factor ( E G F )  and fibrob last grow th factor (F G F ) ,  but a lso  b y  B M P s  
v ia  unknow n m olecu lar m echanism s.
• Term in atio n
W hen the am ount o f  n e w ly  form ed bone equals that w h ich  w as resorbed, the 
rem o d ellin g  cy c le  ends. T h e  m olecu les s ig n a llin g  term ination are la rg e ly  unknow n, 
though osteocytes m ay have a ro le  in that they recom m ence secreting sclerostin , once 
again  suppressing bone form ation. O steoblasts then undergo apoptosis, revert to a
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bone lin in g  phenotype or becom e embedded in  the m ineralised  m atrix  and 
differentiate into osteocytes. T h e  resting bone surface is re-established and 
m aintained u n til the next bone rem o d ellin g cy c le  (S im s  and G o o i, 2008; R aggatt and 
Partridge, 2010).
1.3 Pathogenesis of osteoporosis
A s  the focus o f  this thesis is postm enopausal osteoporosis the pathogenesis o f  this 
type o f  osteoporosis w il l  be considered here. There are a num ber o f  r is k  factors 
associated w ith  the subsequent developm ent o f  osteoporosis (T a b le  1.1).
Decreased bone m ass can occur due to lo w  peak bone m ass, h igh  bone resorption or 
lo w  bone form ation d uring rem odelling. It  is  l ik e ly  that h ig h  bone resorption has the 
greatest contribution to the developm ent o f  osteoporosis in  in d iv id u a ls  (G am ero  et al., 
1996; M elton  et a t,  1997).
Table 1.1: R isk factors for the development of osteoporosis.
T a ke n  from  (W H O , 2003).
Endo geno us Exo gen o u s
Age
Slight body build 
Asian or caucasian race
Premature menopause 
Prim ary or secondary amenorrhoea 
Previous fragility fracture 
Glucocorticoid therapy 
Maternal history o f hip fracture 
Low  body weight 
Cigarette smoking 
Excessive alcohol consumption 
Prolonged immobilisation 
Lo w  dietary calcium intake 
Vitam in D  deficiency
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T w in  studies have established that peak bone d en sity  is  about 7 0 %  heritable 
(M a tko v ic  et a l,  1994; T u rn e r and Beam er, 20 02). H o w e ver, environm ental factors 
such as diet and exercise  d u rin g  ch ild h o o d  and adolescence m a y  influence  peak bone 
m ass (M a tko v ic  et a l,  1979; Johnston el al., 1992; B o n jo u r et a l,  1997).
A  num ber o f  genes have been studied in  order to elucidate a po ssib le  role in  the 
pathogenesis o f  osteoporosis. A  sin gle  nucleotide p o lym o rp h ism  (S N P )  in  the first 
intron o f  COL1 co d in g  fo r type 1 co llagen  has been associated w ith  an increased 
frequency in  osteoporosis (B ro w n  et al., 2001; R a lsto n , 20 01). Further, 
po lym o rp h ism s in  BMP2 have been lin k e d  to lo w  B M D  in  pre- and postm enopausal 
w om en (Styrkarsd o ttir et a l,  20 03). A  m utation o f  LRP5 cau sin g  its activation  results 
in  an increase in  bone m ass (B o yd e n  et a l,  2002; L it t le  et al., 2002). In  addition, a 
S N P  in  LRP5 has been associated w ith  the developm ent o f  osteoporosis and fra g ility  
fractures, the sam e study identified  S N P s  in  genes co d in g  fo r osteoprotegerin, 
oestrogen receptor 1 and R A N K L  also appear to be associated w ith  the subsequent 
developm ent o f  postm enopausal osteoporosis (R ic h a rd s  et a l,  2008).
A n  increase in  the num ber o f  bone-resorb ing sites leads to a tem porary decrease in  
bone m ass. In  norm al in d iv id u a ls, due to co u p lin g  effects, bone form ation w il l  
compensate for this loss, thus restoring the balance. H o w e ver, i f  increased bone 
resorption results in  the breakage o f  trabecular struts in  cancellous bone, the tem plate 
fo r bone form ation is  lost. T h is  d isruption  o f  the m icroarchitecture o f  bone results in  
reduced structural support w ith in  bone, thus in cre asin g  the r is k  o f  fra g ility  fracture.
T h e  reduction in  leve ls o f  oestrogen after m enopause p lays a c r it ic a l role in  the 
developm ent o f  postm enopausal osteoporosis. O estrogen inh ib its bone resorption, thus 
w hen oestrogen leve ls drop during m enopause, bone resorption increases d ram atica lly  
and bone m ass decreases. T h e  rate o f  bone lo ss s lo w s w ith  tim e after m enopause; 
how ever bone lo ss continues to o ccu r years after m enopause (C u m m in g s et a l,  1998). 
C yto k in e s and grow th factors p la y  a ro le  in  the pathogenesis o f  postm enopausal
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osteoporosis. T G F-(3  appears to be in vo lve d  in  the m ediation o f  oestrogen’ s prom otion 
o f  osteoclast apoptosis (H u gh e s et al., 1996). T N F a  has a role in  the developm ent o f  
postm enopausal osteoporosis as it increases osteoclast recruitm ent, thus prom oting 
bone resorption; oestrogen inh ib its the release o f  T N F a , thus preventing bone loss in 
this m anner (A m m an n  et al., 1997).
It  is  c lear that a num ber o f  interleukins p la y  a role in bone turnover, and therefore m ay 
have a ro le  in  the pathogenesis o f  postm enopausal osteoporosis. IL - 1  and IL - 6  are the 
best understood w ith  regard to their role in  bone. IL -1  stim ulates bone resorption, the 
m anner in  w h ich  this is  done is unclear, how ever it has been postulated that IL -1  
receptors or b ind ing-prote ins, as opposed to IL -1  itself, m ay be altered in  response to 
reduced oestrogen leve ls after m enopause (K im b le  et al., 1995; Su n yer et al., 1999). 
I L - 6  is produced b y  osteoblasts and other m arrow  ce lls, its production being 
stim ulated b y  bone resorptive agents P T H , prostaglandin E 2  (P G E 2 )  and IL -1 .  I L - 6  
gene expression has been show n to be elevated in  bone b iopsies taken from  
in d iv id u a ls  w ith  osteoporosis (R a lsto n , 1994).
O ther interleukins also p la y  a role in  bone turnover. I L - 7  m ay have a role in the 
pathogenesis o f  postm enopausal osteoporosis as it stim ulates B -c e ll proliferation, 
w h ich  in  turn stim ulates bone resorption (M iya u ra  el al., 1997). B o th  I L - 4  and IL -1 3  
suppress bone resorption b y  in h ib it in g  cyc lo o xyge n ase -2  ( C O X 2 )  dependent P G E 2  
production in  osteoblasts (K a w a g u c h i et al., 1996; O noe etal., 1996). I L - 1 8 m ay have 
a role in suppressing bone resorption b y  in h ib it in g  osteoclastogenesis, m ediated by 
T N F a .  T h is  effect appears to be m ediated syn e rg istica lly  w ith I L - 1 2 (K ita u ra  et a l,  
2006; M o rita  et al., 2010).
P G E 2  p la ys a crucia l role in bone dynam ics. Dow nstream  o f  C O X 2 ,  its effects are 
m ediated v ia  four receptor sub-types (E P 1 -E P 4 ). The  im pact o f  P G E 2  on bone 
depends on w h ich  o f  its cognate receptors it b inds; E P 2  and E P 4  prom ote bone 
form ation and E P 1  and E P 3  in h ib it it. (S u za w a  et al., 2000; A k h te r et a l,  2001; L i  el 
al., 2005; Z h a n g  et al., 2010).
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T G F P  is  abundant in  bone; it  m a y  p la y  a ro le  as a co u p lin g  factor as it  can in h ib it  bone 
resorption, b y  in d u cin g  osteoclast apoptosis, and stim ulate osteoblast differentiation. 
Som e o f  the effect o f  oestrogen on bone m a y  be m ediated v ia  T G F P  induced apoptosis 
o f  mature osteoclasts (H u gh e s et al., 1996; H o ud e  et ah, 2009; de G orter et a l., 2010). 
It  appears that T G F p  p la ys a ro le  in  the pathogenesis o f  postm enopausal osteoporosis 
as evident b y  a p o lym o rp h ism  in  TGF/3 b e in g  associated w ith  a ve ry  lo w  bone m ass 
phenotype, how ever, the precise  nature o f  its ro le  has yet to be fu lly  elucidated 
(La n g d a h l etah, 1997).
T h e  interp lay and invo lvem en t o f  the num erous proteins d iscussed, though their exact 
re sp o n sib ility  m a y  not yet be understood, underlines the co m p le x ity  o f  the 
developm ent o f  postm enopausal osteoporosis.
1.4 Assessment of osteoporosis
O steoporosis often goes undetected until a fracture occurs, and is therefore frequently 
referred to as a ‘ silent d isease ’ . E a r ly  d iagn o sis and q u antification  o f  bone lo ss has 
becom e more im portant over the last num ber o f  years due to the a v a ila b ility  o f  an 
increasin g  num ber o f  p h arm aco lo g ica l interventions. O steoporosis can be c l in ic a lly  
assessed in  a num ber o f  w ays:
1 . 4 . 1  D u a l  X - r a y  a b s o r p t i o m e t r y
Introduced in  1987, the current go ld  standard in  the d iagn o sis o f  osteoporosis is dual 
X - r a y  absorptiom etry ( D X A )  w h ich  can assess the m ineral content o f  the w hole  
skeleton as w e ll as o f  sites vu lnerab le  to fra g ility  fracture. It  is  referred to as the go ld  
standard as, o f  the techniques ava ilab le  to assess bone m ineral or skeletal m ass or 
structure, D X A  is  the m ost developed, the m ost studied, and the m ost b io lo g ic a lly  
validated. D X A  is a n o n -in vas ive , p a in less m ethod o f  attem pting to assess bone 
strength, in v o lv in g  exposure to rad iation  am ounting to 10 %  o f  that o f  an X - r a y  (F ig u re
1.9 and F igu re  1.10) (Sarto ris  et ah, 1985). T w o  X -r a y s  are used to m easure bone 
m ineral content (B M C ) ,  that is the am ount o f  m ineral detected in  gram s, this is  then 
d iv id ed  b y  the area m easured to g iv e  gram s per centim etre squared (g/cm 2) or B M D . 
T h is  m easurem ent is  com pared to a reference standard co m prised  o f  healthy yo u n g
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adults (B la k e  and Fo ge lm an , 2007). T h e  num ber o f  standard deviations (S D )  aw ay 
from  this reference standard is ca lculated and is referred to as a T -sco re . Z -sco re s are 
generated b y  co m paring the m easured B M D  to that o f  an age-m atched reference 
standard. T h e  W H O  changed the defin ition  o f  osteoporosis in  1994 from  one based on 
the occurrence o f  a fracture w ith lo w  or no im pact to that o f  one u tilis in g  T -sco res 
generated b y  D X A  reports (W H O , 1994).
T h e  fo llo w in g  d iagn o stic categories are now  used:
• N o rm al: A  value o f  B M D  w ith in  1 standard deviation  o f  the yo u n g adult 
reference m ean (T -sco re  between 0 and -1).
• Osteopenia: A  value o f  B M D  m ore than 1 standard deviation  below  the young 
adult reference m ean, but less than 2 standard deviations b e lo w  this value ( T -  
score <-1 and > -2 .5 ).
• O steoporosis: A  value o f  B M D  2.5 standard deviations o r m ore below  the 
yo u n g  adult reference m ean (T -sco re  < -2 .5 ).
• Severe osteoporosis (established osteoporosis): A  va lue o f  B M D  2.5 standard 
deviations or m ore below  the yo u n g adult reference m ean in  the presence o f  
one or m ore fra g ility  fractures.
W h ils t  not considered part o f  the W H O  d iagnostic criteria, Z -sc o re s  can be useful in 
prom pting investigation  into co -e x istin g  factors contributing to the developm ent o f  
osteoporosis.
H o w ever, there are a num ber o f  draw backs associated w ith  D X A .  A s  m entioned, 
bone strength is reflective  o f  both bone quantity and bone quality, D X A  does not 
account fo r bone q u a lity  (A m m an n  and R iz z o l i,  2003). Further, true density w ould  be 
a vo lum etric  measurement, g/cm 3. B e in g  an areal m easurement; B M D  cannot be a true 
m easurem ent o f  bone density. A d d it io n a lly , there are a num ber o f  recognised  sources 
o f  error in  d iagn o sin g  osteoporosis b y  D X A .  T h e y  include osteom alacia,
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osteoarthritis, inadequate reference ranges, inadequate operating procedures, previous 
fracture at the spine, h ip  and w rist, sco lio s is , vertebral deform ities, soft tissue 
ca lc ifica tio n s, (K a n is  etal., 1997). M oreover, the a v a ila b ility  o f  D X A  is  not u n iversa l 
and at —€100 per scan in  Ire land, the cost is  not inconsiderable. F in a lly , it has been 
reported that m uscle  and fat above the bones b e in g  m easured in vivo can be a source 
o f  error in  m easuring B M D  (B o lo tin , 2007).
Figure 1.9: Image of a D X A  scanner.
(Fogelman and Blake, 2000)
D u a l E n e rg y  X - r a y  A b so rtio m etry, or D E X A  scann ing, is  currently  the m ost w id e ly  
used m ethod to m easure bone m ineral density. F o r the test, a patient lie s  dow n on an 
e xa m in in g  table, and the scanner ra p id ly  d irects x -ra y  energy from  two different 
sources tow ards the bone b e in g  exam ined in  an alternating fash io n  at a set frequency.
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Figure 1.10: Images generated by a D X A  scanner of vertebrae L1 -L4 , hip and lateral vertebral 
assessment.
(Fogelman and Blake, 2000)
Portion  o f  com puter printout from  D X A  scan o f  the spine. Printout show s scan im age 
o f  lum bar spine and scan im age o f  p ro x im a l femur.
1 . 4 . 2  Q u a n t i t a t i v e  U l t r a s o u n d
Q uantitative U ltrasound (Q U S )  provides some inform ation  regard ing structural 
o rganisation  o f  bone in addition  to bone m ass. Broad-band  ultrasound attenuation 
( B U A )  and speed o f  sound ( S O S )  at the heel is m easured to p rovide  inform ation on 
the m icroarchitecture and density o f  the calcanus (heel bone). Q U S  is  attractive as it is 
low  cost and portable p ro v id in g  opportunities for large scale screening. H ow ever, 
currently  it cannot be used as a d iagnostic tool fo r osteoporosis, but has proven useful 
in  assess h ip  fracture r is k  in  e ld erly  w om en (H an s et a l., 1996) (F ig u re  1.11).
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Figure 1.11: Imaging bone ultrasonometer. 
www.gehealthcare.com
T h e  w o rk in g  position  o f  the ultrasonom eter are dem onstrated in  the above figure.
1.4.3 Q u a n tita t iv e  co m p u ted  to m o g ra p h y
Q uantitative com puted tom ography ( Q C T )  has been applied  to the spine and 
appendicu lar skeleton but not the p ro x im a l femur. T h e  advantage o f  Q C T  is that it 
can m easure true vo lum etric  density o f  cancellous bone, rather than the area adjusted 
measurem ent that D X A  p ro vid es (R u e g se g ge r et al., 1976; D i  L e o  et al., 2002). 
D ed icated  equipm ent for assessm ent o f  density  at peripheral sites is  used c lin ic a lly  
(p Q C T )  (G enant et a l,  1996). H o w ever, there are d isadvantages associated w ith  Q C T  
in c lu d in g  exposure to h ig h  leve ls o f  radiation, and s ign ifica n t expense w hen com pared 
w ith  D X A .
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1.4.4 Radiography
O steoporosis can be iden tified  o cca sio n a lly  b y  v isu a l inspection o f  p la in -film  x-rays, 
p a rticu la rly  in  the v isu a lisa tio n  o f  vertebral fractures, though its sen sitiv ity  has been 
questioned (W illia m so n  et al., 1990). H o w ever, in  some regions o f  the w o rld  p lain , 
f ilm  x -ra y  w il l  be the o n ly  d iagnostic tool ava ilab le  (E x to n -S m ith  et al., 1969).
1.4.5 Fracture Risk Assessment Tool (FRAX®)
F R A X ®  is  an e lectronic tool developed b y  the W H O  ava ilab le  to c lin ic ia n s on the 
internet. Lau n ch ed  in  2008, F R A X ®  integrates a num ber o f  c lin ic a l r is k  factors w ith  
B M D  at the fem oral n e ck  to calculate the r isk  o f  fracture at the h ip, w rist and 
vertebrae (K a n is  et al., 2011, M c C lo s k e y  and B in k le y , 2011). F R A X ®  utilises e asily  
ava ilab le  c lin ic a l r is k  factors for fracture, w ith  or w ithout B M D  m easurem ents. T h e  
u tility  o f  F R A X ®  has been evaluated in  a num ber o f  countries and can provide 
guidance regard ing B M D  assessm ent and treatment intervention and represents an 
inexpensive  m ethod o f  ass istin g  in  id e n tify in g  in d iv id u a ls  for w hom  a B M D  
m easurem ent m a y  im pact on treatment decisions (K a n is  et al., 2008; C ze rw in s k i et al., 
2010; A z a g ra  et al., 2011; Johansson et al., 2011; L e s lie  et al., 2011; T a m a k i et a l,  
2011).
1.4.6 Biochemical markers of bone turnover
B io ch e m ic a l m arkers o f  bone turnover are frequently m easured to assess response to 
treatment rather than in  the d iagnosis o f  osteoporosis. T h e y  m easure the protein 
products o f  bone form ation and bone resorption released into the circulation. 
Q uantitative changes in  bone m arkers can reflect the d yn am ic process o f  bone 
m etabolism . B o ne  form ation  m arkers are released b y  osteoblasts and are u su a lly  
m easured in  serum. C o m m o n ly  m easured m arkers include osteocalcin  and bone- 
sp e c ific  a lka lin e  phosphatase. B o ne  resorption m arkers are released d u ring osteoclast 
a ctiv ity  and include  the products o f  co llagen  breakdow n N -telopeptide o f  type I  
co llagen  ( N T X )  and C-te lopeptide o f  type I  co llagen  ( C T X ) .  W h ile  it is  apparent that 
m an y current osteoporosis therapies reduce bone turnover, the u tility  o f  b io chem ical 
m arkers in assessing fracture r isk  is  questionable. T h is  is  due to natural variation  in  the 
m arkers them selves and a la ck  o f  robust an a lysis (B ik le , 1997) (T a b le  1.2).
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Table 1.2: Currently measured biochemical markers of bone turnover.
B o n e  turnover m arkers R eference
R e s o r p t i o n  m a r k e r s
N -telopeptide o f  type I  co llagen  ( N T X )
C-te lopeptide o f  type I  co llagen  ( C T X )
Free and total p yrid in o lin e s (P y d )
Free and total d e o xyp yrid in o lin e s (D p d )
F o r m a t i o n  m a r k e r s  
O steo ca lc in
Bo ne sp e c ific  a lka lin e  phosphatase ( B S A P )  
A m in o -te rm in a l propeptide o f  type I  co lla ge n  (P 1 N P ) 
C arb o xy-te rm in a l propeptide o f  type I  co lla ge n  ( P I  C P )
D e lm a s et al., 2000 
D e lm a s et al., 2000 
D e lm a s et al., 2000 
D e lm a s et al., 2000
B ik le , 1997 
B ik le , 1997 
B ik le , 1997 
B ik le , 1997
1.5 Impact of osteoporosis
O steoporosis m anifests its e lf  in  fractures, the m ost com m on o f  w h ich  are o f  the hip, 
vertebrae and forearm  (F ig u re  1.12). T h e  effects o f  fra g ility  fractures can be grouped 
in  a num ber o f  w ays.
2 8
Figure 1.12: Vertebral fracture and fracture of the neck of the proximal femur.
(Poo le  and Com pston, 2006).
( A )  X - r a y  o f  spine, arrow  denotes vertebral fracture.
(B )  X - r a y  o f  p ro x im a l fem ur, arrow denotes fracture o f  the fem oral neck.
1 . 5 . 1  M o r b i d i t y  a n d  m o r t a l i t y
T h e  m o rb id ity  o f  osteoporosis arises from  the associated fra g ility  fractures. Fracture 
o f  the n eck o f  the p ro x im a l fem ur is the m ost severe outcom e o f  osteoporosis on the 
in d iv id u a l, a s ig n ific a n t portion  o f  in d iv id u a ls  sustain ing this type o f  fra g ility  fracture 
w il l  die w ith in  a year o f  that fracture, ran g in g  from  8 .4 -3 6 %  (A braham sen et al., 
2009). T h is  m o rb id ity  decreases over tim e post fracture (Jo h n e ll et al., 2004). H ip  
fractures are often associated w ith  a fa ll, but can o ccu r spontaneously. Treatm ent o f  a 
h ip  fracture necessitates h osp ita lisation  as su rg ica l intervention in  the form  o f  either 
insertion o f  a d yn am ic h ip  screw  ( D H S )  fo r extracapsular fractures or h em i­
arthroplasty for intracapsular fractures, w here the vascu lar fem oral head is replaced 
w ith  a prosthesis (F ig u re  1.13).
O ther m ajo r osteoporotic fractures, those o f  the vertebrae, d ista l forearm , p e lv is , d istal 
fem ur, p ro x im a l tib ia , m u ltip le  rib  fractures and p ro x im a l hum erus are a ll associated 
w ith  an increase in  m o rta lity  (Center et al., 1999).
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Figure 1.13: X-rays of implanted dynamic hip screw and hemiarthroplasty.
w w w .g lac .ac.u k
(A )  D y n a m ic  h ip  screw s are used for internal fixatio n  o f  fractures o f  the fem oral 
n eck and intertrochanteric region. T h e  screw  is a large  cancellous la g  screw  that g lid e  
freely in  a m etal sleeve. T h e  sleeve is attached to a side plate that is f ix e d  to the lateral 
fem oral cortex w ith  screw s. W eight bearing cause the fem oral head to becom es 
im pacted on the fem oral n eck pro d u cin g  d yn a m ic  com pression o f  the fracture. T h e  
shaft o f  the la g  screw  slides dow n the sleeve m ain ta in in g  reduction o f  the fracture as 
com pression occurs.
(B )  M ost co m m o n ly  perform ed after a subcapital fracture o f  the fem oral n e c k  (an 
intracapsular fracture o f  the neck o f  the fem ur, at the point w here the n eck o f  the 
fem ur jo in s  the head). T h e  head o f  the fem ur is rem oved and replaced w ith  a m etal 
com posite.
1.5.2 E c o n o m ic  costs
O steoporotic fractures represent a s ig n ific a n t econom ic burden on healthcare system s. 
A s  m entioned, treatment o f  h ip  fracture in v o lv e s  hosp ita lisation. It is  notew orthy that 
one study found that the num ber o f  hosp ital days resu lting from  h ip  fractures 
outnum ber those resu ltin g from  diabetes, ch ro n ic  obstructive a irw ays o f  d isease 
( C O A D ) ,  m yo card ia l infarction  (M I)  and breast cancer, in d ica tive  o f  the burden
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created b y  h ip  fractures on hcalthcare system s (K a n is  et al., 1997) (F ig u re  1.14). 
Further, a third  o f  h ip  fracture patients require n u rsing hom e care after discharge.
O ther costs inc lu d e  am bulance costs, rehabilitation  costs, and G P  costs. A  recent meta­
an a lysis  o f  p ublications put the econom ic cost o f  fa lls  as between 0 .8 5 %  and 1.5%  o f  
total health care expenditure (H e in rich  et a l,  2010). In  2005 the cost o f  m ore than 2 
m illio n  osteoporotic fractures in  the U nited States was $17 b illio n  (B u rge  et a l,  2007). 
In  2002 the total direct cost o f  h ip  fracture to G erm any w as estim ated at €2.7 b illio n  
per annum  (K o n n o p k a  et a l,  2009). The  total cost o f  fa lls  and fractures in  Ire land is 
estimated at € 4 00  m illio n  (G annon et al., 2008). In  A u stra lia , the total cost o f  fra g ility  
fractures has been estim ated at $700 m illio n  (R a n d e ll et al., 1995).
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Figure 1.14: Hospital bed occupancy in women aged 45 years or more.
D ata from  the Tren t region o f  E n g la n d  (9 %  o f  the U K  population) in d icatin g  num ber 
o f  hospital bed days resu lting from  h ip  fractures com pared w ith other serious illnesses 
experienced b y  w om en aged 45 years and older. C O A D :  C h ro n ic  obstructive airw ays 
o f  disease, M l: M yo ca rd ia l In farction. Take n  from  (K a n is  et al., 1997).
1.5.3 Quality of life
There are further hum an costs associated w ith  osteoporotic fractures. F ra g ility  
fractures cause pain, p h ysica l deform ity, decreased m o b ility , im paired dexterity, 
greater r is k  o f  pressure u lcers and inhib ited pu lm onary function (N e v itt et al., 1998;
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S ch la ich  et al., 1998; F in k  et al., 2003; M a rgo lis  et al., 2003; Ed w a rd s et al., 2010). 
O ne year post-hip fracture, less than h a lf  o f  in d iv id u a ls  w il l  have not regained o rig in a l 
w a lk in g  a b ility  (Sem b o  and Jo h n e ll, 1993). Further, one year post-h ip  fracture 
patients are unable to perform  at least one essential a ctiv ity  o f  d a ily  l iv in g , ( IA D L ) ,  
such as cleaning, sh o p p ing or d r iv in g  (Cooper, 1997). V ertebral fractures are 
associated w ith  not in s ig n ifica n t p a in  and loss o f  height, w h ich  can lead to fe e lin gs o f  
low ered self-esteem  (R o ss  et al., 1991). These factors a ll contribute to an overa ll 
decrease in  q u a lity  o f  life .
1.6 Treatment of postmenopausal osteoporosis
T h e  p rim ary aim  o f  osteoporosis therapy is to reduce r is k  o f  fracture. P h arm aco lo g ica l 
interventions aim  to do this b y  in h ib itio n  o f  further bone loss or b y  prom otion o f  bone 
form ation. T a b le  1.3 sum m arises F D A  approved p h arm aco lo g ica l treatments fo r the 
treatment o f  postm enopausal osteoporosis. A s  a b isphosphonate drug, alendronate, 
w as the first p h arm aco lo gica l treatment to be approved b y  the F D A  in  1995, frontline 
treatment o f  postm enopausal osteoporosis has, to date, in v o lv e d  a bisphosphonate 
drug (B ile z ik ia n , 2009). B isphosphonates are anti-resorptives, in h ib it in g  osteoclast 
function  b y  preventing the form ation o f  the ‘m em brane r u ff l in g ’ required for contact 
between the osteoclast and bone in  order for resorption to o ccu r (F igu re  1.15). 
Bisphosphonate drugs adhere p re ferentia lly  to bones and u ltim ate ly  suppress 
osteoclastic bone resorption b y  encouraging osteoclasts to undergo apoptosis, reducing 
bone turnover and lead ing  to a reduction in  fracture r is k  (R e s z k a  and R odan, 2003). 
Several other bisphosphonate drugs v a ry in g  in  potency and dosage frequency have 
subsequently attained F D A  approval (F ig u re  1.16).
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Table 1.3: F D A  approved medication for postmenopausal osteoporosis. 
T a b le  adapted from  (R o sen , 20 05)
Drug Dose Side effects
Antiresorptives:
Bisphosphonates Oesophagitis,
Alendronate 35 or 70 mg weekly or 5 or 10 mg daily, taken orally osteonecrosis of the jaw
(Fosamax, Merck)
Risedronate 35 mg weekly or 5 mg daily, taken orally
(Actonel, Procter & Gamble)
Ibandronate 150 mg monthly or 2.5 mg daily, taken orally
(Boniva, Roche)
Zolendronate 5mg annual intravenous infusion
(Aclasta, Novartis)
RANKL Inhibitor
Denosumab 60 mg twice annual subcutaneous injection Back pain, musculoskeletal





60 mg daily, taken orally Hot flashes, nausea, deep 
venous thrombosis, stroke, 
leg cramps
Anabolic agents:
Teriparatidc 60 mg daily, subcutaneous injection Nausea, joint aches, pain, leg
(Forteo, Lilly) cramps
PTH 100 ng daily, subcutaneous injection
(Preotact, Nycomed)
Strontium Ranelate 2g daily, taken orally Nausea, eczema, diarrhoea
(Protelos, Servier)
Calcitonin 50 IU daily, taken via nasal spray or intramuscularly Nasal spray: back pain 
Intramuscular: nausea
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Figure 1.15: Mechanism of action of bisphosphonates.
(So lo m o n , 2002)
Bisphosphonates attach to hydroxyapatite  b in d in g  sites on b o n y  surfaces, e sp e c ia lly  
surfaces undergoing active  resorption. W hen osteoclasts b e g in  to resorb bone that is 
im pregnated w ith  bisphosphonate, the b isphosphonate released d u rin g  resorption 
im pairs the a b ility  o f  the osteoclasts to form  the ru ffled  border, to adhere to the bony 
surface, and to produce the protons necessary fo r continued bone resorption. 
B isphosphonates also reduce osteoclast a ct iv ity  b y  decreasing osteoclast progenitor 
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Figure 1.16: Bisphosphonate structure and approximate relative potencies for osteoclast 
inhibition.
(D ra k e  et al., 2008)
( A )  Structurally , bisphosphonates are ch e m ica lly  stable derivatives o f  ino rgan ic 
pyrophosphate (P P i) , a n aturally  o ccu rrin g  com pound in  w h ich  2 phosphate groups are 
lin k e d  b y  esterification. T h e  core structure o f  bisphosphonates d iffers
o n ly  s lig h tly  from  P P i in  that bisphosphonates contain a central nonhydro lyzab le  
carbon; the phosphate groups fla n k in g  this central carbon are m aintained.
(B )  N e a rly  a ll bisphosphonates in  current c lin ic a l use also have a h y d ro xy l group 
attached to the central carbon (term ed the R I  position). T h e  fla n k in g  phosphate groups 
p ro vid e  bisphosphonates w ith a strong a ffin ity  for hydroxyapatite  crysta ls in  bone (and 
are also  seen in P P i), whereas the h y d ro x y l m o tif further increases a b isphosphonate’s 
a b ility  to b in d  ca lcium . C o lle c tiv e ly , the phosphate and h yd ro xy l groups create a 
tertiary rather than a b in ary  interaction between the bisphosphonate and the bone 
m atrix , g iv in g  bisphosphonates their sp e c ific ity  for bone. E a r ly  no n -n itro gen - 
co nta in in g  bisphosphonates (etidronate, clodronate, and tiludronate) are considered 
first-generation b isphosphonates.
( C )  U n lik e  early bisphosphonates, second- and third-generation bisphosphonates 
(alendronate, risedronate, ibandronate, pam idronate, and zo led ro n ic  acid) have 
n itro gen-contain ing R 2  side chains.
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H o w ever, adverse effects o f  oral b isphosphonate drugs inc lu d e  oesophagitis 
(Sp aridan s et a l., 1998). Z o le d ro n ic  acid , adm inistered in traveno usly, avo ids the 
co m p licatio n  o f  oesophagitis. O n ce  annual in fu sio n s, indeed b i-ann u al in fu sio n s 
offered b y  the m ost recently approved pharm aceutical for postm enopausal 
osteoporosis, R A N K L  in h ib ito r denosum ab, go some w a y  to counter-acting non- 
co m pliance  to therapy, regarded as b e in g  an issue in  m any ch ro n ic  illn esses in c lu d in g  
osteoporosis (Com p sto n  and Seem an, 20 06). A  review  o f  76 random ised tria ls and 24 
m eta-analyses confirm ed the reduction in  fracture r is k  o f  a num ber o f  p h arm aco lo gica l 
agents; alendronate, risedronate, zo led ro n ic  acid  and oestrogen (M a cLe a n  et al.,
2008).
In  addition to p h arm aco lo gica l therapies, n o n -p h a n n a co lo g ica l interventions can 
augm ent a patient’s outcom e. T h is  encom passes alterations in  diet, such as in cre asin g  
ca lc iu m  and v itam in  D  intake, life sty le  m o d ificatio n s, such as increased exercise  and 
cessation o f  sm o kin g , a ll o f  w h ich  m ay contribute to a reduction in  overall fracture 
r is k  w hen com bined w ith  pharm aceutical therapies (D e lm as, 2002; Fe sk a n ich  et al., 
2002; T a n g  et al., 2007).
1.7 Biomarker discovery using human serum
Proteom ics, or the large-sca le  study o f  the protein com plem ent o f  a g iven  ce ll-type, 
tissue or organism , has dem onstrated its e lf  to have u tility  in  an sw erin g im portant 
b io lo g ic a l questions, p a rticu larly  in  re lation to the understanding o f  k e y  functions o f  
l iv in g  system s. A n  im portant use o f  proteom ics im pacts upon c lin ic a l research w here 
research questions include  search in g for protein b iom arkers and targets fo r therapy. A  
p rin c ip a l goal o f  c lin ica l proteom ics is to id e n tify  protein m arkers o f  disease and 
develop them into assays for routine m easurem ent co ntributing tow ards c lin ic a l needs. 
A  num ber o f  disease ind icators, or b io m arkers, are sin gle  proteins that are assayed as 
m arkers o f  disease, are approved b y  the F D A  and are used c lin ic a lly  (P o la n sk i and 
A nderson , 2007).
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H u m an  serum  and p lasm a is p otentia lly  the m ost inform ative  sam ple that can  be 
co llected  from  an in d iv id u a l that describes their current state o f  health. T h is  is due to 
the potential o f  b lood to contain  a ll o f  the proteins expressed in  the body. Concerted 
efforts have been made in  recent years, such as the establishm ent o f  the H um an 
P lasm a Proteom e Pro ject b y  the H u m an  Proteom e O rgan isatio n  (H U P O ), to address 
the issue o f  deve lo ping new  blood-based d iagnostics b y  m in in g  the hum an p lasm a 
proteome for b iom arkers o f  disease (H anash, 2004).
It  is  understood that candidate b iom arkers o f  interest w il l  not be c la ss ic  p lasm a 
proteins, but proteins that have arisen from  leakage, secretion and shedding from  the 
affected organ, tissue, ce ll type or pathw ay. H o w ever, the proteom ic investigation  o f  
hum an serum  and p lasm a has proven to be m ore d iff icu lt  than in vitro  or m icro b ia l 
studies (W ashburn  et al., 2001; L ip to n  et al., 2002; L iu  et al., 2005). A s  the volum e o f  
b lood in  a person averages at s ix  litres, these proteins q u ic k ly  becom e diluted and are 
at a lo w  concentration, thereby becom ing m ore d ifficu lt  to detect. Therefore, 
proteom ic efforts in  recent years have focused on im plem enting strategies that 
s im p lify  or partition serum  in  some manner, thus m akin g it m ore am enable to analyse 
or u t ilis in g  a proteom ic p latform  w ith  a h ig h  degree o f  sensitiv ity.
1.8 Proteomics
T h e  term ‘proteo m ics’ w as first used to describe the an a lysis  o f  co m p lex protein 
sam ples b y  2 D  d im ensio nal electrophoresis (2 D E )  in  com bination w ith  am ino acid  
ana lysis. T h is  approach lent its e lf  to the large scale screening o f  the protein expression 
p ro file  o f  a g iven  tissue in  norm al and disease states (W ilk in s  et a l,  1996). W h ilst 
gen o m ic studies can provide  inform ation regard ing the g iven  sequence o f  genes in  an 
organism , as d iscussed p re vio u sly , inheritance o n ly  p a rtia lly  predicts whether an 
in d iv id u a l is predisposed tow ards deve lo ping osteoporosis. Tran scrip to m ics offer an 
insigh t as to the d iffe re n tia lly  expression  o f  m R N A  transcripts between g iven  sam ples. 
H o w ever, draw backs associated w ith  gene expression an a lysis  are that m R N A
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transcript quantitation is  not n ecessarily  related to dow nstream  protein expression; 
further, no inform ation  regard in g post-translational m o d ificatio n s (P T M s )  is g iven . 
P T M s  have cr it ica l roles in  protein structure, function  and lo ca lisatio n . Therefore, the 
use o f  proteom ic a n a lys is  poses a p ro m is in g  m ethod o f  id e n tify in g  d iffe re n tia lly  
expressed proteins in  a g ive n  disease state com pared w ith  control, thus p ro v id in g  an 
insigh t to candidate m arkers o f  d isease states.
1.8.1 Proteomic approaches in bone and osteoporosis research
T h e  w o rk  in  this thesis focuses on the use o f  proteom ics in  serum  sam ples taken from  
postm enopausal w om en w ith  osteopenia and osteoporosis.
A s  m entioned, in  2003 the W H O  h ig h ligh te d  the need for cheap d iagn o stics for 
osteoporosis. B lo o d  tests for b io m arkers in  c lin ic a l situations represent an avenue for 
reasonably inexpensive , h ig h  throughput d iagn o sis. B io m ark ers have been defined b y  
a N IH  w o rk in g  group as ‘a characteristic that is  o b je ctive ly  m easured and evaluated as 
an ind icator o f  norm al b io lo g ic a l processes, pathogenic processes, or p h arm aco lo g ica l 
responses to a therapeutic intervention’ (A tk in so n  et al., 2001). In  other w ords 
b iom arkers can be used to establish  disease status, assess p ro gression  and m onitor 
therapy (T a b le  1.4).
B io m arkers represent a n o n -in va s ive , rap id  and gen era lly  co st-effic ien t m ode o f  
augm enting d iagn o sis o f  a w ide  range o f  diseases. T o  date, F D A  approved biom arkers 
have been proteins, though a num ber o f  p u b lish ed  studies can be found in  the literature 
p roposing autoantibodies, m ic r o R N A s  and S N P  ka ryo typ in g  m arkers o f  disease, 
disease progression  or response to therapy (B a b e l et al., 2011; K im  et al., 2011; Y a n g  
et a l,  2011).
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Table 1.4: Recently F D A  approved biomarkers.
A dapted from  P o la n sk i and A n d erso n  2007. (P o la n sk i and A nderson  2007)
Protein name Disease Limit of 
sensitivity
Reference
Carcinoembryonic Antigen (CEA ) Malignant pleural effusion N A (L i et al. 2003)
C E A Peritoneal cancer 0.5ng/mL (Yamamoto et al. 2004)
ErbB2/HER2 Stage IV  breast cancer 15ng/mL (C o o keta l 2001)
Bladder Tumour Antigen Urothelial cell carcinoma N A (Mian et al. 2000)
Thyro-globulin Thyroid cancer metastasis 2.3ng/mL (Lima et al. 2002)
Alpha-fetoprotein Hepatocellular carcinoma 20 ng/mL (De Masi et al. 2005)
Prostate-specific Antigen (PSA) Prostate cancer 4 ng/mL (GannetaL 1995)
Cancer Antigen (CA)125 Non-small cell lung cancer 95 IU/mL (Dabrowska et al. 2004)
C A  19.9 Pancreatic cancer N A (Tamaguchi et al. 2004)
Leptin, prolactin, osteopontin, a n d IG F -II Ovarian cancer N A (Kozak et al. 2003)
CD98, fascin, sPIgR, 14-3-3 eta Lung cancer N A (Xiao et al. 2005)
Troponin I Myocardial Infarction 1 mg/L (Eggers et al. 2004)
B-type natriuretic peptide Congestive heart failure 8pg/mL (Dao et a l 2001)
Proteom ic approaches towards id e n tify in g  candidate b iom arkers that m ay prove 
useful in  the d ia g n o sis o f  osteoporosis have p re v io u sly  been published. 
Bhattacharyya et al. u tilised  surface enhanced laser desorption/ionisation ( S E L D I )  
to identify  in ter-a lpha-trypsin  inh ib itor h eavy  ch a in  H 4  ( IT IH 4 )  as a candidate 
m arker fo r h ig h  bone turnover in  the serum  o f  postm enopausal w om en 
(B h attacharyya et al., 2008). W h ile  p o sin g  a p ro m is in g  candidate protein for 
measurem ent in  the augm entation o f  d iagn o stics in  osteoporosis, there m a y  be an 
issue o f  n o n -sp e c ific ity  o f  disease as IT IH 4  has been iden tified  as a candidate 
m arker o f  several other diseases in c lu d in g  ovarian  cancer, pancreatic cancer and 
inflam m atory diseases (W h ich e r et a l,  1999; Z h a n g  et a l,  2004; K o o m e n  et a l,  
2005; V illa n u e v a  et al., 2006).
2 D E  com bined w ith  m ass spectrom etry (M S )  w as used to id e n tify  d iffe re n tia lly  
expressed proteins in  w hole  bone protein extracts taken from  an an im al m odel o f  
postm enopausal osteoporosis; ovariectom ised m ice. Fourteen d iffe re n tia lly  
expressed proteins w ere identified, in c lu d in g  proteins in vo lve d  in  energy 
m etabolism  such as enolase (3, cytoskeletal proteins tropom yosin  1 and tropom yosin
2 (P asto re lli et a l,  20 05). T h is  study h igh ligh ted  the a b ility  o f  2 D E  to id e n tify  n ovel 
proteins p re v io u sly  unreported in  their invo lvem e n t in  the effects o f  oestrogen on 
bone.
These studies underline  the point that u s in g  the use o f  a proteom ic approach m ay be 
an appropriate m ethod in  id e n tify in g  candidate b iom arkers o f  postm enopausal 
osteoporosis.
There are num erous m ethodologies that co u ld  be use to d isco ve r candidate 
b iom arkers for m easurem ent in  blood. Candidate  m arkers have been identified  b y  
studying serum  and p lasm a, ce ll culture supernatant, affected tissues, an im al m odels 
o f  disease, p ro x im a l b io flu id s such as cerebrospinal f lu id  and bronchoalveo lar 
lavage  (Jones et a l,  2002; K im  et a l,  2002; A h m ed  et a l,  2004; H o o d  et al., 2005; 
W u et a l,  2005; H e  et a l,  2010; R y b e rg  et al. , 2010). H U P O  recom m ended the use
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o f  p lasm a, rather than serum  in  b io m arker d isco very  projects. Serum  has the 
disadvantage o f  h a v in g  undergone clotting; H U P O  argues that proteins in the serum 
can n o n -sp e c if ic a lly  b in d  to the clo t (O m enn, 2004). T h is  has tw o consequences; 
the rem oved proteins are not ava ilab le  for subsequent analysis and, as the m anner in 
w h ich  the proteins are rem oved is n o n -sp ecific , a certain am ount o f  v a r ia b ility  is 
introduced. H o w ever, H U P O  also h ig h ligh ts  the im portance o f  im plem enting a 
standard co llectio n  protocol, insu rin g  that a ll sam ples analysed are processed in the 
sam e m anner. A n y  deviation from  the protocol w o u ld  introduce unwanted 
va ria b ility . In  c lin ic a l settings, it is serum  rather than p lasm a that is used for 
laboratory testing; therefore, c lin ic a l s ta ff are accustom ed to p rocessing serum  
sam ples. A  change from  taking serum  under norm al protocol to taking serum  under 
a m ore stringent protocol represents a sm aller, m ore m anageable change than 
sw itch in g  from  ta k in g  serum  to ta k in g  plasm a. T h is  m anageable change is more 
e a s ily  im plem ented and therefore m ore lik e ly  to be adhered to. Further, in  a 
situation w here m ore than one in d iv id u a l is ta k in g  b lood sam ples from  study 
participants there co uld  be a r is k  o f  a m ixture  o f  serum  and p lasm a sam ples being 
processed and analysed, introducing unwanted v a ria b ility  in  the study cohort.
T N F a , as d iscussed, is  a secreted protein w h ich  stim ulates the differentiation o f  
osteoclast progenitors and increases the a ctiv ity  o f  mature osteoclasts (C e n c i et al., 
2000; L a m  et al., 2000). Th u s, it m ay appear to be an attractive candidate for a 
c lin ic a l b io m arker o f  osteoporosis. H ow ever, as an inflam m atory cytokine, T N F a  is 
im plicated  in  a num ber o f  diseases in c lu d in g  neuropathic pain, autoim m une 
disorders, in su lin  resistance and cancer (M u elle r et a l,  1993; A rin g e r and Sm olen, 
2004; K w o n  et al., 2010; Le u n g  and C a h ill, 2010). Further, the overall abundance 
o f  T N F a  in  b lo od  is very low , at < p g /m L, potentia lly  m akin g  it d ifficu lt  to assay 
rep ro d u cib ly  and re lia b ly  (D a v id  and Schett, 2010).
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T h e  w o rk in  this thesis focuses on postm enopausal osteoporosis. It  has been 
recognised that there are inherent d ifferences in  the b lo o d  proteom e o f  m en and 
w om en (M iik e  et al., 2010). Therefore, to inc lu d e  serum  sam ples from  both w om en 
and men in  a proteom e a n a lys is  m ay introduce unwanted v a r ia b ility  in  a study 
cohort.
A s  w ith  the expression  o f  T N F a ,  inflam m ation  can have a large  in fluence  on the 
expression o f  proteins in  blood, thus in d iv id u a ls  w ith  in flam m ato ry  d isorders m ay 
not be suitable for in c lu s io n  in  a b io m arker d isco ve ry  study as the presence o f  an 
additional d isorder m a y  c lo u d  the an alysis in  the context o f  a proteom ic study.
1.8.2 Proteome partitioning
A s  m entioned above, serum  and p lasm a have been used in  num erous b io m arker 
d isco ve ry  studies. H o w e ver, there are a num ber o f  d ifficu ltie s  associated w ith  the 
proteom ic an a lysis  o f  serum  and plasm a. A  sm all num ber o f  proteins dom inate the 
overall protein content, the c la ss ica l proteins such as a lbu m in  and Im m u n o glo bu lin  
G  ( Ig G )  w h ilst p erfo rm in g im portant functions in  the b o d y are, fo r the m ost part, 
unim portant from  a b io m arker d isco ve ry  point o f  v ie w  (F igu re  1.17, F ig u re  1.18) 
(A nderson  and A n d erso n , 2002).
T h is  draw back is underlined w hen an investigato r u tilise s 2 D E  or 2 d im ensio nal 
difference ge l electrophoresis (2 D  D IG E ) .  D iscu sse d  below  in  further detail, these 
techniques a im  to reso lve  proteins as discrete spots on an acry lam ide  gel 
m anipulating the in  properties o f  m o lecu lar w eigh t (M W ) and isoelectric po int (p i). 
H o w ever, proteins such  as a lbum in  hide the presence o f  other proteins due to co ­
m igration  to the sam e point on the acry lam ide  gel, thus m a sk in g  their presence. 
Further, w hen an investigato r analyses, fo r exam ple, 50 fxg o f  protein, the m ajo rity  
o f  that protein w il l  not be o f  interest, therefore, re m o vin g  these proteins w il l  result 
in  larger num bers o f  low er abundance proteins b e in g  analysed. T h is  lim itin g  o f
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sam ple load  cap acity  leads researchers to deplete as m any proteins as possib le  from  
serum  or p lasm a as a first step o f  analysis.
A  num ber o f  m ethods for rem o vin g  abundant serum  or p lasm a proteins exist. 
C ib a cro n  b lue is  a ch lorotriazine dye that b inds a lbum in; this depletion method has 
been evaluated in  the past and has been show n to n o n -sp e c ifica lly  rem ove a large 
num ber o f  proteins, through proteins other than a lbum in  b in d in g  the dye and 
proteins n o n -sp e c ific a lly  b in d in g  to a lbum in. T h is  n o n -sp e cific  b in d in g  is thought 
to happen v ia  C ib a cro n  b lu e ’s a ffin ity  for proteins w ith nucleated b in d in g  dom ains 
in  addition  to io n ic  and h ydrophobic interactions (T ra v is  et al., 1976; G ia n a zza  and 
A m a u d , 1982; A h m ed  et al., 2003). C o n ve rse ly , protein A  or G  depletion methods 
also  used in the past, b ind im m unoglobu ins but m ay not b ind  a ll subgroups, thereby 
le a v in g  behind im m u noglobu ins undepleted (G o vo ru kh in a  et al., 2003; W an g et al.,
2003).
T h e  use o f  antibodies poses a p ro m isin g  m ethod o f  rem oval o f  m ajor proteins from  
serum  or p lasm a in  a sp e c ific  m anner. M o no clo n al antibodies, w ith  their h igh  
sp e c ific ity , m a y  seem suitable, how ever, they m ay not recogn ize  a ll form s o f  a 
g iv e n  protein, in c lu d in g  form s co ntain ing post-translational m odifications (P T M s ) 
(Stee l et al., 2003). T h e  use o f  antibodies for depletion o f  scrum  and plasm a 
sam ples a llo w s fo r a more accurate and reproducible  method o f  reducing the 
d yn am ic range o f  serum  proteins.
A  concern regard ing the use o f  depletion m ethods is that every m anipulation 
introduces a m arg in  o f  error, w h ich  m a y  accum ulate and propagate into the 
subsequent analysis. T h is  r is k  in undertaken w ith  the point o f  v ie w  that any 
introduced error w il l  be m in im a l com pared w ith  the benefits o f  increasing the 























Figure 1.17: Pie chart depicting the contributions various proteins make to the total protein 
content of serum/plasma.
(Tirumalai et al., 2003)
Albumin comprises -50% of the protein content of serum and plasma. A total of 10 
proteins constitute 90% of the protein content of serum. Of the remaining 10%, 12 
proteins make up 90% of the remaining portion. Only 1% of the entire protein 
content of serum is made up of proteins that are considered to be in low abundance 
and of great interest in proteomic studies in search of potential biomarkers.
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Figure 1.18: Plasma protein concentrations as described by Anderson and Anderson.
(Anderson and Anderson, 2002) taken from (Schiess et al., 2009).
Plasma proteins can be grouped into three main categories (classical plasma 
proteins, tissue leakage products, and interleukins/cytokines). Red dots indicate 
proteins that were identified by the HUPO plasma proteome initiative (States et al., 
2006) and yellow dots represent currently utilized biomarkers (Anderson et al.,
2004).
1.8.3 Two d im ens iona l gel electrophoresis (2DE)
2DE is the process by which a complex mixture of proteins in separated in two 
dimensions by the use of electrophoresis or migration of charged proteins in an 
electrical field and is commonly used to analyse proteins. The first dimension,
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isoelectric focusing (IEF), utilises the fact that proteins are amphoteric, that is their 
charge is dependent on the pH of their environment. A proteins’ isoelectric point 
(pi) is the pH at which it has no net charge. The first dimension of 2DE involves 
placing a given protein sample on a commercially available plastic-backed agarose 
gel 1mm in depth by 3 mm wide by 7 to 24 cm in length e.g. immobilised pH 
gradient (IPG) strips available from GE Life Sciences. The agarose gel contains a 
given pH gradient, chosen by the user, when the sample is placed on the strip and 
the strip placed in an electrical field, proteins migrate until they reach their pi, 
resulting in proteins becoming concentrated on a given point on the IPG strip. 
Selection of a pH interval will be dictated primarily by the sample being studied. 
The second dimension, dodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS PAGE) separates the focused proteins by size having been 
treated with a detergent, sodium dodecyl sulphate, conferring an overall negative 
charge so that in an electrical field proteins will migrate towards the oppositely 
charged pole, smaller proteins moving more quickly than larger, thus separating 
proteins by size (Figure 1.19 and Figure 1.20).
Since being described in 1975 (O'Farrell, 1975) 2DE has allowed researchers to 
analyse complex mixtures of proteins and is widely used by the proteomic 
community. It has a variety of applications including proteome analysis, cell 
differentiation, therapy monitoring, drug target discovery and the identification of 
markers of disease. 2DE has been used to separate a wide range of protein extracts, 
animal cell lysates, bacterial lysates, cell culture supernatant, tissue extract, plant 
proteins, various biofluids such as serum and plasma, saliva, urine, cerebrospinal 
fluid and amniotic fluid.
In order to visualise the spots of protein separated on the gels, staining techniques 
are used. The technique chosen will depend on the user’s desired sensitivity of 
detection, range of quantitation and compatibility with mass spectrometry, used in 
order to establish the identity of a given protein spot. Further, toxicity and health
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and safety implications will also influence a decision in selecting a visualisation 
technique as is the case with autoradiography and fluorography.
2DE is unique in its ability to identify multiple versions of the same protein, the 
different versions being due to post-translational modifications. No other technique 
in proteomics has the ability to visualise and separate versions of a single given 
protein with multiple post-translational modifications (Rabilloud, 2002).
2DE has been used as a tool in biomarker discovery for a number of years and is the 
subject of a large number of publications utilising plasma, serum, cell culture 
supernatant, animal model tissues and diseased human tissues (Ahmed et al., 2004; 
Ou et al., 2008). However, there are a number of issues with 2DE. The use of 
specific pH intervals mean that proteins with a pi outside of that being used will not 
be resolved. Therefore a user cannot expect to resolve all proteins in a given 
sample. In the context of biomarker discovery, a researcher can only expect to 
identify either by experimentation or literature search which pH interval will 
resolve the greatest number of proteins. System variation can be a significant 
source of error in 2DE; that is gel-to-gel differences can be high, contributing to 
error and meaning that differences noted in the expression of a given protein may 
not be real (Gygi et al., 2000).
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Figure 1.19: Schematic of the principal of two dimensional gel electrophoresis.
Adapted from (Carrette et al., 2006).
IEF: Isoelectric focusing, SDS PAGE: Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis
The first dimension of 2DE, isoelectric focusing (IEF) involves placing a given 
protein sample on an agarose gel containing a pH gradient which is then placed in 
an electrical field in order to separate proteins by isoelectric point (pi). The second 
dimension, SDS PAGE, separates out the proteins by molecular weight (MW).
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S a m p le  p re p a ra t io n
Figure 1.20: Two dimensional gel electrophoresis workflow.
Adapted from (Carrette et al., 2006).
IPG: Immobilised pH gradient
Schematic shows the general workflow for carrying out 2DE; protein sample is 
prepared from the relevant source, the sample is rehydrated on the IPG strip, the 
IPG strip is then subject to isoelectric focusing, the focused strip is prepared for the 
second dimension by treatment in equilibrating buffer, proteins are then separated 
by molecular weight in SDS PAGE. An appropriate visualisation strategy is then 
applied, the visualised protein spots are then subject to analysis by a software 
package.
1.8.4 Two dimensional difference gel electrophoresis (2D DIGE)
The utility of 2DE has been demonstrated in the literature over a number of 
decades. However, as mentioned, there are a number of drawbacks associated with 
using 2DE to identify differentially expressed proteins in the context of a study 
examining a disease sample with that of a control. These drawbacks include system 
variation, whereby differences will be seen in the size of a protein spot from one gel 
to another not due to biological change, but due purely to gel-to-gel variation. 
Further, the use of staining techniques in 2DE, such as Coomassie or silver staining,
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requires a high number of technical replicates in order to be able to distinguish 
system variation from biological variation with any degree of certainty.
2D DIGE was first described by Unlu et al. and represents an evolution of the 
technique that allows for controlling of system variation, allowing a user to identify 
real biological variation, thus overcoming one of the main drawbacks associated 
with 2DE (Unlu et al., 1997). It allows for relative quantitation of protein spot 
intensities across a set of carefully matched gels. Fluorescent dyes are used to label 
protein samples prior to separation by 2DE. In the study by Unlu et al. dyes Cy3 
and Cy5 were used to identify differences between two Drosophila extracts at 
nanogram protein levels. Subsequently, the technique has been commercialised by 
GE Life Sciences.
CyDye DIGE Fluors have an iV-hydroxysuccinimide (NHS) ester reactive group and 
so can covalently bond to the epsilon amino group of lysine residues of proteins in 
an amide bond (Figure 1.20). CyDye DIGE Fluors are matched for size and charge 
so that a given protein labelled with different dyes will overlay if run on the same 
gel. The lysine amino acid in proteins carries a +1 charge at neutral or acidic pH. 
CyDye DIGE Fluors also carry an intrinsic +1 charge which, when coupled to the 
lysine, replaces the lysine’s +1 charge. This ensures that the pi of the protein does 
not change which would affect its migration in IEF.
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Figure 1.21: Schematic of the CyDye D IG E  Fluor labelling reaction.
CyDye DIGE Fluor containing NHS-ester active group covalently binds to lysine 
residue of protein via an amide linkage (Chakravarti et al., 2005).
The DIGE system created by GE Life Sciences involves three CyDye™ DIGE 
Fluor minimal dyes (Figure 1.21). Three labelled samples are separated in parallel 
on a single gel. The system allows for the inclusion of an internal standard, labelled 
with Cy2 (developed by GE Life Sciences) in each gel. This internal standard 
consists of an equal quantity of every sample in the experiment. The inclusion of an 
internal standard allows the user to normalise the Cy3 and Cy5 labelled samples 
within a given gel and allows for comparison across all gels in the experiment. The 
internal standard overcomes the issue of gel-to-gel variation associated with 
traditional 2DE. Further, the use of a sensitive dye such as a fluorescent dye allows 
for greater sensitivity than silver staining as amounts of protein as low as 150 pg 
can be detected (Martin et al., 2004). Additionally, CyDyes used in the DIGE 
system show a liner response to protein concentration up to five orders of
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magnitude. This is of particular relevance when considering serum samples as the 
protein content spans several orders of magnitude.
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Figure 1.22: Schematic of a 3 CyDye D IG E  experiment.
(Timms and Cramer, 2008)
Workflow for 2D DIGE system showing co-separation of three fluorescently 
labeled samples separated on a single 2-D gel. One sample is an internal standard.
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Since its commercialisation, 2D DIGE has established itself as a useful and 
powerful analytical tool in proteomics. However, the technique has evolved over 
time. 2D DIGE incorporated 3 CyDyes used to label two samples and one internal 
standard, thus reducing gel-to-gel variation and improving protein quantitation 
across an experiment (Figure 1.22). A number of recent studies have assessed the 
technical variability associated with the approach with the aim of improving 
subsequent data. The reproducibility of results was assessed in a pair-wise 
comparison of several different CyDye combinations, determining that the use of 
Cy3 and Cy5 together in an experiment was less variable and therefore more 
reliable than other CyDye combinations (Tonge et al., 2001). Further, Cy2 is 
regarded as being the weakest of the three fluors (Karp and Lilley, 2005). As a 
result, the signal detected from Cy2 is closer to background values, thereby 
increasing noise within the data set. Based on this, literature published by Karp and 
Lilley recommends the use of a Cy3/Cy5 combination (Figure 1.23) (Karp and 
Lilley, 2005; Karp et a l, 2007).
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Figure 1.23: Schematic of a 2 CyDye D IG E  experiment.
www.ncc.go.jp/en
An internal control sample, which is comprised of equal quantities of individual 
samples, is created and labeled with a fluorescent dye. The individual samples are 
labeled with Cy5 fluorescent dye. These differently labeled proteins are mixed 
together and separated on the individual gels. The Cy3 laser generates the image of 
the internal control sample and the Cy5 laser scanning generates the image of the 
individual samples. All gels can generate the Cy3 images. Normalization of Cy5 
intensity with Cy3 intensity cancels out gel-to-gel variability. This protocol enables 
the comparative study of several samples using two types of fluorescent dye; Cy3 
and Cy5.
1.8.5 Mass spectrometry (MS)
Mass spectrometry (MS) is used, amongst other applications, to identify an 
unknown protein in a given biological sample. This is achieved by the 
determination of the mass of a charged compound species by measuring the mass- 
to-charge ratio (m/z). Various permutations of MS exist, differing in their 
methodology and levels of sensitivities. All have in common the principle of 
ionising a solid, such as a peptide, forcing it into the gaseous phase, ultimately 
being read by a detector generating a set of peaks or a spectrum. The generated 
spectrum is searched against a database of known proteins in order to establish an
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identity of the unknown protein. The Thermo Fisher LTQ-Orbitrap (Figure 1.24) is 
a mass spectrometer that performs liquid chromatography mass spectrometry 
(LC/MS). This is a sensitive form of M S more likely to positively identify a protein 
spot containing relatively low quantities of protein (nanograms of protein) (Hu et 
al.t 2005).
Figure 1.24: Schematic of an Orbitrap mass spectrometer.
Ions are produced by the electrospray ion source at the extreme left. Ions then 
proceed through the source, collision quadrupole, selection quadrupole and then 
pass into the storage quadrupole. The storage quadrupole serves as an ion 
accumulator and buncher, allowing a pulsed mass analyzer such as the Orbitrap to 
be coupled to a continuous source like an electrospray ionisation source. After 
accumulation and bunching in the storage quadrupole, the exit lens (Lens 1) is 
pulsed low, the ion bunches traverse the ion transfer lens system and are injected 
into the Orbitrap mass analyzer (Hu et al., 2005).
1.8.5 Array technology
Antibody array technology provides a platform to simultaneously assay large 
numbers of biological molecules, establishing protein expression profiles of the 
chosen analyte in a given biological sample. Array technology is available in
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several formats; dependent on the interests of a researcher one can use protein 
arrays to study protein-protein interaction, autoantibody array in the study of 
autoimmune disorders or antibody arrays to examine the expression of hundreds of 
proteins simultaneously.
Unlike DNA microarrays, antibody arrays can measure the abundance of a given 
protein independently of gene expression. They usually take the format of a glass 
slide upon which antibodies against a given set of proteins have been spotted. The 
protein sample is treated in such a way as to allow detection by a fluorescence 
scanner either by direct labelling of the protein in a manner similar to that of 2D 
DIGE or by biotinylation, with the subsequent addition of a streptavidin conjugated 
fluor (Figure 1.25). Drawbacks associated with antibody array technology include a 
narrow dynamic range of detection and potential for high background due to impure 
antigens (Kingsmore, 2006). Antibody array technology has been used in previous 
studies to successfully identify differentially expressed proteins in a number of 
disorders which may be of interest as markers of disease or therapeutic targets 
(Knezevic el al., 2001; Watanabe et al., 2005; Vazquez-Martin et al., 2007).
As antibody array technology involves the use of antibodies generated against 
specific proteins, implicitly, the identity of the assayed proteins is known. This 
differs from that of 2DE based technologies, where no specific protein is selected 
for other than those in the chosen pH range. Therefore, output from similar samples 
analysed by antibody array technology and 2DE technology will inevitably differ as 
the techniques differ in their operating principles.
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Figure 1.25: Schematic of the R ayB io ®  Label based antibody array workflow.
www.raybiotech.com
The proteins within the sample are biotinylated and then dialyzed in preparation for 
incubation with the antibody array. The biotinylated sample is added onto the 
antibody array and incubated at room temperature. After incubation with 
horseradish peroxidase (HRP)-streptavidin or fluorescent dye-streptavidin, the 
signals can be visualized either by chemiluminescence or fluorescence.
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1.9 A im s
The aims of the work in this thesis are to:
• Develop an appropriate protocol for serum samples for subsequent 
proteomic analysis.
o  This will involve optimisation of a serum depletion strategy 
producing depleted serum suitable for subsequent analysis by 2D 
DIGE.
• Identify differentially expressed proteins in the depleted serum of 
postmenopausal women with osteopenia and osteoporosis by 2D DIGE and 
carry out preliminary validation of selected candidates.
o  A quantitative 2D approach will be applied to depleted serum 
samples with subsequent ELISA analysis of a selected sub-set of 
proteins.
• Identify differentially expressed proteins in the serum of postmenopausal 
women with osteopenia and osteoporosis by antibody array analysis and 
carry out preliminary validation of selected candidates.
o  An output differing from that of the 2D DIGE data will be produced 
from this analysis with subsequent ELISA analysis of a selected sub­
set of proteins.
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IChapter 2 Evaluation of IgY proteome partitioning for biomarker 
discovery
2.1 Introduction
There are a number of approaches to identifying candidate molecular markers of a 
given disease. A researcher can choose to analyse several different biological 
materials in order to discover a candidate biomarker, or panel of biomarkers. In the 
literature, examples of candidate biomarkers can be found in patient serum or plasma, 
cell lines, affected tissue and animal models (Omenn, 2004; Arab et al., 2006).
Serum and plasma are frequently used in biomarker discovery for a number of 
reasons. Firstly, the protein content of blood is reflective of the physiological 
condition of the body at a given point in time (Anderson et al., 2004). This is due to 
tissue leakage; the release of proteins from cells into the interstitial fluid. Proteins in 
the interstitial fluid ultimately find their way into circulating blood. Secondly, 
establishment of serum collection protocols in clinical situations is straightforward, as 
taking blood is routine, ensuring sample collection is standardised and reproducible 
and acquiring control material is likewise relatively straightforward. Finally, many 
diagnostic tests for diseases are ultimately earned out on patient’s blood; therefore, it 
is in the interest of a researcher to study proteins detectable in patient’s blood.
Literature has been published putting forth candidate biomarkers identified from cell 
culture studies utilising cell lines of a given cancer generated from a single cell 
isolated from cancer patient, such as breast cancer, hepatocellular carcinoma and 
colorectal cancer, (Kulasingam and Diamandis, 2007; Ou et al., 2008; Srisomsap et 
al., 2010; Xu et al., 2010; Xue et al., 2010). While this may be relevant in the context 
of cancer, the nature of osteoporosis is such that multiple cell types; osteocytes, 
osteoclasts, osteoblasts, are involved in an inteiplay resulting in reduced bone mass 
and a deterioration of bone quality. This inteiplay would be difficult to replicate in 
vitro.
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Candidate biomarkers have also been identified by analysis of the affected tissue, 
again frequently in relation to cancers such as oesophageal cancer, prostate cancer and 
ovarian cancer (Paweletz et al., 2000; Jones et al., 2002; Kim et al., 2002; Ikenberg et 
al., 2010). With regard to bone disease, difficulties are again encountered, with regard 
to attaining samples of both the affected tissue and adequate control material. 
Following fracture of the proximal femur, to replace the head of the femur means that 
prosthesis is put in place of the femoral head. This material is ordinarily discarded, 
however, through collaboration with St. James’s Hospital this laboratory has had 
access to this material. However, as bone biopsies are not performed without due 
cause, available disease control material is only in the form of femoral heads 
ordinarily discarded following total hip arthroplasty carried out on osteoarthritic 
individuals, and so is not in the form of healthy bone. Animal models of disease are 
often useful means of studying a disease and candidate biomarkers have been 
identified in small animal models of breast cancer, cholestasis and preterm labour 
(Whiteaker et al., 2007; Ishihara et al., 2009; Yang el al., 2009). Indeed, differentially 
expressed proteins have been identified in whole bone extract of ovariectomised rats 
(Pastorelli et al., 2005). However, the relevance of small animal models of osteopenia 
and osteoporosis is questionable. Rat bones do not contain Haversian systems as are 
found in larger mammals. An ovine model of high bone turnover has been used in this 
laboratory to successfully study aspects of bone quality such as microarchitecture and 
bone strength (Kennedy et al., 2008; Brennan et al., 2009). However, ovine material 
does not lend itself easily to proteomic analysis due to the lack of commercially 
available antibodies raised against sheep proteins that would be required in order to 
carry out preliminary candidate validation experiments.
Consequently, patient’s blood was chosen for the purpose of identifying novel 
biomarkers of osteoporosis in this study. Our clinical collaborators at St James’ 
Hospital routinely take serum, rather than plasma, for clinical tests. In the interests of 
ensuring reproducibility of sample procurement it was decided that serum would 
therefore be used in analysis in the following studies. It should be noted that this is in
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contrast to the findings of the Human Proteome Organisation’s (HUPO) working 
group on biomarker discovery which recommended that plasma be utilised in 
biomarker studies (Omenn, 2004). In this study, three Clinical Nurse Specialists were 
involved in taking patient samples. In any biomarker study it is important to ensure 
that samples are taken in the same way as the introduction of a new procedure may 
introduce variability in the manner in which samples were taken, possibly introducing 
variation in the samples themselves as a result. Therefore, with a view to reducing 
overall variability, serum was chosen for analysis in our studies.
However, there are difficulties associated with analysing serum in a biomarker 
context; the huge dynamic range of concentration of proteins, covering ten orders of 
magnitude, and a small number of proteins which dominate a large portion of the total 
protein content (Anderson and Anderson, 2002; Tirumalai et al., 2003). These 
abundant proteins can mask the presence of low abundance proteins, amongst which 
are candidate biomarkers. Therefore, a serum depletion strategy is commonly 
implemented in order to remove abundant proteins and increase the number of 
proteins detected, thereby increasing the likelihood of identifying candidate 
biomarkers (Bjorhall et al., 2005; Gong et al., 2006; Byrne et al., 2008; Andersen et 
al., 2010).
There are numerous approaches to depleting abundant proteins from serum/plasma: 
dye-ligand based technology (Cibacron-blue) (Ahmed et al., 2003; Zolotarjova et al.,
2005), precipitation methods for albumin and immunoglobulin (Ig) G (Chen et al., 
2005; Fu et al., 2005; Warder et al., 2009), binding by bacterial protein A/G 
(Fountoulakis et al., 2004; Jmeian and El Rassi, 2009). As mentioned in Chapter 1, 
these methods have been evaluated in the past and have been shown to have the 
potential to introduce unwanted variability into subsequent down-stream analysis.
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.Antibody based technology, in spin-column and HPLC format, represent a specific 
manner for removing proteins from biofluids (Pieper et al., 2003; Yocum et al., 2005; 
Qian et al., 2008).
IgY antibodies are avian, produced in chicken yolk, and display reduced non-specific 
binding compared with IgG antibodies (Huang et al., 2005) and are the subject of a 
number of publications (Fujii et al., 2008; Comunale et al., 2009). In the current 
study, spin column versions were chosen over HPLC columns due to the high initial 
outlay costs of the HPLC column and the ease of use of spin column technology. 
Proteome partitioning technology was developed by Genway to remove 12 primate 
proteins from biofluids and the column has subsequently been developed to remove a 
further 2 proteins (Figure 2.1, Table 2.1).
Figure
W W W .
Serum or plasma is applied to the IgY column and abundant proteins allowed to bind. 
Depleted serum is eluted from the column; bound proteins are incubated with a low 
pH buffer releasing the bound proteins enabling the column to be used to deplete 
subsequent samples.
IgY-Beads
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2.1: Schematic of IgY serum depletion work flow.
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Table 2.1: List of abundant primate proteins bound by IgY columns.
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• To assess the efficiency of depletion of abundant proteins from human serum 
in IgY Spin Column technology using SDS PAGE, 2DE and LC-MS
• To determine its suitability as a preparative technique for 2D D1GE analysis 
for candidate biomarker discovery in postmenopausal osteoporosis.
2.1.1 Aims
The aims of this study were:
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2.2 M ate r ia ls  an d  m eth od s
2.2.1 Serum samples
Blood from four healthy volunteers was collected in Vacutainer tubes without 
additive, allowed to clot at room temperature for 30 min then centrifuged at 2,000 g 
for 15 min. Serum was removed, aliquoted and frozen at -80°C.
2.2.2 Depletion columns
Abundant proteins were removed from serum using the Beckman Coulter IgY12 Spin 
Column (Phenomenexx, Cheshire, England). This column contains IgY antibodies 
against albumin, IgG, fibrinogen, transferrin, IgA, IgM, apolipoprotein A-I and II, 
haptoglobin, a l antitrypsin, a l acidglycoprotein, and a2 macroglobulin. The Seppro® 
lgY14 Spin Column (Sigma-Aldrich, Arklow, Co Wicklow) was also used in this 
study. This column removes 2 proteins in addition to the 12 listed apolipoprotein B 
and complement C3 (Table 2.1)
As these columns have a limited lifetime, 100 depletion cycles each, additional 
columns were required in order to complete these studies. However, during the course 
of optimisation studies the IgY12 Spin Column was replaced by the IgY14 Spin 
Column.
2.2.3 Depletion procedure
Serum was diluted 1:50 with dilution buffer (tris buffered saline pH 7.4) (supplied 
with columns) and filtered using Costar Spin-X centrifuge tubes 0.45^m pore size. 
Filtered diluted serum was applied to the spin column, and incubated at room 
temperature for 15 min. Depleted serum was eluted by centrifugation for 30 seconds 
at 2,000 g. Depleted serum was retained and acetone precipitated (see 2.2.4 Acetone 
precipitation). Spin columns were then washed 3 times with dilution buffer.
Abundant proteins were stripped from the spin columns by 4 steps of incubation in 
stripping buffer (1M glycine-HCl pH2.5) (supplied with columns), followed by 
centrifugation for a total of no more than 15 min. Spin Columns were then 
immediately regenerated with neutralizing buffer (1M tris-HCl pH8) (supplied with
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columns) incubated for 5 min followed by centrifugation. Dilution buffer was then 
added to the columns to enable the subsequent depletion cycle.
2.2.4 Acetone precipitation
Depleted serum was acetone precipitated using 4 volumes ice-cold acetone overnight 
at -20°C. Acetone precipitated samples were pelleted at 13,000 g  for 10 min at 4°C. 
Acetone was pipette off and pellets were air-dried for no more than 5 min, and frozen 
at -80°C until required. Pellets were resuspended in sample buffer (9.5 M Urea (USB, 
High Wycombe, UK), 2% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-l- 
propanesulfonate (CHAPS) (USB), 0.8% Pharmalyte (v/v) (GE Healthcare, 
Buckinghamshire, England), 1% DTT (w/v) (USB)). Crude serum was also subject to 
acetone precipitation.
2.2.5 Protein quantification
Protein quantification was earned out using a modified Bradford assay. This assay 
utilises 0.1M HC1 to account for interference in colour development by constituents of 
the sample buffer, notably urea and CHAPS. Concentrated Bradford dye (Biorad, 
Hertfordshire, England) was diluted 1:5, 3.5 ml of this added in cuvettes to 10p,l 
sample, 1 Ojj.1 sample buffer and 10 |rl 0.1M HC1 and absorbance read at 595nm. 
Bovine serum albumin (BSA) (Sigma-Aldrich) was used to generate standard curve.
2.2.6 Electrophoresis
2.2.6.1 Sodium dodecyl sulphate polyacrylamide gel electrophoreis (SDS 
PAGE)
Atto mini gel vertical apparatus was used to run 4% (w/v) stacking gel, 10% (w/v) 
resolving gel under 20mA current per gel.
2.2.6.2 2D electrophoresis
Protein was passively rehydrated on IPG strips (GE Healthcare) overnight using pH 
interval 4-7. IEF was carried out on IPGphor apparatus (GE Healthcare) for a total of 
9 kVolt hours (7cm IPG strips) or 80 kVolt hours (24cm IPG strips). IPG strips were
6 7
equilibrated for SDS PAGE using 6M urea (USB), 50 mM tris HC1 pH 8.8, 30% (v/v) 
glycerol (USB), 2% (w/v) SDS (USB) and adding 1% (w/v) DTT (USB) for the first 
equilibration and 2.5 % (w/v) iodoacetamide (USB) for the second equilibration. IPG 
strips were applied to 12% (w/v) acrylamide gels and run at 20mA per gel (10x8 cm 
gels) or 1 W per gel (24x20 cm gels).
2.2.7 Gel staining
Gels were stained with either Plus One Silver staining (GE Healthcare) or Simply Blue 
Coomassie stain (Invitrogen, Dublin) following SDS PAGE. Gel Code Blue 
Coomassie stain (Invitrogen) was used as per manufacturer’s instructions. Gels were 
scanned using the Biorad GS-800 Calibrated Densitometer scanner and analysed using 
Quantity One software.
2.2.8 Excision of gel bands and processing for mass spectrometry
Serum proteins bound by IgY Spin Columns were eluted from the column as described
in section 2.2.3. Forty micrograms of the bound abundant proteins were subject to 
SDS PAGE as outlined by 2.2.6.1 and Coomassie stained as outlined in 2.2.7. 
Coomassie stained SDS PAGE bands were excised using a disposable scapel in a dust- 
free hood. A single gel lane was divided into 8 gel slices. Gel slices were destained in 
50% (v/v) acetonitrile, digested overnight with trypsin (Medical Supply Company, 
Dublin) diluted 1:100 in 25mM ammonium bicarbonate (Sigma-Aldrich). Digested 
peptides were extracted in 70% (v/v) acetonitrile/1% (v/v) formic acid.
2.2.9 Liquid chromatography mass spectromctry (LC-MS)
Digested peptides were run on a Thermo Scientific LTQ ORBITRAP XL mass 
spectrometer connected to a Dionex Ultimate 3000 (RSLCnano) chromatography 
system. Tryptic peptides were resuspended in 0.1% (v/v) formic acid. Each sample 
was loaded onto a Dionex C18 Pepmap (0.075mm I.D. 150mm length)/ Biobasic C18 
Picofrit™ column (100 mm length, 75 mm ID) and was separated by an increasing 
acetonitrile gradient, using a 30 min reverse phase gradient at a flow rate of 30 nL 
min"1. The mass spectrometer was operated in positive ion mode with a capillary 
temperature of 200 °C, a capillary voltage of 9V, a tube lens voltage of 100V and with
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a potential of 1800V applied to the frit. All data were acquired with the mass 
spectrometer operating in automatic data dependent switching mode. A high resolution 
MS scan (300-2000 Dalton) was performed using the Orbitrap to select the 7 most 
intense ions prior to MS/MS analysis using the ion trap. TurboSEQUEST (Bioworks 
Browser 3.3.1 SP1; Thermo Finnigan, UK) searching the Human subset of the Uniprot 
Swiss-Prot database for peptides cleaved with trypsin. Each peptide used for protein 
identification met specific SEQUEST parameters, i.e. a cross-correlation values of 
>1.9, >2.5, >3.2 and >3.2 for single-, double-, triple- and quadruple-charged peptides, 
respectively, and a peptide probability of p<0.001.
6 9
2.3 . R e su lts
The protein assay used in these studies was modified to account for the basic nature of 
the sample buffer in which the acetone precipitated proteins were resuspended. 
Accurate protein quantification is particularly important in the context of 2D DIGE 
analysis, for correct labelling of samples by Cy™ dyes and subsequent comparison of 
samples in analysing data generated by a 2D DIGE study. Figure 2.2 is a 
representative plot of the standard curves generated for the protein quantitiation assay. 
Standard curves with an R2 value less than 0.95 were not utilised for protein 
quantitiation.
2.3.1 Protein quantitation assays
Figure 2.2: Sample standard curve generated by Modified Bradford protein assay. 
Bovine Serum Albumin was used as standard. Absorbance was read at 595nm.
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Initial results following the manufacturer’s instructions for both IgY12 and IgY14 
columns showed sub-optimal removal of abundant proteins. Figure 2.3A Lane 3 
shows eluted depleted serum having applied 20\il of serum to the IgY 12 Spin Column 
showing a significant band of protein at the molecular weight of albumin. Further, the 
binding efficiency of the IgY12 Spin Column deteriorated over time. Figure 2.3B 
shows no visible difference between untreated serum (Lane 1) and 20f.il serum applied 
to the IgY12 Spin Column after 50 depletion cycles following the manufacturer’s 
instructions (Lane 2). To demonstrate that the Spin Columns were saturated with 
bound abundant protein, we performed several cycles where no sample was applied to 
the IgY12 Spin Column. Figure 2.3C shows protein eluted from the column 
consistent with a molecular weight of albumin, pointing to incomplete removal of 
protein from the Spin Column during the stripping phase of the previous depletion 
cycles (Lanes 1-4). Figure 2.4A shows SDS PAGE of protein eluted from the IgY 14 
Spin Column depleted once and depleted twice. 20f.il serum was treated once (Lane 1) 
and 20|xl of an identical sample was treated twice (Lane 2). The sample treated twice 
shows a reduced band of protein at the molecular weight of albumin compared with 
the same sample treated once with the IgY12 Spin Column. An increase in high 
molecular weight proteins is observed in Figure 2.4A lane 2; after removal of the 
uppermost abundant proteins, the next most abundant proteins include a number of 
complement proteins that have a molecular weight of ~121.15 kDa. Additionally, 
other high molecular weight proteins are included in the next most abundant proteins; 
factor H (405.47 kDa), ceruloplasmin (218.27 kDa), IgD heavy chain (440.46 kDa) 
retinol binding protein (385.17 kDa) and thyroxin binding protein (785.86). All of 
these proteins contribute to the observed increase in high molecular weight bands. 
Figure 2.4B shows the effect of varying the starting volume of serum using the IgY14 
Spin Column in SDS PAGE. The arrow indicates a band at molecular weight of 
albumin. A strong band of staining at the molecular weight of albumin is visible in the 
following samples: crude (Lane 1), 20)il depleted once (Lane 2), and 15j.il depleted 
once (Lane 3). The 20fj.l depleted twice sample (Lane 6) shows the best depletion of 
abundant proteins.These results point to saturation of the antibody binding sites when
2.3.2 Depletion of abundant serum  proteins by IgY  Spin Colum ns
7 1
applying the protocol supplied by the manufacturer, resulting in abundant proteins 










C ru d e
2
B o u n d
3
D e p le te d
k D a
1
C ru d e
2
D e p le te d
1 2 
C1 C 2  
c y c le  1
3  4
C1 C 2  
c y c le  2
5  6
C1 C 2  
c y c le  3
7  0
C1 C 2  
c y c le  4
9 10
C1 C 2  
c y c le  5
Figure 2.3: IgY12 Spin Column performance analysed by SD S P A G E .
A. SDS PAGE of crude serum, proteins bound, and depleted serum eluted from the 
IgY 12 Spin Column. Starting volume of serum before depletion was 20fil. 40|ig 
protein was loaded in each lane. Arrow indicates band of protein with a molecular 
weight consistent with that of albumin in the eluted depleted serum. B. SDS PAGE of 
crude serum and serum eluted from the column after 50 uses (A. and B. Coomassie 
stained (Invitrogen)). C. SDS PAGE of protein eluted from Beckman Coulter IgY 12 
Spin Column following ‘buffer only’ runs. Band shown is consistent with the 
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Figure 2.4: IgY14 Spin Column performance analysed by SDS PAGE.
A. SDS PAGE of proteins from normal serum eluted from IgY12 Spin Column. 20(4.1 
serum was treated once and 20(4.1 of an identical sample was treated twice (Coomassie 
stained (Invitrogen)). B. SDS PAGE showing the effect of varying starting volume of 
serum using the IgY14 Spin Column. Arrow indicates band at molecular weight of 
albumin. Albumin is visible at a high concentration in crude sample, 20(4.1 depleted 
once, and 15(4,1 depleted once samples. lOug protein was loaded in each lane 
(Coomassie stained (Invitrogen)).
2.3.3 2DE analysis
Initial 2DE experiments were carried out utilising small scale gels; 7cm IPG strips, 
this was due to the low capacity of the IgY12 Spin Column. A maximum of 20j_il of 
serum can be processed in each Spin Column at one time thus limiting the amount of 
depleted protein available for subsequent analysis. Figure 2.5A shows 2DE of serum 
samples before and after treatment with the IgY12 Spin Column. Untreated, 20 |il 
depleted once and 20^1 depleted twice serum samples were subject to 2DE using 7cm 
IPG strips pH 4-7. Little difference is visible between the untreated serum and serum 
treated once, indicative of abundant proteins being eluted, unbound, from the IgY12 
Spin Column. A second application of a 20(4.1 sample to the column reveals a markedly 
different 2DE gel image, indicative of the further removal of abundant proteins during 
the second cycle of depletion. A similar trend is observed using the IgY14 Spin 
Column in 2DE experiments. 50 ¡ig protein was loaded onto 24 cm IPG strips.
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Depletion once with 10p.l serum shows good removal of abundant proteins and good 
resolution of lower abundant proteins in comparison with the untreated serum, 
however, some albumin is still visible, as are IgG light chains. 2DE analysis of 
samples depleted twice shows no albumin and a further reduction in the amount of 
IgG light chains, compared with those depleted once. Further, resolution of higher 
molecular weight proteins is enhanced in the twice depleted gel compared with a 
single depletion (Figure 2.5B). These results, consistent with SDS PAGE results, 
indicate that a reduction in the starting volume of human serum produces an 
improvement in the resolution of proteins detected by 2DE.
In order to assess non-specific removal of proteins by the IgY Spin Columns the 
bound fractions of both columns were analysed. Figure 2.6 shows human serum 
proteins bound by the column, subsequently stripped from the column and subject to 
2DE and silver staining. Proteins were matched by eye comparing with the 2DE of 
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Figure 2.5: IgY12 and IgY14 Spin Column performance by 2DE.
A. Silver stained 2DE of serum samples IgY12 treated: lOpg protein loaded onto each 
7cm IPG strip pH 4-7.
B. Silver stained 2DE of serum samples IgY14 treated: 50pg protein loaded onto 24 
cm IPG strips pH 4-7.
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Figure 2.6: Analysis of proteins bound by lgY12 and IgY14 by 2DE.
Bound proteins eluted from IgY Spin Columns. Human serum was applied to the IgY 
Spin Columns, flow through retained and bound proteins stripped from the column 
and 150 pg subject to 2DE, on 24cm IPG strip ph 4-7 and silver stained. Proteins 
were identified by eye comparing to 2DE image of human plasma available on 
SWISS-2DPAGE Viewer on the ExPASy Proteomics Server, http ://expasy.org/swiss- 
2dpage/viewer
A. Human serum proteins bound by IgY 12 Spin Column
B. Human serum proteins bound by IgY 14 Spin Column
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2.3.4 Mass spectrometry analysis of serum proteins bound by IgY Spin 
Columns
LC-MS was used to confirm the identities of proteins bound by both IgY Spin 
Columns and to ascertain if any proteins were non-specifically removed.
Human serum proteins stripped from the columns were subject to SDS PAGE, 
Coomassie stained, bands excised and trypsin digested and analysed using the Thermo 
Scientific LTQ ORBITRAP XL mass spectrometer. Table 2.2 shows identifications 
with a confidence interval of >99%.
Fibrinogen was not identified by LC-MS, anti-fibrinogen antibodies are included in 
both columns, however, fibrinogen is present in plasma but not serum, and therefore 
its identification was not expected. Of the proteins bound by the IgY 12 column, 7 of 
the 12 proteins listed were identified. The remaining unidentified proteins were: 
apolipoprotein All and a l acidglycoprotein, a l antitrypsin and IgA. Similarly, only 10 
of listed proteins bound by the IgY14 column were identified by LC-MS (C.I.>99%). 
The unidentified proteins were: apolipoprotein All, apolipoprotein B and complement
C.
Some non-target proteins were identified by LC-MS (Table 2.2). Proteins non- 
specifically removed by the IgY12 column were cytochrome C and haptoglobin- 
related protein, representing 4.06% and 7.20% of the total protein content positively 
identified by LC-MS. Non-specifically removed by the IgY14 column were filaggrin 
(0.10% of total protein content positively identified), polymeric immunoglobulin 
receptor (0.95%), statherin (1.57%), dermcidin (0.05%), haptoglobin-related protein 
(0.22%), heat shock protein beta-1 (0.01%), homerin (0.04%) and glial fibrillary 
acidic protein (0.08%).
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Table 2.2: Mass Spectrometry results identifying proteins bound by Ig Y  Spin Columns.
LC-MS/MS results identifying serum proteins bound by the lgY12 Spin Column (A) and the Seppro® IgY14 Spin Column 
(B). The bound proteins were subject to 1D SDS PAGE, Coomassie stained, bands of protein excised, trypsin digested and 
analysed by LC-MS/MS. Non-specifically bound proteins are highlighted in bold. *% Peak Area is used as a measure of 
protein quantity. Mass spectra of proteins with a single identification are shown in Appendix 1.
A








IGHG1 lg gamma-1 chain C 36083.2 P01857 2 20.16 1.83E-10 8.79 2.17
ALB Serum albumin 69321.6 P02768 11 1110.23 7.38E-10 16.09 53.55
IGLV2-14 lg lamba-1 chain C 11340.6 P0CG04 1 10.23 2.33E-10 14.15 2.88
APOA1 Apolipoprotein A-1 30758.9 P02647 2 20.17 3.74E-09 9.36 5.22
CYCS Cytochrome c 11741.1 P99999 1 10.14 5.01 E-08 10.48 4.06
IGKC lg kappa chain C region 11601.7 P01834 1 10.25 1.64E-07 18.87 2.99
A2M Alpha-2-macroglobulin 163188.3 P01023 3 30.17 1.90E-07 2.44 2.46
IGHM lg mu chain C region 49275.6 P01871 1 10.19 1.92E-07 2.65 1.30
HPR Haptoglobin-related protein 390004.7 P000739 3 28.18 8.71 E-06 7.18 7.20
TF Serotransfemn 76999.7 P02787 3 30.14 1.36E-06 4.15 4.52
HP Haptoglobin 45176.6 P00738 3 30.17 2.73E-05 7.88 9.50
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ALB Serum albumin 69321.6 P02768 71 180.25 7.69E-12 24.96 35.52
A2M Alpha-2-macroglobulin 163188.3 P01023 17 120.23 2.58E-11 10.04 1.21
TF Serotransferrin 76999.7 P02787 13 80.20 2.28E-08 11.60 1.97
APOA1 Apolipoprotein A-l 30758.9 P02647 7 60.19 8.14E-10 28.84 0.54
FLG Filaggrin 434921.4 P20930 3 30.27 1.43E-06 2.22 0.10
SERPINA1 Alpha-1-antitrypsin 46707.1 P01009 6 30.26 1.08E-10 11.72 0.45
IGHM Ig mu chain C region 49275.6 P01871 6 30.20 1.28E-09 10.18 2.85
IGHA1 Ig alpha-1 chain C region 37630.7 P01876 9 30.19 1.29E-11 11.90 1.03
IGHG1 Ig gamma-1 chain C region 36083.2 P01857 8 30.17 2.03E-13 13.03 1.63
HP Haptoglobin 45176.6 P00738 6 30.16 6.89E-07 8.13 0.42
PIGR Polymeric immunoglobulin receptor 83231.7 P01833 3 20.23 1.44E-10 4.71 0.95
STATH Statherin 7299.7 P02808 3 20.22 2.03E-08 54.84 1.57
DCD Dermcidin 11276.8 P81605 4 20.17 1.87E-06 20.00 0.05
HPR Haptoglobin-related protein 390004.7 P00739 4 18.16 7.58E-06 7.47 0.22
HSPB1 Heat shock protein beta-1 22768.5 P04792 1 10.22 4.71E-10 8.29 0.01
HRNR Hornerin 282225.7 Q86YZ3 2 10.18 1.34E-10 2.67 0.04
LPA Apolipoprotein (a) 500996.4 P08519 1 10.15 7.10E-05 6.82 0.13
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ORMI Alpha-1-acid glycoprotein 1 23496.8 P027063 1 10.13 3.72E-05 3.98 0.05
GFAP Glial fibrillary acidic protein 49849.7 P14136 1 8.15 3.81 E-06 2.55 0.08
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Spin Column technologies offer a relatively inexpensive and straightforward method 
for the removal of abundant proteins from serum and plasma and are the subject o f a 
number o f publications (de Roos et al., 2008; Andersen et al., 2010; Polaskova et al., 
2010). Further, Spin Column technology has been used with other biological fluids 
such as cerebrospinal fluid and amniotic fluid to reduce sample complexity (Ogata et 
al., 2005; Alam et al., 2010; Wetterhall et al., 2010). However, this study shows 
insufficiencies with the Spin Column format o f two generations of IgY serum 
depletion columns. Specifically, the insufficient removal o f albumin from healthy 
human serum as shown by SDS PAGE and 2DE (Figure 2.3, Figure 2.4, Figure 2.5). 
As the columns purport to remove a number of proteins, this inadequate removal of 
albumin is taken as indicative of overall poor performance of the column when the 
manufacturer’s instructions are followed. However, modification o f the given 
protocol produced much improved results by SDS PAGE and 2DE (Figure 2.4, 
Figure 2.5).
Initially, a significant amount o f albumin was not removed by the IgY 12 Spin 
Column as visible in Figure 2.3A. Further, the ability of the column to remove 
albumin deteriorated over time (Figure 2.3B) and significant amounts of albumin 
were eluted on completion of ‘buffer only’ runs where no sample was loaded (Figure 
2.3C). These issues were addressed with the re-application of depleted serum to 
further remove abundant proteins (Figure 2.4) and by the use of ‘buffer only’ runs 
between samples to remove any remaining bound protein not removed during the 
stripping phase o f the depletion cycle.
This study indicates that the stated manufacturer capacity o f the column for human 
serum (20|ol) is too high. Although reducing the starting volume of serum to 1 Ojal 
improves the resolution of the proteins in the resulting depleted serum by SDS 
PAGE and 2DE, albumin is still visible by 2DE. This is not the case when 20\x\ of
2.4 D iscussion
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human serum is treated twice. The reason for the difference noted between 10pl 
treated once by IgY14 and 20[il treated twice by IgY14 is uncertain. However, it is 
clear that 20(il treated twice produces depleted serum that may prove suitable for 
subsequent analysis by 2D DIGE in a biomarker context.
LC-MS analysis identified 7 of the 12 proteins bound by the IgY12 column (Table 
2.2). As serum samples, and not plasma samples were used, fibrinogen was not 
expected in this analysis. Five proteins whose corresponding antibodies are 
contained in the IgY12 column were not identified. It is unclear as to why this is 
the case; however, a2 acid glycoprotein not identified by LC-MS was visible in 2DE 
of the fraction bound by both IgY Spin Columns (Figure 2.6). Similarly, LC-MS 
analysis identified 10 of the 14 proteins bound by the IgY 14 column; of the proteins 
not identified many are visible by 2DE, namely apolipoprotein All, complement C 
and a2 acid glycoprotein (Figure 2.6).
It is important to note that the bound protein subject to LC-MS/MS was processed 
by ID SDS PAGE and not 2DE. Following SDS PAGE of protein bound by the IgY 
columns a gel lane was divided into eight gel slices, digested and subject to LC- 
MS/MS. The use of two separate proteomic processes to identify protein bound by 
the IgY columns accounts for the disparity observed between the 2DE results and 
the LC-MS/MS results.
A number of LC-MS identifications outlined in Table 2.2 yielded percentage 
sequence coverages that were low relative to the protein’s entire sequence. However, 
it should be recognised that the work in this Chapter complies with the ‘Minimum 
information about a proteomics experiment’ (MLAPE) published in Nature 
Biotechnology in 2007 (Taylor et al. 2007), compliance of which is strongly 
encoraged by journals in the field including Proteomics which the work in this 
Chapter was subsequently published.
In Figure 2.5 mini-gel 2DE images are placed in parallel with large scale 2DE gel 
images. The initial mini-gels were carried out as the amount of protein eluted in the 
depleted serum fraction was relatively small. Repeated processing of a number of
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aliquots is necessary to produce enough depleted serum for analysis by large-scale 
2DE. Figure 2.5A  and 2.5B are not intended for direct comparison between the two 
columns, but as an illustration of a similar trend between the two columns. Both 
Figure 2.5A and 2.5B show that the manufacturer’s protocol produce serum that is 
sub-optimal. However, 2DE of 20(il serum depleted twice shows good overall 
resolution and increased number of spots (Figure 2.5) consistent with that of other 
studies utilising depleted human serum (Byrne et al., 2008; Andersen et al., 2010).
This study points there being some difficulty removing bound proteins from the spin 
columns by the method provided by the manufacturer. The stripping phase works by 
the addition of a buffer with a low pH (2.5), in this environment the bond between 
the protein and binding site loosens and so the protein is removed. The technical 
support service of the company that developed the technology, Genway, informed us 
that alternative methods of stripping such as detergents, high salt buffers and high 
pH buffers were deemed to be inappropriate for use on antibody-agarose conjugate 
such as the ones contained in the spin columns utilised in this study. Therefore, the 
most appropriate approach was to treat the samples twice.
The pH interval used in the first dimension of 2DE in this study was ph 4-7. As 
discussed in Chapter 1 there is a broad range of pH intervals available for IEF, from 
pH 3 to pH 12. From a literature search it appears that while the pH intervals 3-10 or 
3-11 have the potential to resolve the broadest range of proteins, however, in 
practice pH 4-7 resolves a greater number of proteins when analysing serum or 
plasma (Omenn, 2006). Consequently, pH interval chosen for this study and the 
subsequent study in Chapter 3 was pH4-7.
Albumin non-specifically binds large numbers of proteins. Therefore, if a researcher 
wishes to remove albumin there is a risk that many low abundance proteins will be 
of interest will be removed simultaneously. This may result in proteins of interest
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from a point of view of biomarker discovery being lost and could also lead to 
unwanted variability in the study samples on subsequent down-stream analysis. LC- 
MS analysis revealed some non-specifically removed proteins. While this is of some 
concern, it is in line with previously published literature using IgY columns 
(Granger et al., 2005; Gong et al., 2006; Liu et al., 2006).
The findings presented here regarding the issue of non-specific removal of proteins 
are consistent with those of Polaskova et al. who examined the removal of non- 
specifically bound proteins in the HPLC version of the IgY 12 column and found no 
removal of additional proteins by examination of human plasma proteins stripped 
from the IgY12 column in 2DE (Polaskova et al., 2010).
In order to address the sub-optimal performance of both the IgY 12 and IgY 14 
columns, serum samples were treated twice. This approach was utilised in a 
previous study using the HPLC format of IgY-HSA (Human Serum Albumin) 
column, removing albumin solely (Hinerfeld et al., 2004). The current study shows 
that when following the manufacturer’s guidelines the column’s performance 
deteriorated over time, this is in line with findings from previous studies (Seam et 
al., 2007; de Roos et al., 2008) which found that at cycles 25 and 17 respectively, 
increased amounts of protein was being eluted in the depleted fraction. While these 
studies focused on using the column as described by the manufacturer, this study 
demonstrates that with some alteration to the given protocol suitable depleted serum 
can be produced.
However, a drawback associated with the Spin Column version of IgY depletion 
technology is its low serum capacity. This produces low quantities of resulting 
depleted serum, requiring multiple aliquots of serum to be processed for subsequent 
analysis, which is time consuming and labour intensive. An additional consideration 
is the apparent requirement of SDS PAGE analysis as a quality control step in the 
sample preparation protocol. This further increases labour requirements when 
choosing to prepare depleted serum using IgY spin column technology.
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2 .5  C o n clu sio n s
• The manufacturer’s instructions on both IgY12 and IgY14 Spin Columns 
failed to produce serum depleted to a satisfactory level for down-stream 
analysis. However, with some modification to the manufacturer’s protocol 
shown in this study; treating samples twice and introducing ‘buffer only’ 
runs between samples, abundant proteins were removed from human serum 
to a satisfactory level, with an acceptable level of non-specific removal of 
proteins.
• IgY Spin Column technology is an effective method of producing depleted 
serum suitable for subsequent proteomic analysis by 2D DIGE in the context 
o f biomarker discovery in postmenopausal osteoporosis.
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Chapter 3 Identification of differentially expressed proteins in 
postmenopausal women with osteopenia and osteoporosis using 
2D DIGE
3.1 Introduction
Postmenopausal osteoporosis poses a significant burden both on the individual 
and society in the form of fractures and their consequences. As the incidence of 
postmenopausal osteoporosis is set to increase as the worldwide population ages, 
this burden is set to increase. Therefore, the availability of inexpensive 
diagnostics will become increasingly important as the widespread scanning of 
individuals by DXA is not currently recommended.
A biomarker is a substance found in a biological sample such as blood, urine and 
cerebrospinal fluid, which is detected at a higher or lower concentration than 
normal in patients with a given disease (Atkinson et al., 2001). Biomarkers 
present themselves as having the potential to be relatively economical and high 
throughput. As most FDA approved diagnostics markers are proteins, the work in 
this thesis focused on the identification of protein candidate biomarkers of 
osteopenia and osteoporosis in postmenopausal women. The proteome in cells is 
constantly changing through its interaction with the genome and the 
environment. Proteomics is now widely used for analysing protein expression at 
the post-translational level. In addition, insights into disease pathogenesis can be 
obtained by identifying and analysing the proteins in a given disease proteome.
Two dimensional gel electrophoresis (2DE) is an efficient and versatile method 
of separating complex mixtures of proteins and is used for two main reasons; to 
identify new proteins and to measure the relative abundance of proteins between 
comparable samples. Since the first 2DE study, in its current format, was 
published in 1979 this technique has offered an insight into the protein 
expression profile of a wide range of samples. As proteins ultimately carry out 
the biological functions within organisms they are of particular interest in 
relation to disease pathogenesis. Therefore, utilising a 2DE-based approach
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presents itse lf as a suitable m ethodology for identifying protein markers o f 
osteopenia and osteoporosis.
The contribution o f gel electrophoresis, and in  particular 2 D E  and 2D  difference 
gel electrophoresis (2D  D IG E ) to biom arker discovery is apparent in  the large 
volum e o f literature published putting forth candidate m arkers o f disease, now  
num bering several thousand, with an surge o f papers in recent years (Figure 3.1). 
Candidate markers o f disease have been identified by analysing serum b y 2D  
D IG E  and include, but are not lim ited to: stomach cancer (Bones et a l., 2011), 
non-sm all ce ll lung cancer (Hoagland et a l., 2007; Rodriguez-Pineiro et a l., 
2010), head and neck squamous ce ll cancer (G ourin et a l., 2009), autoimmune 
uveitis (Zipp lies et a l., 2009), prostate cancer progression (Byrne et al., 2008), 
response to m ultiple m yelom a therapy (R ajp al et a l., 2011), pancreatic cancer 
(Y u  et a l,  2005; Rong et al., 2010), colorectal cancer (M a et a l., 2009), lung 
squamous cell carcinom a (D ow ling et a l., 2007) and breast cancer (Huang et a l.,
2006).
Figure 3.1: Research studies dealing with electrophoresis and biom arker discovery 
published between 1984 and 2004.
(Issaq and Veenstra, 2007)
A  search o f PubM ed using the phrase ‘electrophoresis and disease biom arkers’ 
identified 1853 articles from  1984 to 2006, including a surge in the number o f 
publications in  years 2003 to 2006.
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In relation to bone disease, 2DE in combination with mass spectrometry has been 
used to investigate osteonecrosis of the femoral head, osteosarcoma, 
osteoarthritis and cartilage degradation (Kang et ah, 2006; Tan et ah, 2006; Guo 
et ah, 2008; Kawai et al., 2008; Wilson et al., 2008; Wu et ah, 2008; Folio et ah, 
2009). Specifically in relation to serum and bone disease, circulating markers of 
osteonecrosis of the femoral head have been studied by Tan et al. in a cohort of 
juveniles (mean age 16.1 years). Tan et al. identified levels of 7 proteins as being 
significantly differentially expressed in juveniles with osteonecrosis of the 
femoral head compared with control in serum samples depleted of albumin prior 
to analysis by 2DE. Of these seven, four proteins were confirmed by ELISA as 
being significantly differentially expressed as compared with individuals with 
osteoarthritis, rheumatoid arthritis and individuals with fracture. These proteins 
were: tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor 
type 1 (PAI-1), [3-crosslaps and anti-p53 antibody (Tan et al., 2006). Wu et al. 
recruited an adult cohort of individuals with osteonecrosis of the femoral head 
(mean age 41.5 years) and subjected their serum samples to 2DE to identify 
circulating serum markers. Interestingly, none of the proteins identified as being 
differentially expressed overlapped with those identified by Tan et al. This may 
be due to the difference in the age profile of the study participants and a different 
pH range in the first dimension of 2DE was used in the two studies. However, it 
is important to note that Wu et al. analysed whole serum whereas Tan et al. 
utilised serum depleted of albumin. In summary, a 2DE approach offers a 
suitable platform in which to identify circulating serum markers of osteopenia 
and osteoporosis.
As mentioned in Chapter 1, 2D DIGE is a form of 2DE where proteins samples 
are labelled with fluorescent dyes prior to separation by 2DE, then scanned using 
the excitation wavelengths appropriate for the fluorescent dyes used. The main 
drawbacks associated with 2DE are gel-to-gel variation hindering the ability to 
detect real biological variation, and accurate spot matching across a set of gels 
within an experiment (Gygi et al., 2000). The use of fluorescent, spectrally 
distinct dyes to label protein samples prior to separation by 2DE allows for 
sample multiplexing or the separation of multiple samples on a single gel. An
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internal standard consists of an equal quantity of every sample in an experiment, 
insuring that every protein species is represented. This internal standard is then 
labelled with a fluorescent dye and separated by 2DE in parallel with an 
individual sample on the same gel.
By the use of an internal standard on every gel in a DIGE experiment, a user can 
normalise spot expression across a set of gels and facilitate inter- and intra- gel 
matching of individual spots thus dramatically increasing confidence in spot 
matching and quantification. The internal standard was first utilised by Alban et 
al. who demonstrated that the inclusion of an internal standard increased 
accuracy of protein quantitation (Alban et al., 2003). Further, studies by 
Friedman et al. and Knowles et al. demonstrate that the inclusion of an internal 
standard reduces the amount of variation measured, thus increasing the number 
of spots identified as being significantly differentially expressed (Knowles et al., 
2003; Friedman et al., 2004).
Therefore, by incorporating an internal standard in a DIGE experiment, the 2DE 
shortcomings of poor reproducibility and poor quantification are overcome 
(Lilley and Friedman, 2004). It also should be noted that DIGE has a wider 
range of detection, spanning four orders of magnitude, than those of traditionally 
used staining techniques such as silver stain and Coomassie, allowing for 
superior quantification of spots. A wide dynamic range is particularly important 
when analysing serum which spans ten orders of magnitude (Anderson et al., 
2004; Marouga et al., 2005).
Protein samples to be processed by 2D DIGE are minimally labelled by 
fluorescent CyDyes. Minimal labelling is so called as the ratio of dye to protein 
is deliberately kept low so that each protein is labelled with only a single 
fluorescent dye and these proteins are ultimately the only ones visualised. In 
total, only ~3-5% of the proteins present in a sample are labelled. Even if some 
proteins contain more than one dye molecule, the overall percentage of double- 
labelled proteins will be too small to be visualised and therefore will have no
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impact on subsequent analysis (Marouga et al., 2005). Proteins become 
minimally labelled with CyDyes when CyDye DIGE fluor minimal dyes 
containing an N-hydroxy succinimidyl (NHS) ester group reacts with the £- 
amino group of a lysine residue of a protein. A covalent amide bond is formed 
between the NHS ester active group of the CyDyes and the E-amino group of the 
lysine residue of a protein in a nucleophilic substitution reaction.
The fluorescent dyes used in 2D DIGE analysis react with proteins in such a way 
as not to affect the overall charge of the labelled amino acid, as any alteration 
would impact on the first dimension of separation as it depends on a protein’s 
isoelectric point; each matched set of dyes reacts with the same amino acid, has a 
similar molecular mass and distinct spectral absorption and emission 
wavelengths (Figure 3.2). The spot pattern obtained from minimal labelling is 
very similar to that of post-electrophoretic staining, such as silver staining. Thus 




5 5 0  5 7 0
400 <150
W avelen gth  (nm )
350 400 450 500 550 GOO 650 700 750
W avelen gth  (nm )
Cy5
6 4 9  6 7 0
Figure 3.2: Spectral characteristics of Cy3 and Cy5. 
www.gehealthcare.com
Excitation and emission spectra of CyDye DIGE Fluor minimal dyes Cy3 and 
Cy5 showing the excitation and emission filters. Black curve depicts excitation; 
blue curve depicts emission for each of the two dyes. The numbers at the top of 
each curve indicate the maxima. Narrow excitation and emission bands mean that 
the CyDye Fluor minimal dyes are spectrally distinct, which makes them ideal 
for multi-color detection.
Though 2D DIGE cannot resolve all proteins in a given sample such as serum, it 
is important to note that no proteomic technique can resolve all proteins in any 
proteome due to the large numbers and concentration dynamic range involved.
A range o f commercial IPG strips are available between pH 3 and 12 for use in 
the first dimension of separation. A user will select a specific pH interval 
dependent on the sample being analysed primarily and secondarily on the desired 
output of the user. The source o f a sample will have a large bearing on the pH
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interval selected. As discussed in Chapter 1, the principal of 2DE is such that 
proteins are separated on the basis of their respective isoelectric points (pi) 
firstly. Therefore, the pis of the proteins within a sample will influence IPG strip 
selection. Samples such as those containing many acidic proteins or basic 
proteins would resolve the greatest number of spots in 2DE if the appropriate pH 
range is implemented. Biofluids such as serum, whilst containing some acidic 
and basic proteins, contain many proteins with pis within the neutral range. 
Consequently, the majority of serum proteins will resolve within the pH range 4 
to 7, though many examples of studies implementing a broad range, 3 to 10 or
11, can be found in the literature. Serum can benefit from the use of a narrow 
neutral range, as greater resolution can be achieved by the use of a larger area 
over which to separate proteins in the first dimension.
Just as 2DE has evolved as a technique over the years, so has 2D DIGE. The 
platform commercialised by Amersham and subsequently purchased by GE 
Healthcare involves the use of 3 distinct fluorescent dyes. However, the Cy2 dye 
created by Amersham is regarded as a weak fluor, having a high background due 
to overlap with the spectral properties of Cy3 (Karp and Lilley, 2005). Further, it 
has been shown that the use of the combination of Cy3 and Cy5 is less variable 
and thus more reliable than the use of the 3 Cy dyes and examples of the use of 2 
way CyDye 2D DIGE experiments can now be found in the literature (Jackson el 
al., 2007; Grassl et al., 2010; Scaife et al., 2010). On these bases, a 2 way CyDye 
approach was selected for the current study.
Quantitative proteomics involves identifying candidate biomarkers by 
quantifying individual proteins showing the separation between one or more 
spots on a gel image. These spots are then compared, using a software package 
such as Progenesis SameSpots, to similar spots on different gels within the same 
study in order to quantify, differences in protein expression in disease 
progression. Progenesis differs from previous generations of 2D gel software 
packages. Software packages such as DyCyder detect spots on each individual 
gel in an experiment; spots are then quantified, normalised and matched across
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the gel set. Using Progenesis, a reference gel image of an internal standard is 
selected, all internal standard gels in an experiment are manually aligned to the 
reference gel using the warping tool, and each individual sample is then aligned 
to its internal standard. Spots are then detected and matched across all the gel 
images in the experiment. Spot volumes are subsequently calculated and 
normalised to allow for accurate quantitation between gels. Statistical analyses 
are then carried out to highlight differentially expressed spots then are excised 
from a preparative gel for subsequent identification by mass spectrometry.
3.1.1 Specific aims
• To evaluate the efficacy of 2D DIGE in identifying differentially 
expressed proteins in serum, depleted of abundant proteins, taken from 
postmenopausal women with osteopenia and osteoporosis compared with 
healthy postmenopausal women.
• To analyse data generated by 2D DIGE by bio informatics and literature 
search and highlight individual proteins for further analysis.
• To carry out preliminary validation on selected candidates.
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3.2 M ateria ls  and M ethods
3.2.1 Sample collection
Ethical approval was obtained from the Research Ethics Committee of the 
Adelaide and Meath Hospital, Dublin incorporating the National Children’s 
Hospital. Informed consent was obtained before each sample was taken. 
Participants were recruited through the Osteoporosis and Falls Unit, an outpatient 
unit of St. James’s Hospital, Dublin, Ireland. Individuals were identified by 
Registrars on the basis of DXA criteria and patient history and excluded from 
participation based on exclusion criteria outlined below. Blood samples were 
taken by a Clinical Nurse Specialist.
All participants were caucasian, subjected to dual X-ray absorptiometry (DXA), 
lateral vertebral assessment (LVA) to assess the presence of vertebral fractures, 
biochemical tests for markers of bone turnover, had no history of other bone 
metabolic disorders and were not prescribed any medication altering bone 
metabolism. Study participants had their BMD measured using a Lunar DXA 
system (GE Healthcare). This provided measurements of mineral content in
o _ _ _ _g/cm together with the T-score and Z-score. BMD was measured at the hip and 
the L1-L4 lumbar vertebrae. The World Health Organisation (WHO) 
classification system was applied, defining osteoporosis as a T score <—2.5 and 
osteopenia as -2.5 to -1 . Study participants were categorized by the lowest T- 
score of the L 1 —4 lumbar vertebrae, femoral neck, or total femur.
Serum vitamin D, parathyroid hormone (PTH), markers of bone formation 
osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP) and 
marker of bone resorption C-telopeptide of type 1 collagen (CTX) were assayed 
at the Department of Biochemistry, St James's Hospital, Dublin, Ireland.
Individuals were excluded on the basis of secondary osteoporosis, chronic 
inflammatory diseases and long-term (>6 months) prescription of corticosteroids 
as inflammation would impact on protein expression profiles and inherent 
variability may make the identification of differentially expressed proteins more
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difficult. Blood was collected in Vacutainer tubes without additives such as 
EDTA, allowed to clot at room temperature for 30 min and then centrifuged at 
2,000 g  for 15 min. Serum was removed, aliquoted and frozen at -80°C. Samples 
underwent no more than 4 freeze thaw cycles prior to analysis. PASW 18.0 
calculated the number of women required per group to achieve power (1-P) >
0.90 where a=0.05 to be 12 in order to detect a fold change of 1.3 in a spot 
between the normal group and the osteopenia group, normal group and the 
osteoporosis group and the osteopenia and osteoporosis group respectively. 
Samples, once categorised by DXA, were selected for inclusion in the 2D DIGE 
study from a larger group of available samples, matched for age to avoid 
differential expression of proteins being attributable to advancing age.
3.2.2 Serum sample depletion
Serum samples were depleted of 14 abundant proteins using Seppro IgY14 spin 
column (Sigma-Aldrich) as described in Chapter 2 section 2.2.3 and by Corrigan 
et ah, 2011. Twelve serum samples in each of the 3 groups (normal, osteopenia, 
and osteoporosis) were subject to depletion. In order to deplete enough serum for 
2D DIGE, 160 |il of each sample was depleted. Briefly, serum was diluted 1:50 
with dilution buffer (tris buffered saline pH 7.4), (supplied with columns) and 
filtered using Costar Spin-X centrifuge tubes 0.45jam pore size. Filtered diluted 
serum was applied to the Seppro IgY14 Spin Column (Sigma-Aldrich), and 
incubated at room temperature for 15 min. Depleted serum was eluted by 
centrifugation for 30 seconds at 2,000 g. Depleted serum was retained. Spin 
columns were then washed 3 times with dilution buffer. Abundant proteins were 
stripped from the spin columns by 4 steps of incubation in stripping buffer (1M 
glycine-HCl pH 2.5) (supplied with columns). Spin Columns were then 
immediately regenerated with neutralizing buffer (1M tris-HCl pH 8), (supplied 
with columns). Depleted serum was then re-applied to the column for a second 
depletion cycle. Depleted scrum was acetone precipitated using 4 volumes of ice- 
cold acetone overnight at -20°C as described in Chapter 2 section 2.2.4. Pellets 
were resuspended in DIGE sample buffer (9.5 M Urea (USB), 2% (w/v) CHAPS 
(USB) to a concentration of approximately 3mg/ml.
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3.2.3 Protein quantification
Accurate protein quantification was carried out using a modified Bradford assay 
as described in Chapter 2 section 2.2.5.
3.2.4 Preparation of CyDye stock and working solution
Lyophilised Cy3 and Cy5 (GE Healthcare) were resuspended in 
dimethylformamide (DMF) (Sigma-Aldrich) to a concentration of 1 mM to create 
a CyDye stock solution. A working solution was created from this stock by 
diluting with DMF to a concentration of 400pg/jil. This working solution was 
used to minimally label the depleted serum samples in the experiment.
3.2.6 Test labelling
In order to assess if the samples would be correctly labelled with the CyDyes test 
labelling was carried out. A single sample was minimally labelled as described in 
section 3.2.5, and subject to ID SDS PAGE (as described in Chapter 2) and 
visualised using the Typhoon 9400 Variable Mode Imager (GE Healthcare). 
Following ID separation of labelling proteins, the gel was removed from the 
glass plates and placed on the glass platen of the scanner and scanned at the 
appropriate settings.
3.2.5 Minimal labelling with CyDyes
On confirmation that the single sample had successfully labelled with CyDyes, 
all 36 depleted serum samples were individually labelled and the internal pooled 
standard was labelled. All 36 samples were labelled in one day with sample 
labelling being carried out in three groups of 12. The pH of samples was 
measured using pH indicator paper (pH 8.0-9.0) to ensure that the samples fell 
within the correct range for the CyDye labelling reaction to occur. Samples were 
labelled with Cy3 and Cy5: individual samples were labelled with Cy3 and the 
pooled standard was labelled with Cy5. The internal pooled standard was created
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by adding an equal quantity of protein from each sample into a single microtube. 
Fifty micrograms of protein were labelled with 40 pmol CyDye. Sample and dye 
were mixed, spun briefly and left on ice for 30 min in the dark. To quench the 
reaction, 1 OmM lysine was added to the labelled samples, mixed, spun briefly 
and left on ice for 10 min in the dark. An equal volume of 2x sample buffer was 
then added to each labelled sample (9.5 M Urea (USB), 2% (w/v) CHAPS 
(USB), 2% (w/v) DTT (USB), 1.6% (v/v) Pharmalyte (GE Healthcare).
3.2.7 Sample multiplexing for 2D DIGE
The analytical sample and the internal standard to be run on a single gel were 
created as follows: 50|ig of each Cy 3 labelled sample was combined with 50(.ig 
Cy5 labelled pooled standard in a microtube. The volume of the sample was then 
made up to 450 |il using rehydration buffer (8 M Urea (USB); 0.5% (w/v) 
CHAPS (USB); 0.2% (w/v) DTT (USB); 0.2% (v/v) Pharmalyte (GE 
Healthcare), vortexed briefly and spun down.
3.2.8 Isoelectric focusing and equilibration
Protein was passively rehydrated on IPG strips overnight using pH interval 4-7 
24cm IPG strips (GE Healthcare). All 36 samples were rehydrated at the same 
time. Each IPG strip was rehydrated with 50(ig Cy3 labelled individual sample 
and 50pg pooled standard. IEF was carried out on IPGphor™ apparatus (GE 
Healthcare) for a total of 84 kVolt hours using the programme outlined below in 
Table 3.1 at a constant temperature of 20 °C. All 36 IPG strips were randomised 
and then focused simultaneously using 3 IPGphor™ apparatus. Following IEF, 
IPG strips were sealed in plastic bags, covered in tin foil, randomised in groups 
of 6 and frozen at -80°C until required for SDS PAGE.
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Table 3.1: GE Healthcare IPGphor™ IEF program for 24cm IPG strips.






1 Step 3500 50 - 75000
2 Gradient 8000 50 0:10 -
3 Step 8000 50 1:00 -
4 Step 100 50 1:00 -
Total -28:00 -84000
3.2.9 SDS P A G E
IPG strips were equilibrated for SDS PAGE using 6M urea (USB), 50 mM tris 
HC1 pH 8.8, 30% (v/v) glycerol (USB), 2% (w/v) SDS (USB) and adding 1% 
(w/v) DTT (USB) for the first equilibration and 2.5 % (w/v) iodoacetamide 
(USB) for the second equilibration. IPG strips were applied to 12% (w/v) 
acrylamide gels and run at 1 W per gel (24x20 cm gels). Gels were run in groups 
of 6. For 2D DIGE, acrylamide gels were cast in low fluorescence glass plates 
and run in the Biorad Dodeca tank covered with a light-excluding cloth. 
Following SDS PAGE, gels were rinsed with distilled water, wrapped in cling 
film and kept at 4°C covered to prevent exposure to light prior to image 
acquisition.
3.2.10 Image acquisition
Gels were scanned on a Typhoon 9400 (GE Healthcare). The scanner was 
allowed to warm up and the glass scanning surface was carefully cleaned with 
ethanol and lint-free tissue prior to image acquisition. One gel was scanned at a 
time. Each gel was allowed to warm to room temperature, protected from the 
light, dried with tissue paper and then cleaned with ethanol and lint-free tissue 
paper prior to scanning.
The scanner was set to fluorescence acquisition mode using 1000 micron pixel 
size to test the photomultiplier tube (PMT) voltage settings and 100 micron pixel 
size for final scans. The focal plane was set to +3mm and laser settings were
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selected to correspond to the dyes being used. PMTs were adjusted to achieve 
intensity of 80-90000 pixels in the spot used for normalisation (the second most 
abundant spot on each gel). Gel images were generated using Image Quant TL 
(GE Healthcare).
3.2.11 Image analysis
2D DIGE images were analysed using Progenesis SameSpots V3.3 (Nonlinear 
Dynamics, Newcastle-upon-Tyne, UK). Gel images generated by Image Quant 
were cropped and uploaded to Progenesis SameSpots where they were subject to 
quality control check by Progenesis. A Cy5 labelled reference image was 
selected; images were then manually aligned to overcome the issue of image 
warping. Each internal standard image was aligned to the reference image, and 
then each individual sample image was aligned to its internal standard image. 
Approximately 25 manual vectors were inserted in order to facilitate automatic 
alignment by Progenesis SameSpots. Automatic alignment was then carried out 
by Progenesis SameSpots, a minimum of 400 automatic vectors were generated. 
Following visual inspection of alignment, automated spot detection, 
normalisation, background subtraction and spot matching were then carried out 
by Progenesis SameSpots. Following automatic detection of spots by Progenesis 
SameSpots, each spot automatically detected was visually inspected to exclude 
any artefacts mistaken as spots. Statistical reports were based on the Student’s t- 
test for paired comparisons and one-way ANOVA for comparison across three 
groups. The normalised volume of a spot was compared across the gels between 
the replicate groups and spots with a p value of <0.05 were considered for further 
investigation. Q values; false discovery rate-adjusted p values, and power were 
also considered.
3.2.12 Mass spectrometry identification of proteins
3.2.12.1 Preparative 2DE for mass spectrometry
Preparative gels were separated using 2DE and depleted serum at loadings of 
200, 400 and 600jig. Multiple samples utilised in the 2D DIGE experiment were 
pooled. Protein was passively rehydrated on IPG strips overnight using pH 
interval 4-7 24cm IPG strips (GE Healthcare). IEF was carried out on IPGphor™
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apparatus (GE Healthcare) for a total of 84 kVolt hours using the program 
outlined above (Table 3.1). IPG strips were equilibrated for SDS PAGE using 
6M urea (USB), 50 mM Tris HC1 pH 8.8, 30% (v/v) glycerol (USB), 2% (w/v) 
SDS (USB) and adding 1% (w/v) DTT (USB) for the first equilibration and 2.5 
% (w/v) iodoacetamide (USB) for the second equilibration. IPG strips were 
applied to 12% (w/v) acrylamide gels and run at 1 W per gel (24x20 cm gels).
Preparative gels were then subjected to silver staining using Plus One Silver 
Stain Kit (GE Healthcare). The reference gel utilised in the 2D DIGE study was 
also silver stained. Briefly, gels were removed from gel cassettes and fixed 
overnight in 40% (v/v) ethanol/10% (v/v) acetic acid in clean glass dishes on an 
orbital shaker. The fixing procedure was then repeated but for a period of 15 min. 
The gels were then sensitised in sensitising solution (30% (v/v) methanol, 4% 
(w/v) sodium thiosulphate, 6.8% (w/v) sodium acetate) for 30 min with agitation. 
The gels were then washed 3 times for 5 min each in ddH20 . The gels were then 
incubatcd in 0.2% (v/v) silver nitrate solution for 20 min. Gels were then washed 
twice for 1 min each in ddll20 . The gels were then developed in 2.5% (w/v) 
sodium carbonate with 0.04% (v/v) formaldehyde until the desired level of 
staining was achieved. The development process was stopped by incubating the 
gels in 1.46% (w/v) ethylenediaminetetraacetic acid (EDTA) solution for 10 
min. The gels were then washed 3 times for 5 min each in ddH20. Gel images for 
visible stain, such as silver stain, were captured using a GS-800 Calibrated 
Densitometer (BioRad) and QuantityOne software (BioRad).
3.2.12.2 Excision of spots and processing for mass spectrometry
A spot pick gel image was generated using Progenesis SameSpots, spots of 
interest being highlighted on the reference gel used in the 2D DIGE experiment. 
Spots of interest were carcfully matched by eye from the spot pick gel image to 
the preparative gels using the silver stained 2D DIGE reference gel as an 
intermediate between silver staining and Cy5 imaging, in order to be certain that 
the spot excised was the same as the spot marked on the reference gel image.
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Silver stained spots were excised in a dust-free hood on a clean transparent 
plastic bag placed over a light box. Spots of interest were cut from gels using a 
1.5mm One Touch Plus Spot Picker (Web Scientific, Cheshire, England) using a 
fresh pipette tip for each sample. The excised gel spots were placed in clean
0.5ml microtubes, covered with ddH20  and stored at 4°C until processed. Spots 
were destained in 50/j.l of a 1:1 mixture of 30mM potassium ferricyanide (Sigma- 
Aldrich) and lOOmM sodium thiosulphate (Sigma-Aldrich). Samples were 
incubated at room temperature with agitation until the gel plugs destained. The 
gel pieces were then washed 3 times in ddH^O with agitation. The gel pieces 
were then incubated in 200 |a,l 200mM ammonium bicarbonate (Sigma-Aldrich) 
for 20 min at room temperature with agitation. The gel pieces were then 
incubated in 70 pi of a 2:3 solution of 200mM ammonium bicarbonate and 
acetonitrile for 10 min at 37 °C in a themomixer. The gel pieces were spun 
briefly, supernatant discarded and gel pieces were then incubated in 70 fj.1 of 
50mM ammonium bicarbonate for 10 min at 37 °C in an Eppendorf®5 
Thermomixer. The gel pieces were spun briefly, supernatant discarded and gel 
pieces were then incubated in 70 pi acetonitrile for 10 min at 37 °C in an 
Eppendorf® Thermomixer. The gel pieces were spun briefly, supernatant 
discarded and gel pieces were then dried in a Speedivac (Eppendorf, Cambridge, 
England). The dried gel pieces were then digested overnight using freshly 
prepared trypsin digestion buffer (4 ng/pl sequencing grade trypsin (Medical 
Supply Company) in 50mM ammonium bicarbonate) at 37 °C with agitation. The 
samples were briefly spun down and the supernatant placed in clean 0.5ml 
microtubes. Digested peptides were extracted from the remaining gel pieces 
using 50 pi of 70% (v/v) acetonitrile/1% (v/v) formic acid 3 times in a sonicating 
water bath. These extracts were combined with the digest supernatant and dried 
in a Speedivac.
3.2.12.3 Liquid chromatography-mass spectrometry (LC-MS)
Digested samples were run on a Thermo Scientific LTQ ORBITRAP XL mass 
spectrometer connected to a Dionex Ultimate 3000 (RSLCnano) chromatography 
system. Tryptic peptides were resuspended in 0.1% (v/v) formic acid. Each 
sample was loaded onto a Dionex C18 Pepmap (0.075mm I.D. 150mm 
length)/Biobasic C l8 Picofrit™ column (100 mm length, 75 mm ID) and was
1 0 2
separated by an increasing acetonitrile gradient, using a 30 min reverse phase 
gradient at a flow rate of 30 nl min'1. The mass spectrometer was operated in 
positive ion mode with a capillary temperature of 200°C, a capillary voltage of 
9V, a tube lens voltage of 100V and with a potential of 1800V applied to the frit. 
All data were acquired with the mass spectrometer operating in automatic data 
dependent switching mode. A high resolution mass spectrometry scan (300-2000 
Dalton) was performed using the Orbitrap to select the 7 most intense ions prior 
to MS/MS analysis using the Ion trap. TurboSEQUEST (Bioworks Browser 3.3.1 
SP1; Thermo Finnigan, UK) searching the reviewed Homo Sapiens (Human) 
9606 data base from Uniprot Release 201111 peptides cleaved with trypsin. 
Each peptide used for protein identification met specific SEQUEST parameters,
i.e. a cross-correlation values of >1.9, >2.5, >3.2 and >3.2 for single-, double-, 
triple- and quadruple-charged peptides, respectively, and a peptide probability of 
<0.001.
3.2.13 Glial fibrillary acidic protein ELISA
Levels of glial fibrillary acidic protein (GFAP) were measured in the whole 
undepleted serum of participants in the 2D DIGE study. A commercially 
available ELISA kit purchased from Uscn Life Science (Wuhan, China) and used 
as described by the manufacturer, to measure GFAP in the undepleted serum of 
participants. Results were analysed using PASW 18.0 statistical analysis 
software by means of a one-way ANOVA with Tukey’s post hoc analysis and 
Pearson’s correlation at an alpha level of 0.05.
3.2.14 Vitronectin ELISA
Levels of vitronectin (aV(33) were measured in the whole undepleted serum of 
participants in the 2D DIGE study. A commercially available ELISA kit 
purchased from Uscn Life Science (Wuhan, China) and used as described by the 
manufacturer, to measure vitronectin in the undepleted serum of participants. 
Results were analysed using PASW 18.0 statistical analysis software by means 
of a one-way ANOVA and Tukey’s post hoc analysis.
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3.2.15 Receiver operator characteristic (ROC) curves
Receiver operator characteristic (ROC) curve was generated based on logistic 
regression from the ELISA data for GFAP and vitronectin. ROC curves were 
then used to generate the area under the curve (AUC), The accuracy of a 
diagnostic test can be measured by the area under the curve; AUC. An AUC of 1 
represents a perfect test that generates no false positives or false negatives; an 
AUC of 0.5 represents a worthless diagnostic test as the result is no better than 
that generated by chance (Fawcett, 2006).
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3 .3  R e su lts
P a t ie n t  d a ta  a r e  s u m m a r is e d  in  T a b le  3 .2  a n d  i n d i v id u a l  p a r t i c ip a n t  d a ta  a re  
a v a i l a b le  in  A p p e n d i x  2 .  P a t ie n t  d a ta  w e r e  a n a ly s e d  b y  P A S W  S t a t i s t i c s  18  f o r  
n o r m a l i t y ,  m e a n s ,  s ta n d a r d  d e v ia t i o n  a n d  A N O V A  w i t h  T u k e y ’ s  p o s t  h o c  te s t .  
N o  s t a t i s t i c a l  d i f f e r e n c e  w a s  f o u n d  in  t h e  a g e  o r  B M I  o f  t h e  p a r t i c ip a n t s  i n  th e  
t h r e e  g r o u p s .  F u r t h e r ,  n o  d i f f e r e n c e  in  m e a n  w a s  f o u n d  in  t h e  le v e ls  o f  
o s t e o c a lc in ,  C T X ,  P 1 N P ,  p a r a t h y r o id  h o r m o n e  ( P T I 1 ) ,  v i t a m i n  D  ( F ig u r e  3 . 3 ) .  
S i g n i f i c a n t  d i f f e r e n c e s  in  h e ig h t  a n d  w e i g h t  b e t w e e n  o s t e o p e n ia  a n d  o s t e o p o r o s is  
g r o u p s  w e r e  o b s e r v e d .  M e a n  v a lu e s  f o r  h i p  a n d  lu m b a r  T  s c o r e  a n d  B M D  
m e a s u r e m e n ts  w e r e  s t a t i s t i c a l l y  s i g n i f i c a n t  d i f f e r e n t  ( p < 0 . 0 0 1 )  f o r  a l l  
c o m p a r is o n s  w i t h  T u k e y ’ s p o s t  h o c  te s t  ( F ig u r e  3 . 4 ) .
3.3.1 Study participants
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Table 3.2: Summarised patient data for participants in 2D DIGE study.













Age (yrs) 61.550 (5.2) 63.283 (7.4) 67.992 (8.1)
Height (cm) 161.04(4.7) 164.23 (5.8) 157.39 (7.7)
Weight (kg) 73.22(10.1) 76.83 (12.5) 63.258 (6.9)
BMI (kg/m2) 28.3 (3.9) 28.2 (3.9) 25.3 (3.2)
Osteocalcin (OC) (|ig/l) 21.542(7.3) 24.0 (6.3) 29.325 (13.6)
C-telopeptide of type 1 collagen CTX (ng/|il) 0.30767 (0.13) .35025 (0.18) .35358 (0.18)
Procollagen Type 1 N-Terminal propeptide (P1NP) (ng/jxl) 45.225 (19.2) 51.542 (18.1) 52.325 (22.9)
Parathyroid hormone PTH (pg/jj.1) 35.458 (14.1) 41.225 (13.3) 45.000 (23.8)
Vitamin D (nmol/1) 56.00 (24.6) 34.92 (23.5) 49.17(26.6)
Serum albumin (g/I) 43.67 (0.99) 43.92 (2.61) 44.08 (2.19)
Vertebral Fx None None None
Hip T score -0.400 (0.36) -0.817(0.99) -2.217 (0.73)
Vertebral T score -0.333 (0.52) -1.467 (0.53) -3.283 (0.79)
Hip BMD (g/cm2) 0.93525 (0.06) 0.88983 (0.12) 0.72108 (0.09)
Lumbar BMD (g/cm2) 1.13958(0.06) 1.00258(0.06) 0.78767 (0.10)
Table shows summarised patient data for individuals included in 2D DIGE study. 
Patients were recruited through an outpatient clinic at St James’ Hospital subject 
to DXA scan, LVA assessment and biochemical tests for markers of bone 
turnover and levels of PTH and vitamin D. Data were normally distributed and 
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Figure 3.3: Patient data statistics for 2D DIGE study participants depicting mean age, 
height, weight, bone mass index (BMI), bone turnover marker, Vitamin D and PTH levels.
Individual patient data were grouped by DXA and subject to ANOVA analysis.
No statistically significant difference was found between the groups normal
(N=12), osteopenia (N=12) and osteoporosis (N=12) with regards to age,
parathyroid hormone levels (PTH), osteocalcin levels, vitamin D levels, C-
telopeptide of type 1 collagen levels (CTX), procollagen type 1 N-terminal
propeptide levels (P1NP), albumin or BMI. A significant difference was
observed between the osteopenia and osteoporosis group with respect to height
and weight. Figure continues overleaf.
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Figure 3.3 continued: Patient data statistics for 2D DTGE study participants depicting mean 
age, height, weight, bone mass index (BM1), bone turnover marker, Vitamin D and PTH 
levels.
Individual patient data were grouped by DXA and subject to ANOVA analysis. 
No statistically significant difference was found between the groups normal 
(N=12), osteopenia (N=12) and osteoporosis (N=12) with regards to age, 
parathyroid hormone levels (PTH), osteocalcin levels, vitamin D levels, C- 
telopeptide of type 1 collagen levels (CTX), procollagen type 1 N-terminal 
propeptide levels (P1NP), albumin or BMI. A significant difference was 
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Figure 3.4: Patient data statistics for 2D DTGE study participants depicting mean hip and 
lumbar BMD and mean hip and lumbar T score.
Individual patient data were grouped by DXA and subject to ANOVA analysis. 
Statistically significant differences was found between the groups normal, 
osteopenia and osteoporosis with regards to bone density parameters hip BMD 
(p<0.05), lumbar BMD and hip and lumbar T score (p<0.001).
3.3.2 Sam ple p re p a ra tio n  for 2D D IG E  analysis
The successful optimisation of the depletion strategy for serum samples 
described in Chapter 2 facilitated the analysis of serum protein expression 
changes in postmenopausal women with osteopenia and osteoporosis compared 
with normal by 2D DIGE. All serum samples were visually inspected prior to 
analysis to exclude any haemolysed samples. Samples were then processed to 
remove 14 abundant proteins by Seppro IgY14 Spin Column as outlined in 
Chapter 2 section 2.2.3. Depleted serum samples were then quantified by 
modified Bradford assay and subject to SDS PAGE in order to confirm adequate 
depletion of abundant proteins as described in Chapter 2 section 2.2.5 and 2.2.6.
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Samples were subject to 2D DIGE, scanned using the Typhoon 9400 scanner, 
images acquired using Image Quant, cropped and imported to Progenesis 
SameSpots as described in sections 3.2.10 and 3.2.11.
3.3.3 2D D IG E  im age analysis using Progenesis S am eSpots
Progenesis SameSpots allows for manual warping of a gel set to a reference gel 
allow accurate spot matching and quantification across an experiment. The 
reference gel selected is shown in Figure 3.5, all internal standards were aligned 
to this reference gel, in turn; each sample was aligned with its internal standard. 
Following warping and automatic detection 914 spots were automatically 
detected by Progenesis. Visual inspection of all spots confirmed 543 spots, 
excluding 371 artefacts from further analysis.
Spots that were identified as having statistically significant differential 
expression firstly had to have an ANOVA value of <0.05 across all three groups. 
The q value (false discovery rate), power and t-test values for each spot was then 
consulted. Twenty one spots were identified as having statistically significant 
differential expression based on ANOVA p<0.05, shown on Figure 3.6 and 
Figure 3.7, the data for which are summarised in Table 3.3.
Of the 21 spots identified as being differentially expressed across all 3 groups 
(Table 3.3), 6 were differentially expressed in the osteopenia group compared 
with normal (p<0.05) (Figure 3.8), 4 were differentially expressed in the 
osteoporosis group compared with normal (p<0.05) (Figure 3.9) and 18 were 
differentially expressed in the osteopenia group compared with osteoporosis 
(p<0.05) (Figure 3.10).
Thirteen spots were identified as being significantly differentially expressed in 
the osteopenia group compared with normal (p<0.05) (Figure 3.8). Eleven spots 
were identified as being significantly differentially expressed in the osteoporosis 
group compared with normal (p<0.05) (Figure 3.9). Fifty two spots were
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identified as being significantly differentially expressed in the osteopenia group 








Figure 3.5: Reference gel image utilised in the 2D DIGE study.
Fifty micrograms of serum depleted of abundant proteins using the IgY14 Spin 
Column as described in Chapter 2 section 2.2.3, was labelled with CyDye and 
subject to separation by 2DE. Following manual warping of all 2D gels in the 2D 
DIGE experiment, Progenesis SameSpots carried out automatic spot detection 
and matching across the gel set; 914 spots were automatically detected across the 
















Fifty micrograms of serum depleted of abundant proteins using the IgY14 Spin Column as described in Chapter 2 section 2.2.3, was labelled 
with CyDye and subject to separation by 2DE. Images of the gels were acquired using a Typhoon scanner and imported into Progenesis 
SameSpots. Following manual alignment, automatic spot detection, spot normalisation and quantitification were carried out. Twenty one spots 
were identified as being significantly differentially expressed across the 3 clinical cohorts (ANOVA p<0.05). These spots are marked on the 
reference gel in Figure 3.6 above. Magnified images are shown in Figure 3.7 and Appendix 3. The data for these spots are shown in Table 3.3. 
Normal N=T2, osteopenia N=12, osteoporosis N=12.
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Figure 3.7: Magnified 2D DIGE gel images of the 2 differentially expressed spots in 
depleted serum taken from postmenopausal women normal, osteopenia and osteoporosis 
subsequently identified as vitronectin (spot no. 356) and glial fibrillary acidic protein (spot 
no. 636).
Fifty micrograms of serum depleted of abundant proteins using the IgY14 Spin 
Column as described in Chapter 2, was labelled with CyDye and subject to 
separation by 2DE. Images of the gels were acquired using a Typhoon scanner 
and imported into Progenesis SameSpots. Following manual alignment, 
automatic spot detection, spot normalisation and quantitification were carried 
out. Twenty one spots were identified as being significantly differentially 
expressed across the 3 clinical cohorts (ANOVA p<0.05). Two of these spots are 
magnified in Figure 3.7 above and are circled in red. Images are representative of 
the twelve samples included in each of the three groups. These spots were 
identified by mass spectrometry as vitronectin (spot no. 356) and glial fibrillary 
acidic protein (spot no. 636). Normal N=12, osteopenia N=12, osteoporosis 
N=12. The data for these spots are shown in Table 3.3. A=normal, B=osteopenia, 
C=osteoporosis.
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Table 3.3: Data relating to differentially expressed spots indentified by Progenesis in the serum of postmenopausal women classified as normal, osteopenia 
and osteoporosis by DXA.
Spots differentially expressed with an ANOVA value of p<0.05 are highlighted in green. Twenty one spots were identified as being 








Normal V Osteopenia Normal V Osteoporosis Osteopenia V Osteoporosis
Fold change T-test (p) Fold change T-test (p) Fold change T-test (p)
238 0.0209 1.7 0.00688 0.727 -1.7 0.021 +1.3 0.284 +1.7 0.023
305 0.0178 1.4 0.00688 0.75 -1.4 0.026 1.0 0.729 +1.4 0.009
308 0.0381 1.3 0.00688 0.635 +1.1 0.249 -1.1 0.174 -1.3 0.015
310 0.009S9 1.5 0.00688 0.813 +1.3 0.064 -1.2 0.226 -1.5 0.01
323 0.00188 1.4 0.00688 0.742 +1.4 0.025 + 1.1 0.674 -1.3 0.047
333 0.042 5.4 0.00688 0.67 -5.0 0.042 +2.2 0.661 +5.0 0.029
341 0.038 1.4 0.00688 0.718 +1.0 0.566 -1.3 0.083 -1.4 0.003
347 0.0069 3.6 0.00688 0.848 -1.5 0.085 +1.9 0.224 +2.8 0.015
350 0.0268 1.7 0.00688 0.668 +1.5 0.0599 +1.7 0.010 +1.1 0.562
356 0.029 1.7 0.00688 0.708 +1.4 0.124 +1.7 0.010 +1.2 0.266
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576 0.034 1.6 0.00688 0.612 +1.2 0.215 -1.3 0.198 -1.5 0.013
583 0.043 1.4 0.00688 0.732 + 1.1 0.220 -1.2 0.190 -1.4 0.014
585 0,00911 1.4 0.00688 0.816 +1.1 0.378 -1.3 0.050 -1.4 0.004
587 0.022 1.4 0.00688 0.717 +1.2 0.145 -1.1 0.217 -1.4 0.02
636 0.0263 1.8 0.00688 0.691 +1.4 0.189 -1.2 0.141 -1.7 0.021
644 0.0398 1.6 0.00688 0.63 -1.3 0.133 +1.2 0.292 +1.6 0.017
645 0.0 KM 1.5 0.00688 0.804 +1.5 0.01 +1.5 0.018 +1.1 0.944
656 0.00178 1.9 0.00688 0.737 -1.1 0.685 +1.5 0.066 +1.7 0.027
662 0,0208 1.6 0.00688 0.737 -1.1 0.541 -1.4 0:019 -1.6 0.009
745 0.0227 1.6 0.00688 0.718 +1.6 0.021 1.0 0.658 -1.6 0.019
858 0.033 1.5 0.00688 0.733 -1.3 0.071 +1.2 0.252 +1.5 0.009
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Figure 3.8: Gel image highlighting spots differentially expressed between normal and osteopenia depleted serum samples identified by 2D DIGE.
Legend overleaf.
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Fifty micrograms of serum depleted of abundant proteins using the IgY 14 Spin Column as described in Chapter 2, was labelled with CyDye and 
subjected to separation by 2DE. Images of the gels were acquired using a Typhoon scanner and imported into Progenesis SameSpots. Following 
manual alignment, automatic spot detection, spot normalisation and quantitification were carried out. Thirteen spots were identified as being 
significantly differentially expressed in the osteopenia group compared with normal (p<0.05). Normal N=12, osteopenia N=12. These spots are 
marked on the reference gel in Figure 3.8 above. The data for these spots are shown in Table 3.3.
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Figure 3.9: Gel image highlighting spots differentially expressed between normal and osteoporosis depleted serum identified by 2D DIGE.
Legend overleaf.
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Fifty micrograms of serum depleted of abundant proteins using the IgY14 Spin Column as described in Chapter 2, was labelled with CyDye and 
subject to separation by 2DE. Images of the gels were acquired using a Typhoon scanner and imported into Progenesis SameSpots. Following 
manual alignment, automatic spot detection, spot normalisation and quantitification were carried out. Eleven spots were identified as being 
significantly differentially expressed in the osteoporosis group compared with normal (p<0.05). Normal N=12, osteoporosis N=12.These spots 
are marked on the reference gel in Figure 3.9 above. The data for these spots are shown in Table 3.3.
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Figure 3.10: Gel image highlighting spots differentially expressed between osteopenia and osteoporosis depleted serum samples identified by 2D DIGE.
Legend overleaf.
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Fifty micrograms of serum depleted of abundant proteins using the IgY14 Spin Column as described in Chapter 2, was labelled with CyDye and 
subject to separation by 2DE. Images of the gels were acquired using a Typhoon scanner and imported into Progenesis SameSpots. Following 
manual alignment, automatic spot detection, spot normalisation and quantitification were carried out. Fifty two spots were identified as being 
significantly differentially expressed in the osteopenia group compared with osteoporosis (p<0.05). Osteopenia N= 12, osteoporosis N=12.These 
spots are marked on the reference gel in Figure 3.10 above. The data for these spots are shown in Table 3.3.
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Principal component analysis (PCA) is a form of multivariate analysis offered by 
Progenesis SameSpots and allows one to investigate further relationships within 
the data. PCA analysis represents the 21 differentially expressed spots in all 36 
samples in the 2D DIGE study (Figure 3.11); normal samples are shown in pink, 
osteopenia in purple and osteoporosis in blue. This cluster analysis shows good 
separation between the osteopenia and osteoporosis groups, this is further evident 
in the fact that, of the 21 spots identified as being significantly differentially 
expressed, 18 were significantly different in the osteopenia group compared with 
osteopenia (Figure 3.10, Table 3.3). There is a less distinct separation between 
the normal group samples and the osteopenia and osteoporosis groups.
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Principal Component 1 > 35.59%
Figure 3.11: Principal component analysis of 21 differentially expressed spots identified across the three groups; normal, osteopenia, osteoporosis.
The above shows a PCA plot of the 21 spots significantly differentially expressed across the three clinical cohorts. PCA can be useful in 
determining gel outliers as it uses spot expression levels across gels to determine the principle axes of expression variation. The data is 
transformed and plotted in principle component space in order to separate gel samples according to expression variation. The above PCA plot 
shows relatively good clustering of spots. The spots represent all 36 samples in the gel set: the normal samples in pink, osteopenia samples in 
purple and osteoporosis samples in blue. A distinct separation between the osteopenia and osteoporosis samples can be seen, however the 
separation between the normal spots and the other clinical cohorts is less clear.
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3.3.4 M ass S pectro m etric  identification  of d ifferentially  expressed 
spots
Preparative gels were run using identical conditions as for the 2D DIGE gels. 
High protein loading of 200, 400 and 600 [ig depleted serum comprising of a 
pooling of samples used in the 2D DIGE experiment was used. A sensitive, Mass 
Spec compatible silver stain, Plus One Silver Stain (GE Healthcare) was utilised. 
The reference gel used in the 2D DIGE experiment was also stained. This 
facilitated the matching of silver stained spots from the Progenesis SameSpots 
output, which is based on the CyDye labelled proteins to the silver stained, high 
protein loading of the preparative gels. Spots were carefully matched by eye and 
excised from the gels. Of the 21 differentially expressed spots 3 were not visible 
by eye even on the highest loading, 600 [ig, and thus were not identified. These 3 
spots were relatively low in abundance, as measured by Progenesis and the fact 
that they were not visible by silver stain can be attributed to the difference in 
sensitivity between the two detection techniques. Liquid chromatography mass 
spectrometry was chosen to identify the differentially expressed spots as it is a 
sensitive form of mass spectrometry. Mass spectrometric data and protein 
identifications are summarised in Table 3.4. One spot, number 656, had no 
positive proteins identifications.
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Table 3.4: Mass Spectrometry data for differentially expressed spots identified by Progenesis analysis of 2D DIGE gel
The 21 spots significantly differentially expressed across the three clinical cohorts normal, osteopenia and osteoporosis were excised 
from a preparative gel, digested using trypsin, subject to analysis by liquid chromatography mass spectrometry (LC-MS) and the 
generated results searched against the Uniprot database to generate identities.
Spot
no
Protein ID Accession no. M atched
peptides
X C  score % Seq. 
coverage
Theoretical M W /p i Experim ental M W /p i
238 Com plem ent factor B P00751 7 70.20 10.21 85532.87/6.67 85478.58/6.7
305 A lp h a -1 -antichym otrypsin POTOll 2 20.15 7.33 47650.87/ 5.33 47620.63/5.2
308 Hem opexin P02790 18 180.26 41.34 51676.37/6.55 51643.3/6.6
Serum A lbum in P02768 17 170.25 37.44 69366.68/5.92 69321.6/5.8
C 4b-binding protein P04003 4 40.18 7.87 67033.19/7.15 66989.4/7.2
310 N o t identified ~ * “ ” —
'
323 V in c u lin P I 8206 1 10.20 0.51 123721.9/5.1 123799.30/5.5
333 Hem opexin P02790 9 90.24 22.73 51676.37/6.55 51643.3/6.6
341 A lp h a -1 -antichym otrypsin P01011 17 170.30 43.74 47650.87/ 5.33 47620.6/5.2
347 Serotransferrin P02787 3 30.21 11.3 77063.89/6.81 77013.67/6.75
350 Angiotensinogen P01019 8 80.24 20.4 53154.20/5.87 53120.61/5.9
1 2 6
356 V itronectin P04004 5 50.17 15.48 54305.59/ 5.55 54271.2/5.5
576 F ico lin -3 075636 2 20.17 7.69 30353.77/6.22 32882.0/6.2
583 F ico lin -2 Q 15485 2 20.18 7.30 34001.14/6.31 33979.5/6.3
585 Serum album in P02768 1 10.14 3.6 69366.68/5.92 69321.63/5.87
587 Hem opexin P02790 1 10.14 2.40 51676.37/ 6.55 51643.3/6.6
636 G lia l f ib r illa ry  acidic protein P14136 1 8.16 2.50 49880.21/5.42 49849.7/5.3
644 Apo lipopro te in  A - I P02647 8 80.17 33.70 30777.83/ 5.56 30758.9/5.5
645 Clusterin P I 0909 1 10.12 5.6 52494.58/5.89 52461.05/5.85
656 N o t identified “ “ * * ~
662 N o t identified * * “ *
745 N o t identified * “ “ “ “ “
858 N o t identified
'
“ “ “ “ *
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The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
is an online resource containing a number of bioinformatic tools that provide 
functional interpretations of lists of genes and proteins arising from genomic and 
proteomic studies. Gene ontology (GO) analysis using DAVID Functional 
Annotational tool available online at http://david.abcc.ncifcrf.gov/ revealed that a 
number of biological processes and molecular functions were altered in the 
depleted serum analysed using 2D DIGE. Using GO analysis, an insight can be 
gained into the pathogenesis of osteoporosis. The list of proteins identified by 
mass spectrometry was compared to all annotated proteins by functional 
groupings based on GO annotations. Each protein was assigned to one or more 
functional categories. A number of over-represented categories were identified; 
these contained more member proteins from the dataset than could be expected if 
the member proteins were randomly distributed among the available categories. 
This considers category bias presented within the genome as a whole. The results 
of GO analysis are graphically depicted in Figure 3.12. The largest proportion of 
differentially expressed proteins, 4 proteins each, are involved in transport and 
are transport or carrier proteins respectively. This indicates that the alteration of 




■  Transfer/carrier protein (n=4)
□ Cell-adhesion mediated signalling (n=3)
□ Cell adhesion (n=3)
■  Antibacterial response protein (n=2)
■  Defense/immunity protein (n=3)
■  Serine protease inhibitor (n=2)
□ Other transfer/camer protein (n=2)
■  Protease inhibitor (n=2)
Figure 3.12: Pie chart showing Gene Ontology functional classification of differentially 
expressed proteins identified using 2D DIGE.
Proteins identified by Progenesis SameSpots as being significantly differentially 
expressed in the serum depleted of abundant proteins taken from postmenopausal 
women classified as normal, osteopenic or osteoporotic by DXA were identified 
by liquid chromatography mass spectrometry. These proteins were then subject 
to analysis by the web-based bioinformatic tool DAVID. This programme 
classifies proteins into functional groups based on their involvement in biological 
processes as provided by the Gene Ontology framework.
3.3.5 E xpand ed  analysis o f 2D D IG E  da ta
Protein identifications were then matched to the graphical depictions of the log 
normalised value of the differentially expressed spots, generated by Progenesis 
SameSpots, depicting the expression of the identified proteins across the three 
clinical cohorts (Figure 3.13 and Figure 3.14). Of the identified proteins, 5 are 
down regulated in osteopenia relative to normal only to increase in expression so 
that they are up-regulated in osteoporosis relative to normal; complement factor 
B, a l antichymotrypsin, hemopexin, transferrin, and apolipoprotein al. Four 
proteins were up-regulated in osteopenia relative to normal, but down-regulated 
in osteoporosis compared with osteopenia, with an overall up-regulation in 
osteoporosis compared with normal; albumin, ficolin-2, ficolin-3, glial fibrillary
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acidic protein. One protein, vinculin, was up-regulated in normal compared with 
both osteopenia and osteoporosis, but down-regulated in osteoporosis compared 
with osteopenia. Three proteins had a consistent overall trend of up-regulation 
across the three clinical cohorts; clusterin, angiotensinogen and vitronectin.
A literature search using Pubmed was carried out to ascertain the function of the 
identified proteins and to discover any association of differentially expressed 
proteins with bone, osteoporosis or bone cells previously published in the 
literature. None of the proteins listed have previously been affiliated with 
postmenopausal osteoporosis. The findings of the literature search are 
summarised in Table 3.5.
Figure 3.13: Graph of normalised expression values of vitronectin in the depleted serum 
taken from postmenopausal women who are normal, osteopenic and osteoporotic analysed 
by 2D DIGE and Progenesis SameSpots and identified by mass spectrometry.
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G lia l fib r illa ry  a c id ic  
p ro te in
Normal Osteopenia Osteoporosis
Figure 3.14: Graph of normalised expression values of proteins in the depleted serum taken from postmenopausal women who are normal, osteopenic and 
osteoporotic analysed by 2D DIGE and Progenesis SameSpots and identified by mass spectrometry.
The software programme Progenesis SameSpots generated normalised graphs of significantly differentially expressed spots that were 
then matched to the protein identities produced by liquid chromatography mass spectrometry. Figure continues overleaf.
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Figure 3.14 continued: Graph of normalised expression values of proteins in the depleted serum taken from postmenopausal women who are normal, 
osteopenic and osteoporotic analysed by 2D DIGE and Progenesis SameSpots and identified by mass spectrometry.
The software programme Progenesis SameSpots generated normalised graphs of significantly differentially expressed spots that were 
then matched to the protein identities produced by liquid chromatography mass spectrometry. Figure continues overleaf.
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Figure 3.14 continued: Graph of normalised expression values of proteins in the depleted serum taken from postmenopausal women who are normal, 
osteopenic and osteoporotic analysed by 2D DIGE and Progenesis SameSpots and identified by mass spectrometry.
The software programme Progenesis SameSpots generated normalised graphs of significantly differentially expressed spots that were 
then matched to the protein identities produced by liquid chromatography mass spectrometry. Figure continues overleaf.
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Table 3.5: Known functions and associations with bone of proteins highlighted as being differentially expressed by Progenesis SameSpots and identified 
by mass spectrometry.
Protein spots highlighted by Progenesis SameSpots as being significantly differentially expressed across the three clinical cohorts and 
subsequently positively identified by liquid chromatography mass spectrometry. The identified proteins were then subject to a literature
search.
Protein Accession no. Function Relevance to  bone Reference
Com plem ent factor B P00751 Component o f  the alternative pathway o f  complem ent
activation
M a y  be invo lved  in  cartilage destruction in 
arthritis
(H ie ta la  et al., 2004; Banda
et al., 2006)
A lp h a -1 -antichym otrypsin P01011 Serum m arker o f  in flam m ation, acute phase prote in Inactivates PSA. PS A can stimulate 
osteoblast d ifferen tia tion  and OPG 
production in  v itro .
(Y onou et al., 2007)
V in c u lin P I 8206 Focal adhesion protein Recruited to adhesion contact points 
fo llo w in g  activation by av P3 b inding
(D uong et a i,  2000)
Hem opexin P02790 Acute-phase protein None
Serotransferrin P02787 Iron  transport cells to a ll p ro life ra ting  cells in  the body Unclear; transferrin transports iron, iron 
defic ient rats have low er bone density.
(Parelman et al., 2006; 
D A m e lio  et a i,  2008)
Angiotensinogen P01019 Invo lved  in m ainta in ing blood pressure and in  the 
pathogenesis o f  essential hypertension and preeclampsia
Precursor to Angiotensin I I.  A ctiva tio n  o f  
R enin-Angiotensin System induces 
osteopenia in  a mouse model independently 
o f  hypertension
(Asaba et a i ,  2009)
V itronectin  (avP3) P04004 E C M  protein promotes cell adhesion and spreading, 
inh ib its  the membrane-damaging e ffect o f  the term inal 
cy to ly tic  com plem ent pathway
V itronectin  binds oivPs receptor on surface 
o f  osteoclasts, im portant fo r osteoclast 
m igra tion  and form ation o f  resorption
sealed zone
(Nakam ura et a i ,  1999)
F ico lin -3 075636 Therm olabile  beta-2-m acroglycoprotein found in  all 
human serum
None
F ico lin -2 Q 15485 Expressed in the live r None
Serum album in P02768 Carrier protein fo r  steroids, fa tty  acids, and thyro id  
hormones and plays a role  in s tabiliz ing extracellular 
flu id  volum e
None
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G lia l f ib r illa ry  acidic 
protein
P14136 Distinguish astrocytes from  other g lia l cells Expressed by osteocytes and elastic 
cartilage
(Kasantiku l and 
Shuangshoti. 1989)
A po lipopro te in  A 4 P02647 M ajo r protein component o f  high density lipoprotein 
(H D L ) in plasma
promotes cholesterol e fflux  from  tissues to the live r
Elevated in atherosclerosis, has been linked 
osteoporosis and atherosclerosis. Required 
fo r osteoclast form ation.
(Luegm ayr et al., 2004; 
C e lilog lu  et ai., 2009)
Clusterin P I 0909 Appears to be involved in several basic b io log ica l events 
cell death, tum our progression, and neurodegenerative 
disorders.
Secreted by oncogenic hypophosphatémie 
osteomalacia tum our, cyto tox ic  i f  
overexpressed in human osteosarcoma
(Rowe et al., 2000; 
Trougakos et al. , 2005)
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3.3.6 E L IS A  analysis
3.3 .6 .1  V itro n e c tin
Vitronectin (aV(33) is a cell adhesion and spreading factor found in both serum 
and tissues. Vitronectin is recognised by members of the integrin family 
including aVp3 receptor found on the surface of osteoclasts, the blockade of 
which inhibits bone resorption (Engleman et al., 1997). Further, the presence of 
vitronectin alone is sufficient to induce resorptive behaviour by osteoclasts in 
vitro (Fuller et al., 2010). A commercially available ELISA kit was used to 
measure levels of vitronectin in whole, undepleted serum. One way ANOVA 
revealed a significant difference between the normal group (mean 23.92 |ig/ml 
(SD 4.01)) and the osteopenia (29.50 }ig/ml (SD 3.76)) (p=0.021) and 
osteoporosis groups (28.98 jig/ml (SD (4.40)) (p=0.043). No significant 
difference was noted between the osteopenia and osteoporosis groups (p=0.959) 
(Figure 3.15). Correlation and linear regression analysis was performed between 
whole serum levels of vitronectin and bone density parameters. No statistically 
significant inverse correlation was observed between whole serum levels of 
vitronectin and lumbar BMD, lumbar T score, hip BMD, hip T score, lumbar Z 
score or hip Z score. Further, correlation and linear regression analysis was 
performed between vitronectin and bone turnover markers, with no significant 
correlations noted: osteocalcin (r=-0.099, p=0.609), CTX (r=-0.202, p=0.294) 
and P1NP (r=-0.223, p=0.245).
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Figure 3.15: Whole serum level of vitronectin (ng/ml) in postmenopausal women classified 
as normal, osteopenia and osteoporosis by DXA.
The Uscn ELISA kit was used to assay vitronectin levels in whole, undepleted 
scrum in postmenopausal women from the 2D DIGE study (N=36). The results 
of the ANOVA analysis of this assay demonstrated a significant increase in the 
level of vitronectin between both the osteopenia and osteoporosis groups 
compared with normal (p<0.05). No significant difference was noted between the 
osteopenia and osteoporosis groups.
3 .3 .6 .2  G lia l f ib r i l la ry  a c id ic  p r o te in
Glial fibrillary acidic protein (GFAP) is an intermediate filament expressed 
primarily in the central nervous system (CNS) and distinguishes astrocytes from 
other glial cells. However, in addition to this it is also expressed in the cytosol of 
osteocytes (Kasantikul and Shuangshoti, 1989). On the basis that GFAP 
represented the potential to be a very specific marker it was selected as a 
candidate for further validation. A commercially available ELISA kit was used to 
measure levels of GFAP in whole, undepleted serum. One way ANOVA 
revealed a significant difference between the Normal group (mean 95.87 ng/ml 
(SD 43.1)) and the osteopenia (175.7 ng/ml (SD 47.6)) (p=0.038) and 
osteoporosis groups (175.2 ng/ml (SD (73.1)) (p=0.030). No significant 
difference was noted between the osteopenia and osteoporosis groups (p=1.0) 
(Figure 3.16). Correlation and linear regression analysis was performed between 
whole serum levels of GFAP and bone density parameters adjusted for age and 
BMI. A statistically significant inverse correlation was observed between whole 
serum levels of GFAP and lumbar T score (r=-0.530, p=0.004) (Figure 3.17A)
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and between whole serum levels of GFAP and lumbar Z score (r=-0.401, 
p=0.038) (Figure 3.17B). A correlation approaching significance was observed 
between GFAP and lumbar BMD (r=-0.371, p=0.057) (Figure 3.17C). No 
statistically significant correlation was observed between GFAP and hip BMD 
(p=0.476), hip T score (p=0.532), hip Z score (p=0.602). Further, correlation and 
linear regression analysis was performed between GFAP and bone turnover 
markers with no significant correlations noted: osteocalcin (i^O. 117, p=0.545), 
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Figure 3.16: Whole undepleted serum levels of GFAP (ng/ml) in postmenopausal women 
classified as normal, osteopenia and osteoporosis by DXA.
The Uscn ELISA kit was used to assay GFAP levels in whole, undepleted serum 
in postmenopausal women from the 2D DIGE study (N=36). This results o f the 
ANOVA analysis of this assay demonstrated a significant increase in the level of 
GFAP between both the osteopenia and osteoporosis groups compared with 
normal (p<0.05). No significant difference was noted between the osteopenia and 
osteoporosis groups.
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Figure 3.17: Correlation and linear regression analysis performed between whole serum 
GFAP (ng/ml) expression levels and lumbar bone density parameters.
Whole serum levels of GFAP were measured using a Uscn ELISA (N=36).
Correlation and linear regression analysis were then performed between GFAP
levels and bone density parameters. Correlations were adjusted for age and BMI.
Statistically significant inverse correlations were observed between whole serum
levels of GFAP and (A) lumbar T score (r=-0.530, p=0.004), (B) lumbar Z score
(r=-0.401, p=0.038). The correlation between GFAP and lumbar BMD was
relatively close to significance (C) (r=-0.371, p=0.057). No significant
correlation was observed between GFAP levels and hip BMD, hip T score, hip Z
score (data not shown).
3.3.7 R eceiver o p e ra to r  ch arac te ris tic  (R O C ) analysis
To determine the potential impact of the use of GFAP and vitronectin as
serological markers of BMD, the ELISA data for these two proteins (N=36) were 
used to generate ROC curves. The accuracy of a diagnostic test can be measured 
by the area under the curve; AUC. An AUC of 1 represents a perfect test that 
generates no false positives or false negatives; an AUC of 0.5 represents a 
worthless diagnostic test as the result is no better than that generated by chance. 
The area under the curve was determined for both proteins alone and the two 
proteins combined to ascertain which protein or proteins had the greatest power 
to identify individuals with reduced BMD. Figure 3.18 shows the AUC values
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for GFAP and vitronectin for the distinction of individuals with reduced bone 
density (osteopenia and osteoporosis combined) from Normal individuals. 
Vitronectin was found to have an AUC of 0.675, with GFAP displaying an 
improved AUC of 0.766. GFAP and vitronectin combined displayed the best 
AUC of 0.825. ROC analysis was also carried out to establish if GFAP and 
vitronectin could be utilised to distinguish between individuals with osteopenia 
from those with osteoporosis. AUC values generated were poor; vitronectin AUC 
value 0.492, GFAP AUC value 0.467, GFAP and vitronectin combined AUC 
value 0.517 (data not shown).
ROC Curve
Source of the C ure
—  GFAP and Vitronectin AUC 0.B25 
GFAP A X  0.766 
Vitronectin AUC 0.675
—  Reference Lfrie
Figure 3.18: Receiver operating characteristic curves for the identification of reduced BMD 
through protein markers.
The curves depict results using logistic regression that include GFAP and 
vitronectin alone and combined for distinguishing individuals with osteopenia 
and osteoporosis from normal individuals.
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3.4 D iscu ssio n
3.4.1 2D D IG E  as a tool fo r the  identification  of d ifferentially  
expressed  p ro te in s in  postm enopausal osteoporosis
Two dimensional gel electrophoresis has proven to be an invaluable tool in the 
analysis of complex protein samples taken from a huge variety of sources from 
entire organisms such as Drosophila to single cells isolated via laser-capture 
microdissection from formalin-fixed, paraffin-embedded sections of tissue. The 
evolution of 2D in the commercialisation of 2D DIGE represents the 
advancement of proteomic analysis that has further underlined the utility of 2DE. 
The introduction of a common internal standard run on all gels in an experiment 
eliminates the effect of gel-to-gel variation found in 2DE and leads to accurate 
spot matching between gels and more reliable spot quantification, increasing 
confidence in the data produced.
Though 2D DIGE cannot resolve all proteins in a serum sample, it is important to 
note that no single electrophoretic or chromatographic technique can resolve all 
proteins in any proteome due to the large numbers and concentration range 
involved. In the case of the blood proteome, where the concentration range of 
proteins spans ten orders of magnitude, the employment of a protein depletion 
strategy to remove the most abundant proteins is critical in reducing sample 
complexity and reducing the dynamic range of concentration. Thus, the 
development of the sample preparation protocol in Chapter 2 and subsequently 
published (Corrigan et al., 2011) was critical to the ability to utilise 2D DIGE 
successfully as it is widely accepted in the literature that good sample preparation 
is crucial to obtaining acceptable 2DE based data.
It is noteworthy that a mass spectrometry based approach has been utilised with 
the aim of identifying circulating markers of high bone turnover. Bhattacharyya 
et al. used surface enhanced laser desorption/ionisation (SELDI) to identify inter- 
alpha-trypsin inhibitor family heavy chain 4 (ITI1I4) as being differentially
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expressed in postmenopausal women with high bone turnover and low BMD 
compared with healthy women (Bhattacharyya et al., 2008). SELDI and 2DE 
differ fundamentally in their basis. The suitability of ITIH4 as a marker for low 
BMD and high bone turnover is questionable as it is also differentially expressed 
in a number of cancer diseases including breast cancer, epithelial ovarian cancer 
and germ cell ovarian carcinoma (Mohamed et al., 2008; Gast et al., 2009). The 
serum levels of ITIH4 have been shown to rise during acute phase processes, and 
thus it would seem to be inappropriate as a marker of low BMD or high bone 
turnover owing to its lack of specificity (Pineiro et al., 1999).
Whilst the employment of 2DE in relation to bone biology and bone disease has 
gained in popularity in recent years, as evident by the increase in the number of 
studies published that utilise a proteomic approach to bone biology, no study has 
been published in the literature that uses a 2DE or 2D DIGE approach to identify 
a circulating marker of osteopenia or osteoporosis, having the potential to 
develop into an inexpensive diagnostic or that provide a new insight into the 
proteome alterations occurring in postmenopausal osteoporosis on a whole body 
basis. Previous proteomic studies in this field have often focused on in vitro 
alterations of osteoblasts, osteocytes and osteoclasts. Thus, there are no studies in 
the literature with which one can compare the current study directly.
In order to determine if  2D DIGE was an appropriate tool for identifying 
differentially expressed proteins in postmenopausal women with osteopenia and 
osteoporosis compared with normal, three groups of twelve postmenopausal 
women were recruited. Their blood was drawn and serum isolated, from which 
14 abundant proteins were depleted in order to increase the number of lower 
abundance proteins resolved by 2D DIGE downstream. The use of a 
serum/plasma depletion strategy prior to analysis by 2DE or 2D DIGE is one that 
has been successfully utilised in the literature in the search for candidate 
biomarkers of a variety of diseases (Yu et al., 2005; Huang et al., 2006; Andersen 
et al., 2010; Zhao et al., 2011).
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The spots were then subjected to liquid chromatography mass spectrometry, a 
more sensitive technique than matrix assisted laser desorption/ionisation mass 
spectrometry (MALDI MS) frequently used in the literature, increasing the 
likelihood of receiving an identification and of the confidence of identifications 
received. Of the 21 spots, 17 were given protein identifications (Table 3.4).
The approach of utilising a univariate test in identifying significant changes in 
expression in 2DE studies has come under some scrutiny. This is due to the fact 
that applying an alpha level of 0.05 in an experiment where hundreds of 
statistical tests are carried will generate a number of false positives (type I errors) 
and false negatives (type II errors). However, applying corrections such as the 
familywise error rate utilised in microarray studies has been deemed 
inappropriate for some proteomic studies as it does not consider between-feature 
dependence in the data (Karp et al., 2007). Therefore, in line with this a p value 
of 0.05 was applied to the current study. Statistical analysis revealed that 21 
protein spots were significantly differentially expressed (p<0.05) across the three 
cohorts (Figure 3.6, Figure 3.7, Table 3.3). However, q values provided by 
Progenesis SameSpots were consulted in the analysis. It should be noted that the 
indicator of false discovery rate, q value, was sub-optimal at 0.00688, possibly 
owing to the inherent variation associated with analysing patient samples. In the 
case of 2D DIGE studies involving cell-line or animal models, biological 
variation is much reduced, and the resultant q value will be reflective of that 
(Karp et al., 2007). Successful isolation of significantly differentially expressed 
proteins between postmenopausal women with osteopenia and osteoporosis and 
their positive identification by mass spectrometry demonstrates that the use of 
2D DIGE is an appropriate strategy for the analysis of the depleted serum 
proteome of the three clinical cohorts.
3.4.2 P ro te ins d ifferen tially  expressed betw een th e  p a tien t g roups
Following identification of differentially expressed proteins highlighted in the 
2D DIGE study by mass spectrometry, a literature search was performed to 
assess whether any of the proteins had a role in bone, bone dynamics or bone 
disease. None of the proteins identified has previously been associated with
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postmenopausal osteopenia or osteoporosis. This finding underlines the ability of 
2D DIGE to identify novel proteins not previously associated with a given 
disorder. A synopsis of each protein’s function is given below and is also 
summarised in Table 3.5.
A number of the identified proteins are of relatively low abundance, ordinarily 
found in the cytoplasm of cells, e.g. glial fibrillary acidic protein, and would 
therefore be considered a tissue leakage protein. The positive identification of 
differentially expressed tissue leakage proteins is indicative of the successful 
reduction in the dynamic range of concentration of serum proteins by use of the 
Seppro IgY14 Spin Column, underlining the importance of its involvement in the 
2D DIGE study. Had a serum depletion strategy not been employed tissue 
leakage proteins may not have been identified. Additionally, the identification of 
a relatively low abundance protein by 2D DIGE highlights its utility as a 
sensitive proteomic technique.
Several proteins identified as being significantly differentially expressed have 
not previously been associated with bone or bone disease. These proteins were: 
alpha-1-antichymotrypsin, hemopexin, ficolin-2, ficolin-3, clusterin and 
complement factor B. The identification of these novel proteins highlights the 
utility of 2D DIGE in providing an insight into the molecular mechanisms of 
disease pathogenesis. However, it is unclear if these changes are particular to 
bone or reflective of systemic change secondary to pathogenesis of bone loss.
A number of identified proteins are relatively abundant proteins such as clusterin 
and complement factor B. These identifications are common in 2D DIGE studies 
involving serum or plasma samples isolated from patients with various diseases 
(Yu et al., 2005; Hoagland et al., 2007; Byrne et al., 2008; Rong et al., 2010). 
Synthesised by the liver, they may be part of a non-specific systemic reaction and 
potentially may be useful as markers of bone loss if used in conjunction with 
other clinical parameters.
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It is interesting to note that the rise in expression of a number of proteins in the 
normal group compared with osteopenia, followed by a drop in expression in the 
osteoporosis, and indeed the inverse, a fall and subsequent rise in expression, is 
observed as is the case with GFAP and vinculin. This fluctuation in expression 
levels may be reflective of the pathogenesis of bone loss. It has been reported in 
an ovine model of osteoporosis where ovariectomy is used to induce bone loss by 
oestrogen deficiency, that while bone turnover rises initially, it subsequently 
drops (Kennedy et al., 2008). Whilst it is difficult to draw parallels between an 
animal model and clinical cohorts, the use of an animal model provides a useful 
insight into the pathogenesis of bone loss.
This rise and fall in expression levels is observed in proteins vinculin and glial 
fibrillary acidic protein. Vinculin is a focal adhesion protein that binds to F-actin, 
anchoring it to the cell membrane and is thus involved in cell-matrix adhesion 
and cell-cell adhesion. Vinculin appears to have a role in dilated cardiomyopathy 
(Olson et al., 2002). Upon binding of avP3 receptor on the surface of osteoclasts, 
vinculin is involved in the reorganisation of the cytoplasm in order to create the 
sealed zone, allowing bone resorption to proceed (Duong et al., 2000). Glial 
fibrillary acidic protein is an intermediate filament protein located in the 
cytoplasm, used originally as a marker to distinguish astrocytes from other glial 
cells, but has subsequently been identified in other cell types; rat kidney 
glomeruli, keratinocytes, chondrocytes of elastic cartilage of the epiglottis and of 
relevance to the current study, it has been identified in the cytoplasm of 
osteocytes (Kepes andPerentes, 1988; Kasantikul and Shuangshoti, 1989; 
Buniatian et al., 1998; Danielyan et a l, 2007). Its function is unclear but has 
been linked to the neurodegenerative disorder Alexander disease (Wang et a l,
2011). Glial fibrillary acidic protein has not been previously associated with 
osteopenia or osteoporosis. It is possible that glial fibrillary acidic protein 
released from the cytoplasm of osteocytes as bone is resorbed by osteoclasts. 
Specificity is an attractive feature in a marker of disease, and both vinculin and 
glial fibrillary acidic protein would appear to be a specific marker.
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The renin-angiotensin system (RAS) plays a pivotal role in the regulation of 
blood pressure. The action of renin on angiotensinogen creates angiotensin I, 
which is inactive but is the precursor to angiotensin II, following cleavage by 
angiotensin-converting enzyme (ACE), ultimately acting as a vasoconstrictor. 
Hypertension and osteoporosis were linked in a study by Asaba et al. where a 
mouse model was used to demonstrate that activation of RAS induces high bone 
turnover and subsequent bone loss in a manner independent of hypertension 
(Asaba et al., 2009). It is therefore interesting to note angiotensinogen is 
upregulated in both osteopenia and osteoporosis compared with normal.
However, it may be the case that in the postmenopausal women recruited on to 
this study, blood pressure may be elevated. As blood pressure was not measured 
in study participated it cannot be ruled out that an elevation in angiotensinogen is 
unrelated to DXA classification.
Vitronectin is a glycoprotein found in serum and the extracellular matrix and is 
involved in cell adhesion and spreading, inhibition o f the complement pathway 
and binds to serpin serine protease inhibitors. Vitronectin has two forms; a single 
polypeptide or two polypeptides bridged by a disulphide bond. It has a role in 
haemostasis as it contains a domain that binds plasminogen activator inhibitor-1 
(PAI-1) thus stabilising it. Vitronectin contains an Arg-Gly-Asp sequence which 
is a binding site for integrins, thus involving it in cell adhesion. An integrin 
bound by vitronectin is avp3 or vitronectin receptor, found on the surface of 
platelets and interestingly, also on the surface of osteoclasts. It has been 
suggested that avP3 plays a role in osteoclast migration and the formation of the 
sealing zone formed by osteoclasts during the resorption phase of bone 
remodelling (Nakamura et al., 1999). Vitronectin alone has been shown to be 
sufficient to induce resorption behaviour from osteoclasts in vitro via its 
interaction with aVp3 receptor on the cell surface (Fuller et al., 2010). This 
receptor is highly expressed on the surface of osteoclasts and can also interact 
with other matrix proteins such as osteopontin. It has been reported that 
unoccupied aVp3 receptors on the surface of osteoclasts induces apoptosis (Zhao
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et a l, 2005). The resorption of damaged bone by osteoclasts is a sequential 
process commencing when osteoclasts attach to the mineralised bone matrix. 
Therefore, the interaction of cell surface adhesion molecules with the bone 
matrix is imperative, illustrated by aV(33 knock out mice not experiencing 
ovariectomised induced bone loss (Zhao et al., 2005).
The 2D DIGE study showed that vitronectin was significantly differentially 
expressed with an overall pattern of up-regulation from normal to osteopenia 
through to osteoporosis. It should be noted that plasma levels of vitronectin have 
been shown to fall in cases of a number of liver diseases in comparison with 
healthy individuals (Inuzuka et a l,  1992). However, the current study shows an 
up-regulation of expression of vitronectin in individuals with osteopenia and 
osteoporosis compared with normal postmenopausal women.
Vitronectin was one of only three proteins identified as being significantly 
differentially expressed across the three clinical cohorts to display an overall 
trend of up-regulation in all three comparisons (Table 3.3, Figure 3.13). Clusterin 
and angiotensinogen also were consistently up-regulated across all three 
comparisons (Table 3.3, Figure 3.14). No proteins were consistently down- 
regulated.
When considering a candidate to select for further validation an ideal candidate 
would not necessarily be an acute phase protein as they may not have the 
specificity and sensitivity, that is, the likelihood of generating a false positive or 
false negative, that is desired of a biomarker. In order to increase the chance of 
disease specificity, it may be desirable to select a candidate marker of disease 
understood to have a role in either the disease itself or affected tissue. Further, on 
analysing a study involving three or more clinical cohorts, such as the current 
study, it may be useful to select a protein that displays a similar overall trend. On 
the basis that vitronectin was significantly differentially expressed in the depleted 
serum of all three clinical cohorts, normal, osteopenia and osteoporosis,
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displayed the same overall trend of up-regulation across the three comparisons 
and that vitronectin has the ability to bind a receptor on the surface of 
osteoclasts, critical for bone resorption to proceed, it would appear to be a 
candidate for further validation experiments. In addition, as GFAP is expressed 
in the cytoplasm of osteocytes, it was also chosen for initial validation 
experiments by ELISA analysis as it represents a marker specific to osteocytes in 
the context of the individuals recruited for the current study.
3.4.3 V alidation  o f d iffe ren tia l expression o f v itronec tin
The data presented in the 2D DIGE study showed an overall up-regulation of 
vitronectin in depleted serum from postmenopausal women with osteopenia and 
osteoporosis. Subsequent analysis of whole undepleted serum by ELISA showed 
that there was a significant increase in expression of vitronectin in the osteopenia 
and osteoporosis groups compared with normal (Figure 3.15). No difference was 
observed by ELISA between the osteopenia and osteoporosis groups. It is 
possible that an increase in circulating vitronectin levels could lead to increased 
osteoclast viability and enhanced osteoclast function, thus enhancing bone 
resorption. However, firm conclusions could not possibly be drawn without 
further study most likely involving in vivo animal model analysis.
From ELISA analysis vitronectin would appear to be a promising serological 
marker of BMD, however, it should be noted that whilst vitronectin has a role in 
bone dynamics, it represents a non-specific marker of BMD as it is produced by 
the liver. Further, it has been observed that serum levels of vitronectin are 
markedly decreased in individuals with liver cancer (Zhao et al., 2010). It is 
worth noting that none of the participants in this chapter had albumin or alkaline 
phosphatase levels outside the reference ranges of 35-50 g/1 and 40-129 IU/1 
respectively, low albumin levels being suggestive of liver disease as do elevated 
alkaline phosphatase levels. Any further analysis of vitronectin as a marker of 
bone density may need to be employed on the basis of the ruling out of any 
history of liver disease in addition to further elucidation of its utility as a 
serological marker of BMD.
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GFAP is a cytoplasmic protein belonging to the family of intermediate filaments; 
that along with microtubules and microfilaments comprise the cytoskeleton of 
most eukaryotic cells. GFAP has been identified as a being a protein 
distinguishing astrocytes from other glial cells in the nervous system. 
Subsequently, it has been identified in the cytoplasm of osteocytes and 
chondrocytes (Kasantikul and Shuangshoti, 1989). GFAP was identified as being 
significantly differentially expressed by 2D DIGE analysis of serum taken from 
postmenopausal women and depleted of 14 abundant proteins. ELISA 
measurement of whole undepleted serum levels of GFAP revealed that there was 
a statistically significant increase in the level of GFAP in the osteopenia and 
osteoporosis groups compared with normal (Figure 3.16) and a statistically 
significant inverse correlation between serum levels of GFAP and bone density 
parameters lumbar T score and lumbar Z score (Figure 3.17). As GFAP is found 
in the cytoplasm of osteocytes it is possible that GFAP is being released into 
circulation as bone is increasingly being resorbed as bone density declines. 
Therefore, GFAP has the potential to be a very specific marker of bone loss. 
However, the value of GFAP as a serological marker would need to be confirmed 
via a longitudinal study to assess the expression of levels of GFAP continue to 
rise as bone density declines further, or if a plateau is reached at some stage. Full 
elucidation of the dynamics of GFAP loss into the circulation would require 
animal model analysis.
It is interesting to note that while both 2D DIGE and ELISA analysis identified 
GFAP as being significantly differentially expressed across the three clinical 
cohorts, the patterns of expression differed between analyses. The observed spot 
intensity by 2D DIGE increased in the osteopenia group with respect to the 
normal group, with a subsequent drop in expression in the osteopenia group, to 
below that of the normal group. However, ELISA quantification revealed that the 
serum levels of GFAP were elevated in the osteoporosis group compared with 
both the normal and osteoporosis groups. The reason for this discrepancy is 
unclear; the two techniques differ fundamentally in their approach with ELISA 
analysis being wholly quantitative. In total eight isoforms of GFAP have been 
described, the most abundant form being GFAPa. Other isoforms such as
3.4.4 Validation of differential expression of G F A P
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GFAP8 and GFAPe have been measured in human tissues (Nielsen et al., 2002, 
Pemg et al., 2008). However, the capture antibody used in the ELISA analysis in 
the current study was a monoclonal antibody raised against GFAPa only. The 
difference in expression levels of GFAP observed in the 2D DIGE study as 
compared with the ELISA study maybe be attributed to the fact that GFAP was a 
protein removed from serum during the depletion process as shown by LC- 
MS/MS in Chapter 2, Table 2.2. It is possible that GFAP was removed from 
serum samples from the osteoporosis group prior to analysis by 2D DIGE. 
Follow-up ELISA analysis was carried out on undepleted serum.
Ultimately, a clinical diagnostic test for a given protein will be based on an 
ELISA principal. Therefore, the finding that serum levels o f GFAP measured by 
ELISA are significantly inversely correlated with bone density parameters 
lumbar T score and lumbar Z score is of particular interest (Figure 3.17). While 
no significant inverse correlations were found between the hip bone density 
parameters, there may be benefit in further analysis utilising an increased number 
of study participants. As an astrocyte cytoplasmic protein and due to its 
protective role in case o f ischemic brain damage, it is perhaps unsurprising that 
GFAP has been evaluated as a marker of traumatic brain injury (Nawashiro et 
al., 2000). Released into the blood circulation following head injury elevated 
serum levels of GFAP have been proposed as a predictor of a poor outcome (Vos 
et al., 2004; Honda et al., 2010).
In addition to its presence in the central nervous system and osteocytes, GFAP is 
also expressed in the liver by a subpopulation of quiescent stellate cells, and an 
increase in expression may be an indicator of liver fibrosis progression (Carotti et 
al., 2008). GFAP has not previously been associated with postmenopausal 
osteoporosis, thus the data presented in this Chapter represents novel data. While 
the data presented demonstrates GFAP to be a promising candidate serological 
marker of hip bone density dynamics, further study into the temporal kinetics of 
the release of GFAP into circulation and indeed further elucidation of GFAP 
serum levels in clinical cohorts is required in order to further ascertain GFAP’s 
utility as a blood based marker of BMD.
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Important characteristics of any diagnostic test are high specificity and 
sensitivity, that is, the ability to accurately separate the group being assayed into 
those with and without the disease in question. These features can be assessed by 
measuring the area under the ROC curve. To further investigate the potential of 
GFAP and vitronectin as serological markers of BMD, ROC curves were 
generated using logistic regression. The ROC curves were then used to calculate 
AUC values for the patient samples (N=36) for both proteins alone and both 
proteins combined (Figure 3.18). The combination of GFAP and vitronectin was 
found to have the greatest power to discriminate individuals that have no 
reduction in BMD (i.e. those classified as normal by DXA) from individuals with 
either osteopenia or osteoporosis. This result is supportive of the concept that a 
panel of protein markers may be more appropriate for clinical use rather than 
relying on a single protein in isolation as a panel may offer increased specificity 
and sensitivity.
The ROC curves were also generated for GFAP and vitronectin with the aim of 
establishing whether they could be utilised to distinguish individuals with 
osteopenia from those with osteoporosis. AUC values calculated were close to 
those indicative of a diagnostic test with no real value (0.5) as the result is no 
better than that generated by chance. This outcome is reflective of the ANOVA 
analysis of the ELISA data for GFAP and vitronectin shown in Figures 3.15 and 
3.16, with no statistical difference between the osteopenia and osteoporosis 
groups in either case.
ROC curves were generated in the current study as it is a requirement for 
candidate biomarker publications in proteomic journals. However, it is important 
to recognise that there are some limitations associated with ROC analyses. 
Methods in addition to AUC values in assessing the utility of a new biomarker 
have been proposed; net reclassification improvement and integrated 
discrimination improvement, representing an acceptance of the shortcomings of 
ROC analyses (Pencina et al., 2008). The introduction of additional variables, 
even in the case of strong risk factors, have minimal impact on AUC values 
(Bolland et al., 2011). AUC values cannot reliably be compared between studies
3.4.5 R O C  analysis
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and even within studies (Hillier et al., 2011). Additionally, the current study 
utilises ELISA data from the same study participants as those used to generate 
the 2D DIGE data. Therefore, the possibility of the introduction of bias cannot be 
ruled out. Any future work will greatly benefit from the inclusion of study 
participants independant of those included in this study.
These results indicate that assaying GFAP and vitronectin combined has the 
potential to be a useful serological marker of a reduction in BMD. However, 
much further validation is required in order to fully ascertain vitronectin and 
GFAP’s clinical utility. Larger cohorts including individuals with other bone 
metabolic disorders such as Paget’s disease, osteoarthritis and rheumatoid 
arthritis, will be required in order to assess disease specificity. The current study 
included only postmenopausal women, therefore in order to assess whether the 
observations made are specific to postmenopausal women, further validation 
studies would require the inclusion of younger, pre-menopausal women and 
elderly women (>80 years old). The inclusion of male participants will be 
required to ascertain if  the changes are specific to women. Further, the inclusion 
of individuals with secondary osteoporosis will further elucidate disease 
specificity of vitronectin and GFAP. These futher validation studies will build 
upon the novel data generated in the current study.
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3.5 C o n c lu s io n s
• 2D DIGE successfully highlighted 21 significantly differentially 
expressed protein spots in the depleted serum o f postmenopausal women 
with osteopenia and osteoporosis, of which 18 were identified by mass 
spectrometry.
• None of the 18 proteins have previously been associated with 
postmenopausal osteoporosis, underlining the ability of 2D DIGE to 
generate novel data, thus providing a new insight into a systemic disorder 
on a whole body basis.
• Measuring circulating levels of GFAP and vitronectin combined is a 
promising method of identifying postmenopausal women with osteopenia 
and osteoporosis compared with women with normal BMD.
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C h a p te r  4 Id e n tif ic a tio n  o f d iffe re n tia lly  ex p ressed  p ro te in s  in  
p o s tm e n o p a u sa l w om en  w ith  o s teo p en ia  a n d  o s teo porosis  by  
a n tib o d y  a r r a y  techno logy
4.1 In tro d u c tio n
Osteoporosis is a debilitating disorder characterised by reduced bone strength; a 
combination of bone quantity and bone quality, manifesting itself in fragility 
fractures (Sambrook and Cooper, 2006; Seeman and Delmas, 2006). While not 
strictly a disease of the elderly, osteoporosis is associated with aging. Therefore, as 
the population dynamic of many countries tends towards a more elderly population, 
the importance of ascertaining a high risk of fragility fracture, in order to expedite 
medical intervention and commence treatment to reduce fracture risk, is of the 
utmost importance (Cooper et al., 1992; Burge et al., 2007; Dodds et al., 2009). 
Current diagnosis of osteoporosis is most frequently achieved by dual X-ray 
absorptiometry (DXA), introduced in 1987 and brought to the fore by the World 
Health Organisation changing the definition of osteoporosis in 1994 to refer to the 
output generated by DXA scanners. However, there is a need for a cost effective 
method of identifying individuals that may be at risk of sustaining fragility fractures. 
Routine blood tests in a clinical setting are a relatively inexpensive method of 
providing invaluable information to healthcare professionals. Currently markers of 
bone turnover are measured clinically, these include osteocalcin and procollagen 
type 1 amino-terminal propeptide (P1NP) both of which measure bone formation, 
and collagen type 1 cross-linked C-telopeptide (CTX) which measure bone 
resorption. However, these markers are used primarily in the monitoring of 
treatment as they do not give an indication of bone strength (Delmas et al., 2000; 
Meier et al., 2009).
The contents of circulating blood are reflective of the physiological state of an 
individual and therefore may contain protein markers of a given disorder. Blood 
based protein biomarkers have made a significant contribution to, and are FDA
155
approved for, clinical diagnostics in a number of diseases. Measurements of serum 
levels of cardiac troponin T- and B-type naturiuretic peptide have assisted in the 
diagnosis of myocardial infarction and congestive heart failure respectively 
(Mukoyama et al., 1990; Mair etal., 1991; Morita et al., 1993; Johnson etal., 1999). 
In recent years, in relation to cancer diseases, biomarkers have had a significant 
impact. Alpha-fetoprotein levels have been utilised, alongside with ultrasound, to 
diagnose hepatocellular carcinoma (De Masi et al., 2005). Circulating bladder 
tumour antigen has been approved for diagnosis of urothelial cell carcinoma (Mian 
et al., 2000).
Modem proteomic technologies provide an opportunity to study the protein 
expression patterns of biofluids thereby giving an insight into the molecular 
dynamics of a disease. Antibody array technology has emerged as a useful platform 
for studying the protein expression profile of a given complex sample and is the 
subject of a number of publications (Knezevic et al., 2001; Goldstein et al., 2005; Jin 
et al., 2008). As discussed in Chapter 1, the use of proteomics in bone biology is 
becoming more prevalent in the literature, however, antibody array technology has 
not been used to analyse postmenopausal osteoporosis in any published study. In this 
study, an antibody array simultaneously assaying 507 known proteins was used to 
identify differentially expressed proteins in the serum of postmenopausal women 
with osteopenia and osteoporosis in order to isolate candidate protein markers of 
disease.
Multiplexed measurement is a suitable platform for biological discovery with 
proteins because they constitutively function within pathways, interactions and 
families (Petricoin et al., 2005). The use of antibody array technology is particularly 
appealing in the case of rare specimens as relatively small amounts of serum/plasma 
are required for analysis (~20-50|j.l). Further, antibody array technology can lend
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itself to automation in a manner that two dimensional gel electrophoresis (2DE) 
cannot, giving rise to the potential for high throughput analysis.
Antibody arrays provide a platform to simultaneously study the expression of a large 
number of proteins in patients with a given condition compared to healthy controls. 
The RayBio0 Biotin Label-based Antibody Array was used to identify differentially 
expressed protein in serum taken from postmenopausal women with osteopenia and 
osteoporosis. The array assays 507 proteins qualitatively, including cytokines, 
chemokines and growth factors. The RayBio® antibody array format utilised in this 
study is represented in a schematic in Figure 4.1. Briefly, samples are subject to 
biotinylation, i.e., the process of attaching biotin to the primary amine (attached to 
the side chain of a lysine residue), the biotinylated sample is then applied to the 
array and proteins allowed to bind to their respective antibodies, a cy3 equivalent 
fluorescent dye conjugated to streptavidin is then applied to the array. The biotin- 
avidin interaction is the strongest found in nature and is commonly exploited to 
detect proteins because of the high specificity that biotin and avidin have for each 
other. The array is then scanned with a suitable fluorescence scanner and the data 
generated subject to analysis by a software package provided by the manufacturer.
It is important to note that the output of an antibody array is to measure the 
expression levels of specific known proteins in a given sample. This approach 
differs fundamentally in principal from that of 2D DIGE utilised in Chapter 3 where 
proteins identified may be known or unknown. In addition, the nature of 2D DIGE in 
relation to serum samples depleted of highly abundant proteins is such that medium 
abundance proteins will feature most prominently in analysis, whereas the antibody 
array utilised in the current study facilitates the measurement of a large number of 
low abundance proteins such as cytokines and chemokines. Therefore, one can 
expect to generate a different data output by utilising a different proteomic platform, 
thereby providing a further insight into the molecular mechanism of a given disease. 
It is also important to acknowledge the potential contribution to the body of
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knowledge of disease pathogenesis in addition to any candidate biomarkers that may 
be identified.
H R P -strep tavkU n  or
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Figure 4.1: RayBio antibody array principal of action schematic. 
www.raybiotech.com
The figure shows a schematic of the mechanism of action of an antibody array. 
Antibodies are affixed to a solid matrix, following biotinylation the sample is 
incubated with the array allowing the protein to bind to its antibody. After 
incubation with HRP-streptavidin or Fluorescent dye-Streptavidin, the signals can be 
visualized either by chemiluminescence or fluorescence.
4.1.1 Aims
• To use antibody array technology in the form of the RayBio® Label based 
array to identify differentially expressed proteins among the 507 human 
proteins assayed in the serum of postmenopausal women with osteopenia and 
osteoporosis compared with controls.
• To analyse the generated data using bioinformatics and literature search to 
highlight individual proteins for further analysis.
• To validate the differential expression of selected individual proteins by 
ELISA.
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4.2. M a te ria ls  and m ethods
4.2.1 S tudy partic ipan ts
Individuals were recruited to the current study in the same manner to that in outlined 
in Chapter 3. Participants were otherwise healthy postmenopausal women with 
osteopenia N=33, osteoporosis N=32 and a control group (normal) N=36. All 
participants were Caucasian, subjected to dual X-ray absorptiometry (DXA), lateral 
vertebral assessment (LVA) to assess the presence of vertebral fractures, 
biochemical tests for markers of bone turnover, had no history of other bone 
metabolic disorders and were not prescribed any medication altering bone 
metabolism. Study participants had their BMD measured using a Lunar DXA system 
(GE Healthcare). This provided measurements of BMD in g/cm2 together with the 
T-score and Z-score. T-score is generated by comparing the BMD generated for the 
patient to that of a young healthy individual of the same sex and ethnicity, whereas 
Z-score compares the generated BMD to that of an age and sex-matched individual 
of the same ethnicity. BMD was measured at the hip and the L1-L4 lumbar 
vertebrae. The WHO classification system was applied, defining osteoporosis as a T 
score <-2.5 and osteopenia as -2.5 to -1 . Study participants were categorized by the 
lowest T-score of the L l^ l lumbar spines, femoral neck, or total femur. Serum 
vitamin D, parathyroid hormone (PTH), markers of bone formation osteocalcin 
(OC) and procollagen type 1 N-terminal propeptide (P1NP) and marker of bone 
resorption C-telopeptide of type 1 collagen (CTX) were assayed at the Department 
of Biochemistry, St James's Hospital, Dublin, Ireland. Statistical analysis was 
performed using PASW Statistics 18.0. Values were normally distributed and thus 
presented as mean values. A p value threshold of 0.05 was applied on ANOVA 
values. Individuals were excluded on the basis of experiencing inflammatory 
disorders or undergoing long term regimes of steroids (<6 months). Individuals were 
also excluded on the basis of secondary osteoporosis. This study was approved by 
the Research Ethics Committee of the Adelaide and Meath Hospital, Dublin 
incorporating the National Children’s Hospital. Informed consent was obtained from 
each participant prior to involvement in the study.
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4.2.2 Serum  isolation
Blood was drawn into vacutainers; samples were centrifuged at 1000 g  for 10 min. 
Serum was removed, aliquoted and frozen at -80°C.
4.2.3 A ntibody a rra y
Equal volumes of serum from each of the participants were pooled according to 
group as determined by DXA; normal, osteopenia, and osteoporotic, and subject to 
analysis by antibody array. An aliquot from the specific pooled groups was then 
applied to the RayBio® Biotin Label-based Human Antibody Array which detects 
507 human proteins (RayBiotech; Norcross, Georgia, USA) and the procedure was 
carried out as per the manufacturer’s instructions. Briefly, 20 (il serum was diluted 5 
fold with phosphate buffered saline (PBS) (Sigma-Aldrich) and dialysed in a 
dialyser twice for 3 hours in 500 ml PBS at 4°C. Sample was combined with an 
Internal Control (supplied) and biotinylated by the addition of Labelling Reagent 
(supplied). Internal controls are included to be able to assess the success or failure 
of the biotin labelling reaction and sample incubation. In addition, positive controls 
are included on the array consisting of biotinylated protein which can be used to 
normalise intensity values prior to analysis. The positive control acts as a measure of 
the relative signal response to a known amount of biotin, thus making it an ideal 
parameter for normalization of the signal intensities on the array due to differences 
in signal detection. This allows for comparison of the relative signal densities for 
individual proteins between arrays.
Stop reagent (supplied) was added to halt the reaction and the samples were dialysed 
again. The arrays were blocked using Blocking Buffer (supplied) for 30 min, the 
buffer was then decanted and the biotinylated sample added and allowed to incubate 
at room temperature for 2 hours. Samples were decanted and the arrays washed 
several times using Wash Buffer I (supplied) followed by Wash Buffer II (supplied). 
Fluorescent dye conjugated Streptavidin (cy3 equivalent) was then incubated on the 
arrays for 2 hours at room temperature. Arrays were then washed several times using 
Wash Buffer I and allowed to dry. Arrays were scanned using the Axon 4000B;
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images were acquired using Axon GenePix Pro. Intensity values were extracted, 
background removed and analysed using the RayBio Analysis Tool to produce 
normalised intensity values. Array output intensities were normalised with respect to 
the positive control on the array. The positive controls are known amounts of biotin- 
labelled that are spotted directly onto the array. Because of this fact, the positive 
control acts as a measure of the relative signal response to a known amount of biotin, 
thus making it an ideal parameter for normalization of the signal intensities on the 
array due to differences in signal detection. Statistical analysis was performed using 
PASW Statistics 18.0. A p value threshold of 0.0001 was applied to ANOVA values 
generated by Tukey’s post hoc analysis in line with published recommendations 
regarding multiple testing and pooling strategies (Zhang and Gant, 2005). Values 
were normally distributed and thus presented as mean values.
4.2.4 Gene Ontology analysis
Gene Ontology (GO) analysis was carried out using the DAVID database available 
at http://david.abcc.ncifcrf.gov/home.isp. The differentially expressed proteins 
identified in the serum of normal, osteopenia and osteoporosis serum samples taken 
from postmenopausal women were subject to clustering by molecular function and 
biological process. The analysis represents the top 10% enriched genes expressed in 
the differentially expressed proteins. As many serum proteins have multiple 
functions, any given protein may be found in more than one functional group.
4.2.5 ELISA  analysis
Levels of Gremlin, Dkkl and Wnt inhibitory factor 1 (WIF 1) were measured in 
whole serum by commercially available ELISA kits. Gremlin and WIF 1 ELISA kits 
were purchased from USCN Life Sciences and Dkkl ELISA kit was purchased from 
R&D systems. ELISA was carried out as per manufacturer’s protocol. Statistical 
analysis was carried out using PASW version 18.0 using ANOVA at an alpha level 
of 0.05. Values were normally distributed and thus presented as mean values.
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Receiver operator characteristic (ROC) curve was generated based on logistic 
regression from the ELISA data for Dkkl and WIF 1. ROC curves were then used to 
generate the area under the curve (AUC). The accuracy of a diagnostic test can be 
measured by the area under the curve; AUC. An AUC of 1 represents a perfect test 
that generates no false positives or false negatives; an AUC of 0.5 represents a 
worthless diagnostic test as the result is no better than that generated by chance 
(Fawcett, 2006).
4.2.5.1 Receiver operator characteristic curves
1 6 2
4.3. R esu lts
4.3.1 P atient data
Postmenopausal women, total N=101, were recruited through an outpatient clinic in 
St James’ Hospital, the largest hospital in Ireland. Subjects were chosen for this 
study on the basis of their BMD in the same manner to that of Chapter 3. Larger 
sample sizes were utilised in the current study in line with previously published data 
regarding pooling strategies in biological studies (Zhang and Gant, 2005). The 
World Health Organisation (WHO) classification system was applied, defining 
osteoporosis as a T score <-2.5 and osteopenia as -2.5 to —1. Data for study 
participants are summarised in Figure 4.2 and Figure 4.3 and shown in Appendix 2. 
Figure 4.2 shows that the osteoporosis group were statistically significantly older 
than both the normal and osteopenia group (p<0.05). Further, an overall pattern of 
up-regulation of the bone turnover markers; osteocalcin, CTX and P1NP was 
observed with statistically significant increases noted in the osteoporosis groups 
compared with normal with respect to both CTX and P1NP and in osteopenia 
compared with osteoporosis in addition to normal compared with osteoporosis with 
respect to osteocalcin. There was no difference between the groups with respect to 
PTH or vitamin D levels. Figure 4.3, as expected, declines in lumber and hip BMD 
and T scores were observed between the three clinical cohorts (p<0.001).
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Table 4.1: Antibody array study participant information.
Table summarizes patient information for antibody array study participants (N=101). 
All subjects were postmenopausal women. All data are shown as mean (SD). Study 
participants grouped by DXA output. Individual patient information is available in 
Appendix 3.
C h a ra c te ris tic N o rm a l
N = 3 6
O steopen ia
N = 3 3
O steoporosis
N = 3 2
A g e  (y rs ) (S D ) 56 .6  (5 .0 ) 59 .6  (6 .5 ) 6 4 .6 (9 .1 )
H e ig h t (c m ) 162.6 (6 .4 ) 162.3 (6 .3 ) 158.4 (6 .8 )
W e ig h t (k g ) 74 .4  (9 .8 ) 7 1 .6 (1 1 .1 ) 62 .7  (6 .6 )
B M 1  (k g /m 2) 29.3 (6 .9 ) 27.1 (3 .5 ) 25.1 (3 .2 )
O ste o ca lc in  (O C ) (ng/1) 2 0 .3 2 (6 .8 4 ) 2 5 .6 6 (1 0 .2 5 ) 3 3 .2 7 (1 7 .1 1 )
C -te rm in a l te lo pe p tid e s  o f  ty p e  1 c o lla g e n  ( C T X ) (n g / | i l) 0 .3 0 (0 .1 2 ) 0 .3 5 (0 .1 6 ) 0 .44  (0 .2 2 )
P ro co llag e n  typ e  1 N - te rm in a l p ro p e p tid e  (P 1 N P ) (n g / | i l) 4 3 .9 8 (1 7 .5 4 ) 54.35 (2 7 .4 4 ) 60.81 (24 .0 3 )
P a ra th y ro id  ho rm o n e  (P T H ) (p g /jx l) 3 5 .8 4 (1 0 .1 7 ) 3 5 .7 6 (1 1 .0 1 ) 4 1 .40  (2 3 .6 3 )
V ita m in  D  (nm ol/1 ) 50 .25  (2 3 .0 2 ) 4 5 .2 7  (2 3 .3 4 ) 48 .03  (2 3 .6 5 )
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Figure 4.2: Patient data for antibody array study participants depicting mean age, weight, 
height, BMI, bone turnover markers, vitamin D and PTH levels.
Patient data were grouped by DXA and subject to ANOVA analysis. No statistically 
significant difference was found between the groups normal (N=36), osteopenia 
(N=33) and osteoporosis (N=32) with regards to age, parathyroid hormone levels 
(PTH) or vitamin D levels. Statistically significant differences were observed in 
relation to height, weight, BMI, osteocalcin levels, C-telopeptide of type 1 collagen 
levels (CTX) or procollagen type 1 N-Terminal propeptide levels (P1NP) (p<0.05). 
Levels were assayed at the Department of Biochemistry, St James's Hospital,
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Figure 4.2 continued: Patient data for antibody array study participants depicting mean age, 
weight, height, BMI, bone turnover markers, vitamin D and PTH levels.
Patient data were grouped by DXA and subject to ANOVA analysis. No statistically 
significant difference was found between the groups normal (N=36), osteopenia 
(N=33) and osteoporosis (N=32) with regards to age, parathyroid hormone levels 
(PTH) or vitamin D levels. Statistically significant differences were observed in 
relation to height, weight, BMI, osteocalcin levels, C-telopeptide of type 1 collagen 
levels (CTX) or procollagen type 1 N-Terminal propeptide levels (P1NP) (p<0.05). 
Levels were assayed at the Department of Biochemistry, St James's Hospital,
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Figure 4.3: Patient data for antibody array study participants depicting mean hip and lumbar 
BMD and mean hip and lumbar T score.
Individual patient data were grouped by DXA and subject to ANOVA 
analysis.Statistically significant differences was found between the groups normal 
(N=36), osteopenia (N=33), and osteoporosis (N=32), with regards to bone density 
parameters hip and lumbar BMD (p<0.05) and hip and lumbar T score (p<0.001 ). 
Individual patient information is available in Appendix 4.
4.3.2 A ntibody a rray  analysis
In order to assay the relative levels of a large number of proteins simultaneously in 
postmenopausal women with osteopenia and osteoporosis serum was isolated from 
our patient cohort (N=101) and applied to the RayBio label based antibody array. 
The identities of the each of the 507 proteins assayed by the antibody array are listed
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and their relative positions mapped in Appendix 4. Figure 4.4 shows representative 
images generated by the Axon GenePix Pro scanner.
Figure 4.4: Representative image of RayBio antibody array produced assaying 507 proteins in 
serum taken from postmenopausal women diagnosed as normal, osteopenic and osteoporotic by 
DXA.
Whole undepleted serum was taken from postmenopausal women classified as 
normal (N=36), osteopenia (N=33) and osteoporosis (N=32) by DXA conjugated 
with a cy3 equivalent, equal volumes pooled and then applied to the antibody array 
to detect 507 proteins and scanned by Axon GenePix Pro scanner. Experiment 
performed in triplicate.
Images were then examined to assess how well each of the three controls; positive, 
negative and internal, functioned (Figure 4.5). The positive control comprises a 
known quantity of biotinylated protein, producing a strong signal which can be used 
for the purpose of normalisation and, additionally, controls for the streptavidin 
incubation step. As expected, a very strong signal is produced by the positive 
controls indicative of a successful streptavidin incubation step. The negative controls 
are antibodies for bovine serum albumin, and thus produce a background signal 
indicative of satisfactory sample specificity. The internal controls are ‘spiked in’ 
non-mammalian proteins that do not interact with any other antibody on the array. A 
relatively strong signal is visible indicative of a successful biotinylation step.
1 6 8
A B C
Figure 4.5: Images highlighting positive, negative and internal controls within the antibody 
array.
Antibody array images were examined to determine how well the three controls; 
positive (green squares), negative (red squares) and internal (blue squares), 
functioned respectively. Controls are highlighted within squares in main images and 
magnified below main images. Representative images are shown. Positive controls 
are a known quantity of biotinylated protein, used to normalise pixel intensity values 
within each array and assess the streptavidin incubation step. As expected a very 
strong signal is visible. Negative controls are antibodies against bovine serum 
albumin and as expected generate no discemable signal. Internal controls are 
proteins ‘spiked’ into the sample used to assess how well the sample has 
biotinylated; a strong signal is visible. (A) Normal (B) osteopenia (C) osteoporosis.
Large numbers of proteins were up and down regulated among the 507 proteins 
assayed across the three clinical cohorts. In total, 156 individual proteins were 
significantly differentially expressed across the three clinical cohorts (p<0.0001). In
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a manner similar to that adopted in Chapter 3, where one of the three comparisons 
reached the significance threshold, the protein was considered to be significantly 
differentially expressed. In addition, fold change levels were consulted.
In the normal group, 40 proteins were down-regulated and 136 proteins up-regulated 
compared with osteopenia. In the normal group 172 proteins were down-regulated 
and 6 up-regulated compared with osteoporosis. In the osteopenia group 178 
proteins were down-regulated and no proteins were up-regulated compared with 
osteoporosis (Table 4.2, Figure 4.4).
Tabic 4.2: Summary of differentially expressed proteins in the three clinical cohorts identified 
by antibody array analysis.
Whole undepleted serum was taken from postmenopausal women classified as 
normal (N=36), osteopenia (N=33) and osteoporosis (N=32) by DXA, equal 
volumes pooled then conjugated with a cy3 equivalent, applied to the antibody array 
to detect 507 proteins, scanned by Axon GenePix Pro scanner, normalised to the 
positive control and mean pixel density analysed using PASW 18.0 ANOVA 





In order to cluster the data, a Gene Ontology analysis using the DAVID 
bioinformatic tool, was carried out in order to classify the 156 differentially 
expressed proteins by their involvement in biological processes. Gene Ontology data 
are depicted in Figure 4.6. In order to further analyse the 156 differentially 
expressed data, Pubmed literature searches were also performed. The results of this 
grouping are depicted in Figures 4.7, 4.8 and Appendices 3-6. Significantly 
differentially expressed proteins were grouped by; previously published genome
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wide association studies (Figure 4.7), known or putative role in bone turnover and 
bone cells (Figure 4.8), T-cell mediated immunity (Appendix 5), B-cell and antibody 
mediated immunity (Appendix 6), macrophage mediated immunity (Appendix 7), 
granulocyte mediated immunity (Appendix 8). Additionally differentially expressed 
proteins are also depicted (Appendix 9). Gene Ontology analysis revealed that the 
majority of the significantly differentially expressed proteins have a role in signal 
transduction (N=94). Significantly, six proteins were identified as having a role in 
skeletal development (Figure 4.6).
A literature search revealed 16 differentially expressed proteins as containing 
polymorphisms associated with BMD identified by genome wide association studies 
(Figure 4.7). The literature search revealed that 68 proteins identified as being 
differentially expressed had been previously highlighted as having a known or 
putative role in osteoblasts, osteoclasts, osteocytes, bone turnover, bone homeostasis 
and bone repair (Figure 4.8).
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Figure 4.6: Chart depicting Gene Ontology analysis of differentially expressed proteins in 
postmenopausal women identified by antibody array analysis across the three clinical cohorts.
Proteins that were identified by antibody array analysis as being differentially 
expressed in whole serum taken from postmenopausal women were classified into 
functional groups using Gene Ontology via the DAVID database. Functional 
classifications that were found to be over-represented within the generated data were 
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Figure 4.7: Differentially expressed proteins identified by antibody array analysis with associations with BMD from published genome wide association 
studies.
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show fold change calculated based on mean pixel density values normalised to a positive control on the array. Fold changes 
are relative to normal. Error bars show standard deviation. Experiment performed in triplicate, (ANOVA p<0.000l). The literature 
search revealed that 16 proteins had previously been identified in genome wide association studies as containing polymorphisms 
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Figure 4.8: Differentially expressed proteins identified by antibody array analysis with known or putative roles in osteoblasts, osteoclasts, osteocytes, 
bone dynamics and bone repair.
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show fold change calculated based on mean pixel density values normalised to a positive control on the array. Fold changes 
are relative to normal. Error bars show standard deviation. Experiment performed in triplicate, (ANOVA p<0.0001). The literature 
search revealed that 68 proteins have a link or putative link with osteoblasts, osteoclasts, osteocytes, bone dynamics or bone repair.
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Figure 4.8 continued: Differentially expressed proteins identified by antibody array analysis with known or putative roles in osteoblasts, osteoclasts, 
osteocytes, bone dynamics and bone repair.
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show fold change calculated based on mean pixel density values normalised to a positive control on the array. Fold changes 
are relative to normal. Error bars show standard deviation. Experiment performed in triplicate, (ANOVA p<0.0001). The literature 
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Figure 4.8 continued: Differentially expressed proteins identified by antibody array analysis with known or putative roles in osteoblasts, osteoclasts, 
osteocytes, bone dynamics and bone repair.
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show fold change calculated based on mean pixel density values normalised to a positive control on the array. Fold changes 
are relative to normal. Error bars show standard deviation. Experiment performed in triplicate, (ANOVA p<0.0001). The literature 
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Figure 4.8 continued: Differentially expressed proteins identified by antibody array analysis with known or putative roles in osteoblasts, osteoclasts, 
ostcocytes, bone dynamics and bone repair.
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show fold change calculated based on mean pixel density values normalised to a positive control on the array. Fold changes 
are relative to normal. Error bars show standard deviation. Experiment performed in triplicate, (ANOVA p<0.0001). The literature 
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Figure 4.8 continued: Differentially expressed proteins identified by antibody array analysis with known or putative roles in osteoblasts, osteoclasts, 
osteocytes, bone dynamics and bone repair.
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show fold change calculated based on mean pixel density values normalised to a positive control on the array. Fold changes 
are relative to normal. Error bars show standard deviation. Experiment performed in triplicate, (ANOVA p<0.0001). The literature 
search revealed that 68 proteins have a link or putative link with osteoblasts, osteoclasts, osteocytes, bone dynamics or bone repair.
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Figure 4.8 continued: Differentially expressed proteins identified by antibody array analysis with known or putative roles in osteoblasts, osteoclasts, 
osteocytes, bone dynamics and bone repair.
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show fold change calculated based on mean pixel density values normalised to a positive control on the array. Fold changes 
are relative to normal. Error bars show standard deviation. Experiment performed in triplicate, (ANOVA p<0.0001). The literature 
search revealed that 68 proteins have a link or putative link with osteoblasts, osteoclasts, osteocytes, bone dynamics or bone repair.
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4.3.3 Identification of proteins for further analysis
In order to further explore selected individual proteins identified by antibody array 
analysis, ELISA analysis was carried out on Gremlin, Wnt inhibitory factor 1 
(WIFI) and Dkkl (Dickkopf 1).
Gremlin is a protein secreted by osteoblasts that acts as a BMP antagonist. It is 
required for both skeletal development and postnatal skeletal homeostasis (Canalis et 
al., 2011). Further, overexpression of Gremlin in the skeleton of transgenic mice 
results in an osteopenic phenotype displaying spontaneous fractures (Gazzerro et al., 
2005). Antibody array analysis revealed a 1.452 fold change in the levels of Gremlin 
in the osteopenia group compared with normal (SD 0.23) and a 0.577 fold change in 
the osteoporosis group compared with normal (SD 0.01) in addition to a fall in the 
mean normalised pixel density values in the osteoporosis group compared with 
osteopenia (p<0.0001), and normal (p=0.015) (Figure 4.8 and 4.9).
Wnt inhibitory factor 1 (WIF 1) is a secreted protein that acts as a Wnt signalling 
antagonist by binding Wnt proteins in the extracellular space, thus preventing them 
from interacting with LRP5/6 receptor required to initiate the Wnt signalling 
pathway. Canonical Wnt signalling is critical for osteoblastogenesis and bone 
formation (Li et al., 2006). Antibody array analysis showed a fold change of 0.425 
in the osteopenia group compared with normal (SD 0.06) and a 0.174 fold change in 
the osteoporosis group compared with normal (SD 0.04) in addition to a fall in the 
mean normalised pixel density values in both the osteopenia and osteoporosis groups 
compared with normal and in the osteopenia group compared with osteoporosis 
(p<0.0001) (Figure 4.8 and 4.9).
Dkkl (Dickkopf-1) is a secreted protein that acts as a Wnt signalling antagonist. 
Postnatally, it is produced primarily by osteoblasts and osteocytes, is important in 
bone homeostasis and is an emerging drug target (Li et al., 2006; Morvan et al.,
2006; MacDonald et al., 2007; Glantschnig et al., 2011). Antibody array analysis 
showed a fold change of 1.04 in the osteopenia group compared with normal (SD 
0.33) and a 0.211 fold change in the osteoporosis group compared with normal (SD 
0.08) in addition to a fall in the mean normalised pixel density values in both the
1 8 0




*  p<o ooo 1 N o r m a l  O s t e o p e n i a  O s t e o p o r o s i s
D X A
3 0 0 “
*  p<n.oooi N o rm al O s t e o p e n ia  O s t e o p o r o s i s
D X A
* p<o.oooi Normal O steop en ia  O steop oro sis
D X A
Figure 4.9: Bar charts depicting normalised pixel density of Dkkl, Gremlin and Wnt inhibitory 
factor 1.
Whole, undepleted serum was taken from postmenopausal women classified as 
normal (N=36), osteopenia (N=33) and osteoporosis (N=32) by DXA, an equal 
volume of each sample pooled and subject to analysis by RayBio antibody array to 
assay 507 proteins. Graphs show pixel density normalised to a positive control on 
the array. Error bars show standard deviation. Experiment performed in triplicate, 
(ANOVA p<0.0001).
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4.3.3.1 G rem lin
The serum concentration of Gremlin in the osteopenia group (459.6 pg/ml 95% SD 
(72)) was significantly increased compared with normal (110.7 pg/ml 95% SD 
(374)) (p=0.008). Similarly, the serum concentration of Gremlin in the osteopenia 
group was significantly increased compared with osteoporosis (146.9 pg/ml 95% SD 
(106)) (p=0.015). There was no significant difference in the levels of Gremlin 
between the normal and osteoporosis groups (p=0.939) (Figure 4.10). Normal N=12, 










Figure 4.10: Gremlin levels (pg/ml) in serum measured by ELISA in postmenopausal women, 
classified as normal, osteopenia and osteoporosis by DXA.
The USCN ELISA kit was used to assay Gremlin levels in whole serum from a sub­
group of antibody array study participants selected randomly (normal N=12, 
osteopenia N=12, osteoporosis N=12). This assay demonstrated a significant 
increase in circulating levels of Gremlin in the osteopenia group compared with both 
normal and osteoporosis groups, p=0.008 and p=0.015 respectively by ANOVA 
analysis.
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Serum levels of Wnt inhibitory factor 1 were measured in the postmenopausal 
women in this study; normal N=12, osteopenia N=12, osteoporosis N=12. ANOVA 
analysis of the mean levels of WIF 1 showed a statistically significant up-regulation 
in the serum level of Wnt inhibitory factor 1 in the osteoporosis group (Mean 943.8 
pg/ml SD (781.2)) compared with osteopenia (318.2 pg/ml SD (198.2)) (p=0.045). 
There was no statistically significant difference between the normal group (601.8 
pg/ml SD (534.0)), and the osteopenia or osteoporosis groups (Figure 4.11). There 
was no significant inverse correlation between Wnt inhibitory factor I levels and 
bone density parameters hip or lumbar BMD, T score, Z score hip Z score (data not 
shown). Further, correlation and linear regression analysis was performed between 
WIF 1 and bone turnover markers with no significant correlations noted: osteocalcin 
(r=0.150, p=0.438), CTX (r=0.322, p=0.088) or P1NP (r=0.039, p=0.840).
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Figure 4.11: Wnt inhibitory factor 1 levels (pg/ml) in serum measured by ELISA in 
postmenopausal women classified as normal, osteopenia and osteoporosis by DXA.
The USCN ELISA kit was used to assay Wnt inhibitory factor 1 (WIF 1) levels in 
whole serum from a sub-group of antibody array study participants selected 
randomly (normal N=12, osteopenia N=12, osteoporosis N=12). This assay 
demonstrated a significant increase in circulating levels of Wnt inhibitory factor 1 in 
the osteopenia group compared with osteoporosis (Figure 4.11) by ANOVA 
analysis.
1 8 4
4.3 .3 .4  D k k l
Serum levels of Dkkl were measured in the postmenopausal women in this study; 
normal N=12, osteopenia N=12, osteoporosis N=12. ANOVA analysis of the mean 
levels of Dkkl showed no statistically significant difference between any of the 
three cohorts: normal (2297.1 pg/ml SD (1177.6)), osteopenia (2551.5 pg/ml SD 
(879.4)) or osteoporosis (3242.8 pg/ml SD (1285)) (Figure 4.12). However, 
correlation and linear regression analysis revealed an inverse correlation between 
serum levels of Dkkl and hip BMD (r=-0.371, p=0.028) (Figure 4.13a), hip T score 
(Pearson statistic r=-0.383, p=0.023) (Figure 4.13b), lumbar BMD (r=-0.381, 
p=0.024) (Figure 4.13c), lumbar T score (r=-0.384, p=0.023)(Figure 4.13d), lumbar 
Z score (r=-0.343, p=0.044) (Figure 4.13e). There was no significant inverse 
correlation between Dkkl levels and hip Z score (r=-0.315, p=0.065) (not shown). 
Serum levels of Dkkl were not significantly correlated with advancing age (r=0.062, 
p=0.725) (Figure 4.13f). Further, correlation and linear regression analysis was 
performed between Dkkl and bone turnover markers with no significant correlations 







Figure 4.12: Dkkl levels (pg/ml) in serum measured by ELISA in postmenopausal women 
classified as normal, osteopenia and osteoporosis by DXA.
The R+D Systems ELISA kit was used to assay Dkkl levels in whole serum from a 
subgroup of antibody array study participants selected randomly (normal N=12, 
osteopenia N=12, osteoporosis N=12). No statistically significant difference 
between the groups was found by ANOVA analysis, however an overall pattern of 
up-regulation was observed.
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Figure 4.13: Correlation and linear regression analysis performed between serum Dkkl levels 
(pg/ml) and BMD parameters.
Whole serum levels of Dkkl were measured using an R+D Systems ELISA (N=36). 
Correlation and linear regression analysis was then performed between Dkkl levels 
and (A) hip BMD, (B) hip T score, (C) lumbar BMD, (D) lumbar T score, (E) 
lumbar Z score, (F) lumbar Z score. Statistically significant inverse correlations (p< 
0.05) were observed between whole serum levels of Dkkl and the bone density 
parameters listed. No significant correlation was observed between Dkkl levels and 
age (F) or Dkkl levels and hip Z score (data not shown).
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To measure the potential utility of measuring circulating levels of proteins Dkkl and 
Wnt inhibitory factor 1 as serological markers of a reduction in BMD, the ELISA 
results for these proteins were subject to logistic regression analysis and ROC curves 
generated in order to calculate the AUC. AUC values were calculated for Dkkl and 
Wnt inhibitory factor 1 alone and in combination to determine which protein had the 
greatest discriminatory power. Figure 4.14a shows the AUC values for Dkkl, Wnt 
inhibitory factor 1 and the two proteins combined for the differentiation of Normal 
postmenopausal women from those with osteopenia and osteoporosis. Dkkl 
displayed an AUC value of 0.619 whereas Wnt inhibitory factor 1 had an AUC 
value of 0.768. Combining the two proteins decreased AUC value from that 
generated by Wnt inhibitory factor alone to 0.720. However, Figure 4.14b shows 
that the combination of Dkkl and Wnt inhibitory factor 1 has the optimum AUC 
value of 0.736 when distinguishing individuals with osteopenia from those with 
osteoporosis, superior to the AUC values of Dkkl alone, 0.655 or Wnt inhibitory 
factor 1 alone, 0.645.
4.3 .3.5 R O C  curves
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Figure 4.14: Receiver operating characteristic curves for the differentiation of reduction in 
BMD through proteins Dkkl and WIFI.
The curves depict results using logistic regression for Dkkl and Wnt inhibitory 
factor 1 alone and combined. (A) AUC values for Dkkl, Wnt inhibitory factor 1 for 
the differentiation of individuals that have experienced any reduction in BMD from 
those who have not. (B) AUC values for Dkkl, Wnt inhibitory factor 1 for the 
differentiation of individuals with osteopenia from those with osteoporosis. ROC 
curves were generated using logistic regression of ELISA data depicted in Figures 
4.9 and 4.10. (N=36).
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In the post-genomic era a number of multiplex solutions for assaying biomolecules 
and identifying novel biomarkers exist. DNA microarrays are utilised to measure 
gene expression levels (Schena et al., 1995; Hacia et al., 1999; Pollack et al., 1999). 
However, gene expression is not always reflective of actual levels of a given protein 
(Gygi et al., 1999; Pascal et al., 2008; Taniguchi et al., 2010). Additionally, the 
discovery in recent years of microRNAs (miRNAs) as regulators of mRNA 
translation has added an additional layer of complexity to the current understanding 
of cellular processes.
Whilst not having been in existence for as long as two dimensional gel 
electrophoresis (2DE), antibody array technology has still made a significant 
contribution to the proteomic community and biomarker discovery. Han et al. 
utilised serum isolated from lung cancer patients on an antibody array platform to 
identify a panel of 6 differentially expressed proteins that can identify cases of lung 
cancer with a sensitivity of 88% and a specificity of 80% (Han et al., 2009).
Carlsson et al. used antibody array technology to identify a panel of 11 proteins that 
distinguished breast cancer in whole serum samples with a specificity and sensitivity 
of 95% (Carlsson et al., 2008). The same group used a similar approach to identify 
novel markers of systemic lupus erythematosus and glioblastoma in whole serum, 
and markers of Helicobacter pylori infection in stomach tissue (Ellmark et al., 2006; 
Carlsson et al., 2010; Carlsson et al., 2011). Mor et al. identified four proteins by 
antibody array analysis, capable of identifying cases of epithelial ovarian cancer 
with a specificity and sensitivity of 95% (Mor et al., 2005)
Further examples of diseases for which candidate biomarkers have been identified 
using antibody array technology include an additional ovarian cancer study, prostate 
cancer, pancreatic cancer, bladder cancer, cystic fibrosis, inflammatory bowel 
disease, cerebral palsy; and meningitis (Miller et al., 2003; Kaukola et al., 2004;
Gao et al., 2005; Kader et al., 2005; Kastenbauer et al., 2005; Orchekowski et al., 
2005; Sanchez-Carbayo et al., 2006; Srivastava et al., 2006; Loch et al, 2007).
4.4. D iscussion
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Whilst antibody array technology has been used to identify differentially expressed 
proteins in relation to a number of diseases, there are no previously published studies 
that utilise this particular proteomic platform in relation to osteopenia or 
osteoporosis. The RayBio Biotin Label-based Antibody Array used in this study 
successfully identified 156 differentially expressed proteins in the serum of 
postmenopausal women with osteopenia and osteoporosis.
Proteomic and microarray studies frequently produce lengthy lists of proteins and 
genes. However, in order to gain a better insight into the biological processes and 
molecular functions that are altered in the disease state under study bioinformatic 
tools present themselves as a means of clustering the data. Over-representation 
analysis is often used to annotate lists of proteins, particularly when analyzing from 
data from proteome states measured under different conditions. DAVID is a popular 
tool for over-representation analysis as it incorporates more data than other similar 
bioinformatic tools and is a user friendly method of producing a Gene Ontology 
analysis of a list of proteins (Malik et al, 2010).
The results of the Gene Ontology analysis depicted in Figure 4.6 show that the two 
largest functional groups of proteins that are significantly differentially expressed 
are involved in cell signalling, those being signal transduction (N=95) and cell 
surface receptor mediated signal transduction (N=77). This is indicative of the 
alterations occurring in the various signalling pathways involved in the process of 
the measured decline in BMD. As discussed in Chapter 1, a number of cytokines 
and growth factors govern the activity of bone cells during bone remodelling 
including members of the RANK/RANKL/OPG signalling axis and its downstream 
signalling pathway the MAPK cascade. Further, the canonical Wnt signalling 
pathway is involved in bone formation. The finding that a large number of proteins 
that are significantly differentially expressed in our patient cohort are involved in
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cell signalling underlines the importance of the alteration of molecular events to the 
progression of the observed decrease in BMD.
Due to the adjacent nature of bone marrow to bone it is unsurprising that there is 
much cross-talk between the immune system and bone, on a molecular and cellular 
basis, giving rise to the field of osteoimmunology. Indeed, osteoclasts share the 
same hematopoietic lineage as leukocytes. Further, macrophages specific to the bone 
niche, osteomacs, have recently been discovered (Chang et al., 2008). Additionally, 
the RANK-RANKL-OPG signalling axis is one that functions in both systems. The 
identification of a large number of significantly differentially expressed proteins 
involved in immunity and defence (N=60) by Gene Ontology analysis across three 
patient cohorts is of note (Figure 4.6, Appendices 5-8). This result is in keeping with 
the recent Immunos study which analysed lymphocytes isolated from healthy 
postmenopausal women compared with those from postmenopausal women with 
osteoporosis. This study concluded that immune changes occur in postmenopausal 
women with osteoporosis regardless of oestrogen levels or age (Breuil et al., 2010).
It has been reported that T-cells may have a role in the pathogenesis of oestrogen 
deficient bone loss in mouse models (Roggia et al., 2001). However, this remains 
controversial as other studies have argued against a critical role for T-cells in animal 
models of bone loss (Grcevic et al., 2000; Grcevic et al., 2006). It has been argued 
that T-cells may have a role in cortical bone loss but not cancellous bone loss (Lee et 
al., 2006). In terms of clinical studies, it has been demonstrated that T-cells isolated 
from women with postmenopausal osteoporosis are more active than T-cells isolated 
from healthy postmenopausal women (DAmelio et al., 2008). In line with this 
study, 8 proteins involved in T-cell immunity were identified by antibody array 
analysis as being differentially expressed across the three clinical cohorts in the 
current study (Appendix 5). Recently, the CD40/CD40 ligand signalling axis has 
been implicated in the mechanism of postmenopausal bone loss, though the precise
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nature of this mechanism remains to be fully elucidated (Li et al., 2007; Gao et al, 
2008; Li et al, 2011). Further, polymorphisms in the CD40 and CD40 ligand genes 
have been associated with low BMD (Pineda et al., 2008; Pineda et al., 2011). The 
significant increase in expression of CD40 observed in the osteoporosis groups 
compared with both normal and osteoporosis may be reflective of a putative role for 
CD40 in the pathogenesis of bone loss (Appendix 5).
The finding that TNFp was significantly differentially expressed is noteworthy in the 
context of a previous study that measured mRNA levels of TNFp bone biopsies 
taken from postmenopausal women with osteoporosis and detected TNFp mRNA 
transcripts in a subgroup of osteoporotic postmenopausal women, and not at all in 
healthy postmenopausal women (Ralston, 1994). The pattern of expression observed 
in the current study differs however, to that observed in the Ralston study, this may 
be explained by the fact that mRNA levels and protein expression levels do not 
always correlate with each other (Figure 4.6, Appendix 5).
It is becoming apparent that B-cells have a role in bone homeostasis with a study 
reporting that B-cell knock out mice are osteoporotic compared with wild-type (Li et 
al., 2007). Further, a genome wide expression study on mRNA isolated from 
circulating B cells isolated from postmenopausal women with low BMD compared 
with high BMD identified by micro array, 29 genes as being differentially expressed. 
Both CD40 and TNFp in addition to roles in T-cell immunity, have roles in B-cell 
mediated immunity. It is therefore interesting to observe that 6 proteins with roles in 
B-cell and antibody related immunity were significantly differentially expressed 
(Figure 4.6, Appendix 6).
However, the cytokine purported to have a significant impact on osteoclastogenesis, 
TNFa, secreted by T-cells, was not identified as significantly differentially 
expressed. This may be because the change in the level of expression was beyond 
the limit of detection of the array.
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In addition to Gene Ontology analysis, a literature search was also carried out in 
order to group proteins identified by antibody array analysis by a protein’s previous 
publication in genome wide association studies and by known or putative roles in 
osteoblasts, osteocytes, osteoclasts, bone dynamics or bone repair.
It has been apparent for some time that the development of idiopathic osteoporosis 
can be attributable, to some extent, to a genetic component. This is indicated by the 
incidence of maternal femoral neck fracture increasing the likelihood of an 
individual sustaining a fracture of the femoral neck (Looker and Beck, 2004). There 
have been a large number of genome wide association studies carried out with the 
aim of linking specific genes or gene polymorphisms with BMD and a large number 
of candidates have been identified (Hosoi, 2010; Ralston and Uitterlinden, 2010; 
Mitchell and Yerges-Armstrong, 2011). It is of note that a number of proteins, 16 in 
total, identified as being significantly differentially expressed by antibody array 
analysis have been identified in genome wide association studies as being associated 
with an altered BMD. .Discussed below are two of the 16; osteoprotegerin and IGF1.
Significantly up-regulated in the osteopenia group compared with both normal and 
osteoporosis was osteoprotegerin (OPG), a decoy receptor for RANKL (Figure 4.7) 
Whilst it has been clear for some time that OPG has a role in the pathogenesis of 
osteoporosis, the numerous published studies measuring circulating levels of OPG in 
postmenopausal women with osteoporosis have had conflicting outcomes (Liu et al., 
2005; Chiba et al., 2009; Nabipour et al., 2009; Jabbar et al., 2011). The rise and 
subsequent fall in expression of OPG observed in the current study may be in 
keeping with the hypothesis that levels of OPG can be expected to rise in the case of 
increased bone loss, as part of a mechanism to minimise bone turnover thereby 
reducing bone loss (Jabbar et al., 2011). It is unclear as to why there is such 
variation in the outcomes of different studies measuring circulating levels of OPG 
and RANKL. One possible explanation is that the different ELISA assays used may 
have differing levels of sensitivities and thus produce different results.
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Insulin like growth factor 1 (IGF1) was found to be significantly differentially 
expressed by antibody array analysis, with both the osteopenia and osteoporosis 
groups being down-regulated compared with Normal (Figure 4.7). The IGF system 
has been linked to the attainment of peak bone mass and may have a role in bone 
homeostasis (Rosen, 2004). While much has been learned in recent years, its precise 
role has yet to be elucidated. The differential expression of IGF 1 observed in the 
current study is reflective of a correlation between plasma IGF1 and BMD observed 
in a previous study (Romagnoli et al., 1993). However, it has been observed that 
circulating levels of IGF 1 decline with aging, as growth hormone (GH) levels 
decline (Bonjour et al., 1997). Further, it appears that dietary protein intake 
influences levels of circulating IGF1 (Bonjour et al., 1997). This may be a cause for 
concern in the current study as there are significant differences between the mean 
ages of the three cohorts. However, there are no data available regarding study 
participants’ diets; therefore, the observed decline in circulating levels in IGF1 may 
not be specific to a decline in BMD.
Literature search via Pubmed revealed that a large number of proteins identified as 
being differentially expressed by antibody array analysis in the current study have a 
role or a putative role in bone dynamics Figure 4.8 depicts 68 significantly 
differentially expressed proteins identified by previously published studies, 
including in vitro analysis, animal model studies and clinical studies, as being 
involved in the process of bone turnover, bone dynamics, bone repair, or in bone 
cells; osteoblasts, osteoclasts and osteocytes. While this inclusion criterion is 
admittedly broad, this can allow for a greater appreciation of the overall alteration in 
bone dynamics as bone loss is occurring.
Evidence has emerged in recent years that members of the activin and inhibin 
protein families are involved in the regulation of osteoblastogenesis and 
osteoclastogenesis. While referred to as sex hormones as they were originally 
isolated from the gonads, Inhibins influence bone cells via an endocrine mechanism, 
whereas activins are additionally produced and stored in bone (Nicks et al., 2009).
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Activin appears to have a role in bone formation; a soluble chimeric form of activin 
receptor type IIA, which acts to block activin signalling, is an emerging anabolic 
therapy for osteoporosis (Ruckle et al., 2009; Lotinun et al., 2010). It was therefore 
interesting to note the significant differential expression of a number of activin and 
inhibin proteins in the current study: inhibin A, activin C, activin RIA and activin 
RIIA (Figure 4.8).
As outlined in Chapter 3, there are several considerations to take into account when 
selecting differentially expressed proteins for further analysis, in the context of 
identifying candidate markers of disease. Specificity to a given disease is desirable, 
but not always attainable as considerable overlap of protein function exists in the 
human body. When considering three clinical cohorts, an overall down- or up- 
regulated pattern of expression is desirable in order to clearly differentiate between 
groups. Further, knowledge of involvement in the particular disease process or 
pathways critical to that disease; can be desirable in order to increase specificity. 
Because of their potential functional relevance and their possible correlation with a 
reduction in BMD, Gremlin, Dkkl and Wnt inhibitory factor 1 were selected for 
further validation by ELISA.
Gremlin is a cytokine secreted by osteoblasts, which acts as a BMP antagonist and is 
required for early limb outgrowth, skeletal development and postnatal bone 
homeostasis as observed in animal models (Hsu et al, 1998; Canalis et al., 2011; 
Stafford et al, 2011). As it was identified as being significantly differentially 
expressed by antibody array analysis (Figure 4.8, 4.9), and serum levels are 
measureable by ELISA and with a role in bone homeostasis; it was selected for 
further investigation. ELISA measurements of whole scrum levels of Gremlin 
revealed a similar pattern of expression, that of a significant up-regulation in the 
osteopenia group compared with Normal and a significant down-regulation in the 
osteoporosis group compared with osteopenia (Figure 4.8). While of interest from a
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point of view of the pathogenesis of the decline in bone density, the pattern of 
expression observed is not of assistance with a view to developing a candidate 
biomarker of disease. While a marker of the early stages of decline in BMD would 
be of great utility in terms of diagnostics with a view to implementing as early an 
intervention as possible; a protein whose circulating level increases which is then 
followed by a decline would produce confusing clinical outcomes as a low level of 
circulating protein could be indicative of normal or osteoporotic BMD status. It is 
interesting to note that an animal model that overexpresses Gremlin exhibits 
osteopenia and fragility fractures. It may be the case that the up-regulation of 
Gremlin observed in the osteopenia group by both antibody array analysis and 
ELISA is contributing towards the decline in bone density. It has been suggested that 
there is some crosstalk between the BMP and Wnt signalling pathways in relation to 
bone formation as evident by a reduced level of cytosolic p-catenin present in bone 
marrow stromal cells that overexpresses Gremlin. However, this effect may not be 
specific to Gremlin but as a result of BMP antagonism in general (Gazzerro et al., 
2005). The subsequent fall in circulating Gremlin may be as a result of a 
compensation mechanism, to overcome the inhibition of bone formation caused by 
the increase in Gremlin expression as it has been reported that a transgenic deletion 
of Gremlin causes an increase in bone mass and bone formation (Gazzerro et al., 
2007). Further investigation would be required to fully elucidate the role of Gremlin 
in the decline of bone density in postmenopausal women.
Wnt proteins are a group of secreted lipid-modified signalling proteins involved in a 
number of biological processes including embryonic development, cell 
differentiation and oncogenesis (Milat and Ng, 2009). The canonical Wnt signalling 
pathway is critical in the induction of bone formation. Wnt proteins binds the 
frizzled receptor on the surface of osteoblasts, allow the receptor to complex with its 
co-receptor LRP5/6. This results in the induction of a signalling cascade culminating 
in the translocation of an increased amount of P-catenin to the nucleus. P-catenin 
induces the expression of genes related to bone formation (Krishnan et al., 2006). 
Dkkl or Dickkopf related protein 1 is a protein secreted postnatally primarily by 
osteoblasts and osteocytes and is a potent inhibitor of canonical Wnt signalling as it
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complexes with Kremen receptor and LRP5/6, thus antagonising Wnt signalling
(Mao et ah, 2001; Mao et ah, 2002).
The interest in the role of Dkkl in bone has increased in recent years following a 
number of animal knock out studies. Dkklv‘ knockout mice die shortly after birth 
displaying severe head formation defects, polydactyly and vertebral fusions 
(Mukhopadhyay et ah, 2001). The removal of one Dkkl allele produces Dkk ' 
mutant mice with increased bone mass (Morvan et al., 2006). Conversely, the 
overexpression of Dkkl in mice results in a reduction in bone mass (Li et al., 2006). 
Further, a study that produced four Dkk phenotypes displaying a range of Dkkl 
expression levels showed that peak bone mass is inversely proportional to the level 
of Dkkl expressed in vivo (MacDonald et al., 2007). Additionally, Dkkl has 
emerged as a therapeutic target for postmenopausal osteoporosis, with the use of an 
anti-Dkk 1 antibody in a mouse and primate model of postmenopausal osteoporosis 
(Glantschnig et al., 2011).
A number of clinical studies have measured Dkkl levels in circulation; increased 
levels of Dkkl have been observed in postmenopausal women with osteoporosis 
undergoing treatment with teriparatide for more than 12 months, compared with 
controls, coinciding with the time point at which the effectiveness of the anabolic 
agent begins to decline (Gatti et ah, 2011). Further, elevated levels of Dkkl have 
been observed in a number of other diseases that experience bone destruction; 
rheumatoid arthritis, psoriatic arthritis and systemic lupus erythematosus (Dalbeth et 
ah, 2010; Liu et ah, 2010; Long et ah, 2010).
The current antibody array analysis found that whole serum levels of Dkkl were 
significantly differentially expressed (Figure 4.7, 4.9). On ELISA analysis, an 
overall trend of up-regulation was noted; however, this trend was not statistically 
significant and also did not reflect the pattern of expression observed by antibody 
array analysis (Figure 4.12). Despite this, statistically significant inverse correlations
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between whole serum levels of Dkkl and hip BMD, spine BMD, hip T score, 
lumbar T score and lumbar Z score were observed (Figure 4.13 a-e). In order to rule 
out the possibility that increasingly levels of Dkkl in serum were merely a result of 
advancing age a correlation analysis between those two variables was carried out, 
with a weak positive correlation noted between serum levels of Dkkl and age that 
was not statistically significant (Figure 4.13f). Importantly, these observations are 
similar to those published previously by Butler et al. who observed inverse 
correlations between serum Dkkl and hip T and Z scores and lumbar T and Z scores 
in a cohort of male and female individuals with DXA measurements (Butler et al., 
2011). From these data, Dkkl warrants further analysis as a circulating marker of 
bone mass.
Wnt inhibitory factor 1 is a conserved Wnt-binding protein that prevents Wnt 
proteins from interacting with membrane-bound LRP5/6 receptors and subsequent 
translocation to frizzled receptors, thus inhibiting the activation of the Wnt 
signalling cascades (Hsieh et al., 1999). This inhibition leads to the formation of a 
‘destruction complex’ comprised of core proteins axin, adenomatous polyposis coli 
(APC) and glycogen synthase kinase-3 (GSK3). This complex rapidly 
phosphorylates cytosolic (3-catenin, targeting it for ubiquitination and proteasome- 
mediated destruction. However, in the presence of Wnt signalling, the cytosolic 
protein dishevelled is recruited by the Wnt/LRP5/6/Frizzled complex, leading to the 
inhibition of the destruction complex. This leads to an accumulation of cytosolic p- 
catenin, which can then translocate to the nucleus to initiate transcription of target 
genes (Chien et al, 2009). Dkkl and Wnt inhibitory factor 1 inhibit Wnt signalling, 
but do so in different manners. While Dkkl competitive binds LRP5/6 via a complex 
it forms with Kremen receptor, Wnt inhibitory factor 1 binds Wnt proteins, 
sequestering them in the extracellular space.
The antibody array study identified Wnt inhibitory factor 1 as significantly 
differentially expressed (Figure 4.7). ELISA analysis of a subset of study 
participants (N=36) revealed a significant increase in the level of Wnt inhibitory
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factor 1 in the osteoporosis group compared with osteopenia. An increase in Wnt 
inhibitory factor 1 between normal and osteoporosis was also noted; however this 
difference was not statistically significant (Figure 4.9). No significant inverse 
correlation between Wnt inhibitory factor 1 and bone density parameters (data not 
shown). From the ELISA data it would appear that an elevated level of circulating 
Wnt inhibitory factor 1 is indicative of low BMD.
There are no reports of elevated levels of Wnt inhibitory factor in postmenopausal 
women with osteoporosis. It is unclear as to whether the observed elevated levels of 
Wnt inhibitory factor 1 contributes towards, or is as a result of the reduction in bone 
density observed by DXA in the study participants. Further studies would be 
necessary in order to fully elucidate both the temporal dynamics of Wnt inhibitory 
factor 1 expression in the development of postmenopausal osteoporosis and the 
value of Wnt inhibitory factor 1 as a serological marker of low BMD.
Interest has grown in recent years with regard to manipulating the Wnt signalling 
pathway for therapeutic gain as it would appear to offer the potential for novel 
anabolic therapies to increase bone density (Canalis et al., 2007). However, it has 
been suggested that caution should be taken when manipulating this pathway as 
depression of Wnt signalling by inhibiting Wnt antagonists in osteoblasts may 
increase the likelihood of the development of osteosarcoma (Kansara et al., 2009).
ROC curves were generated from logistic regression of the ELISA data for 
circulating levels of Dkkl and Wnt inhibitory factor 1 in postmenopausal women 
(N=36) (Figure 4.12). From these curves the AUC values for both Dkkl and Wnt 
inhibitory factor 1 alone and combined were calculated. Figure 4.12a shows the 
AUC values for the discrimination of postmenopausal women with no reduction in 
BMD from those with either osteopenia or osteoporosis. Wnt inhibitory factor 1 
alone was found to have the greatest discriminatory power with an AUC value of 
0.768, superior to that of Dkkl alone (AUC 0.619). Further, combining the two
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proteins, Dkkl and Wnt inhibitory factor 1 resulted in a decrease in the AUC value 
on that generated by Wnt inhibitory factor 1 alone (AUC 0.720). This result is in 
contrast to those presented in Figure 4.12b which shows that the AUC values for the 
discrimination of postmenopausal women with osteopenia from those with 
osteoporosis is optimal when Dkkl and Wnt inhibitory factor 1 measurements are 
combined (AUC 0.736).
Whilst these results are encouraging, and somewhat support the concept that a panel 
of protein markers may provide increase specificity and sensitivity in in vitro 
diagnostics, it should be noted that the AUC values generated of <0.8 would be 
considered sub-optimal. A diagnostic test utilised in a clinical setting with an AUC 
value of less than 1 will inevitably produce false positives and false negatives. 
However, it is important to realise that diagnostic tests that are used in conjunction 
with other clinical parameters and not used as an isolated diagnostic sub-optimal 
specificity and sensitivity values can be tolerated. In summary, assaying circulating 
levels of Dkkl and Wnt inhibitory factor 1 in combination is a promising serological 
methodology of assessing BMD status.
Dkkl, Wnt inhibitory factor 1 and Inhibin A produced different patterns of 
expression by antibody array analysis as by ELISA analysis. The reason for this 
difference is unclear. The two methods of analysis differ in that the array is semi- 
quantitative and ELISAs are fully quantitative. Further, the arrays and the ELISA kit 
were purchased from different manufacturers, therefore different antibodies will 
have been utilised, potentially with different affinities for their respective antigens, 
thus contributing to the discrepancy between the two sets of results. The antibody 
array data presented in this Chapter are not truly quantitative, but semi-quantitative. 
While useful for generating candidate molecular markers of disease, many of which 
are novel, ultimately diagnostic assays of disease need to be quantitative. Due to the 
semi-quantitative nature of antibody array technology, one may be concerned that 
follow-up ELISA data may not reflect the pattern of expression displayed by the
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antibody array. Previous unpublished data carried out in this laboratory assayed 
homologous to /ymphotoxins, exhibits /nducible expression, and competes 
with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes 
(LIGHT) in the serum of a small cohort of postmenopausal women (N=16) by 
ELISA. LIGHT is a member of the TNF superfamily that potentially has a role in 
promoting RANKL mediated osteoclastogenesis and is elevated in the serum of 
individuals with Rheumatoid Arthritis (Edwards et al., 2006). Whilst the trends seen 
by ELISA were not statistically significant, the overall expression in the three 
cohorts, normal, osteopenia and osteoporosis, mirrored those seen in (Figure 4.9). 
This indicates that follow-up studies analysis for individual proteins identified as 
significantly differentially expressed by antibody array analysis may produce a 
similar pattern of expression by quantitative ELISA analysis. This is in addition to 
the pattern of expression levels of Gremlin observed by ELISA mirroring those 
observed by antibody array analysis in the current study.
As discussed earlier, there are no previously published studies in the literature that 
utilise an antibody array approach to identifying differentially expressed proteins in 
postmenopausal women with osteopenia and osteoporosis. Therefore, it is to be 
expected that many of the 507 proteins assayed have not previously affiliated with 
osteopenia or osteoporosis. As all the current study participants were 
postmenopausal, it is likely that at least some of the 156 significantly differentially 
expressed proteins may be attributable to oestrogen status. However, the 75 
significantly differentially expressed proteins tabulated in Appendix 7 have 
previously not associated with postmenopausal osteopenia and osteoporosis 
providing a novel insight into the molecular mechanism of disease pathogenesis. 
However, further investigation into individual proteins is required before one can 
definitively link any of these novel proteins with postmenopausal bone loss.
The current study has some limitations; the pooling strategy implemented in the 
antibody array analysis has the benefit of reducing the very significant costs 
involved, however, measured output may be skewed by some outlier in the patient
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cohort. Further, validation analysis was carried out only on a sub-group of array 
participants due to cost constraints. Future work could include the ELISA analysis of 
the circulating levels of Dkkl and Wnt inhibitory factor 1 in the additional antibody 
array participants, in addition to further independent patient samples.
ROC curves were generated in the current study as it is a requirement for candidate 
biomarker publications in proteomic journals. However, as outlined in section 3.4.5 
there are some limitations associated with ROC analyses. ROC analyses are not 
sensitive to additional variables and AUC values cannot be compared between 
studies and occasionally within studies. Further, ROC cannot be used within the 
context of a clinical tool to identify risk categories for therapeutic intervention. 
Additionally, the current study utilises ELISA data from the same study participants 
as those used to generate the antibody array data. Therefore, the possibility of the 
introduction of bias cannot be ruled out. Future work will require the inclusion of 
study participants independent of those included in this study.
Further validation experiments could be valuable on a number of other candidates 
identified as being differentially expressed by antibody array analysis and are of 
relevance to osteopenia and osteoporosis. Osteocrin is a recently identified protein 
expressed by osteoblasts and young osteocytes that appears to act as a soluble 
osteoblast regulator (Hingorani et al, 2003). It is highly expressed at sites of bone 
remodelling, and thus a role in bone formation has been suggested (Ahmed et al, 
2005). A transgenic mouse model that over expresses Osteocrin displays elongated 
limbs and kyphosis due to vertebral overgrowth (Moffatt et al., 2007). It is 
interesting to note, therefore that there is an overall down-regulation of expression in 
the antibody array analysis across the three clinical cohorts in the current study. 
While there are no previous clinical studies measuring circulating levels of 
Osteocrin, it would seem worthy of further investigation as a candidate marker of 
osteopenia and osteoporosis. However, the inclusion of additional clinical groups 
such as osteoarthritis, rheumatoid arthritis would be required to ascertain disease 
specificity.
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• Antibody array analysis is a suitable methodology for identifying 
differentially expressed proteins in postmenopausal women with osteopenia 
and osteoporosis.
• Of the 156 significantly differentially expressed proteins identified by 
antibody array analysis 75 have no previous associations with bone, bone 
turnover or bone loss thus providing a novel insight into the molecular 
mechanism of disease.
4.5 C onclusion
• Serum Dkkl and Wnt inhibitory factor 1 are promising circulating markers 
of bone density parameters in postmenopausal women.
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Chapter 5 Discussion
Ireland, like many other countries, is in the midst of a process of population ageing. 
This is mainly due to longer life expectancy. Population ageing will have significant 
impacts both on the individual, who can expect to live longer than the previous 
generation, and for society, as a significant burden is placed on healthcare provision. 
The number of individuals in Ireland aged 65 years and over is projected to increase 
160% between 2011 and 2041 from 535,000 to just under 1.4 million (CSO, 2008). 
Whilst osteoporosis is not strictly a disease of the elderly, it is associated with 
ageing. Therefore, as the population ages, the incidence of osteoporosis is due to 
rise. A recent report revealed that the total number of fractures occurring in the UK, 
France, Italy, Germany, Spain and Sweden combined is set to rise from 2.46 million 
in 2010 to 3.17 million in 2025, an increase of 28.9% (Strom et ah, 2011).
The interest in the impact of an ageing population is becoming increasingly 
prevalent. The establishment in 2006 of The Irish Longitudinal Study on Ageing 
(TILDA) led by Trinity College in collaboration with a number of other Irish third 
level institutions including the Royal College of Surgeons in Ireland, is the most 
comprehensive study on ageing carried out in Ireland due to be completed in 2018 
and is demonstrative of this interest. The output from studies such as TILDA have 
the potential to influence policy makers regarding the provision of healthcare into the 
future.
One finding of the first report from TILDA pertinent to the work in this thesis was 
that a large proportion of TILDA study participants had undiagnosed osteoporosis, 
as determined by heel ultrasound. Of the female participants in the study assessed as 
having osteoporosis 66%, had no such previous diagnosis. A more striking outcome 
was that none of the male participants in TILDA assessed as having osteoporosis had 
such a previous diagnosis (Barrett, 2011). It is therefore of concern that unless 
awareness of osteoporosis is raised, the burden of this debilitating disorder will only 
increase. These factors underline the importance of awareness on the part of 
individuals and healthcare providers. Availability and utility of diagnostics will be 
crucial in the coming years. This importance is underlined by the development of 
FRAX® as a web-based tool for the calculation of ten year risk of fracture and the
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emerging potential utility of Raman spectroscopy to predict risk of fracture (Moran 
et al., 2007; Kanis et al., 2010).
Diagnosis in itself is not enough to prevent fragility fractures, effective therapies 
must be prescribed and adhered to. On ascertaining that an individual would benefit 
from therapeutics to reduce risk of fracture, there are a range of effective 
pharmaceutical and lifestyle modifications available. Anti-resorptive drugs 
bisphosphonates; alendronate, risedronate, ibandronate and zoledronate, OPG 
analogue antibody denosumab and selective oestrogen receptor modulator (SERM) 
raloxifene; and anabolic agents teriparatide and PTH (1-84), and strontium ranelate 
all aim to exhibit anti-fracture efficacy at various skeletal sites (Rachner et al.,
2011). However, long-term compliance to therapy is an issue with osteoporosis, 
declining dramatically after the first year, in a manner similar to other chronic 
diseases. The advent of one yearly intravenous infusion of zoledronate and twice 
yearly subcutaneous infusions of denosumab may go some way towards dealing with 
this issue (Cadarette and Burden, 2010; Imaz et al., 2010). However, it is also worth 
noting that, as most fragility fractures are associated with a fall, reducing the risk of 
falls is also of use when considering therapeutic interventions for osteoporosis. 
Therapeutic methodologies could be greatly ameliorated by the inclusion of an 
assessment of a patient’s risk of falls and the execution of appropriate interventions 
to reduce the risk of falls where deemed necessary.
5.1 Proteomics as a tool for the analysis of human serum
Proteomic technologies provide an opportunity to gain an insight into the overall 
expression profile of a patient cohort. In the post genomic era there has been much 
interest in the use of microarray technologies to analyze gene expression in various 
diseases. Whilst gene expression can provide a valuable understanding of the 
changes in molecular mechanisms, gene expression profiles may not resemble 
protein expression profiles. The discovery of microRNAs in recent years, which can 
result in translational repression of mRNA, is an additional layer of complexity 
added to the comprehension of molecular mechanisms.
Ideally, diagnostic tests for individual proteins should display specificity and 
sensitivity levels close to 100%, thus reducing the possibility of producing a false 
positive or false negative. A recent study comparing the death rate from prostate
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cancer in a cohort of men screened for prostate cancer compared with a control 
group over a twenty year period and found no difference between the groups. 
Screening involved assaying prostate specific antigen (PSA), regarded as one of the 
first molecular markers. However, the specificity and sensitivity of PSA has been 
established for some time as being below 100%, which may account for the poor 
outcome of screening for prostate cancer. Despite this, PSA represented the first 
generation of circulating biomarkers; a non-invasive method of diagnosing a solid 
tumour, involving minimal sample preparation.
Serum and plasma are the preferred specimens for the non-invasive sampling of 
normal individuals, at-risk groups and patients for protein biomarkers discovered and 
validated to reflect physiological and pathological phenotypes. Serum and plasma 
present challenges due to their extreme complexity in that potentially all proteins in 
the body are represented with, ten orders of magnitude in protein concentration and 
individual variation due to genetics, environmental factors, diet and smoking.
Further, sample processing in a non-standard manner can prove a significant source 
of variation.
Reducing the complexity of serum by depletion or fractionation of intact proteins 
greatly simplifies the task of down-stream analysis by platforms such as 2D DIGE. 
There are numerous studies, some of which were carried out as part of the Human 
Proteome Organisation (HUPO) Plasma Proteome Project, supporting the fact that 
the removal of abundant proteins from plasma and serum increases the number of 
proteins detected in down-stream analysis (Bamea et al, 2005; Cho et al., 2005; 
Echan et a l,  2005; Huang et al., 2005; Li et a l,  2005; Misek et a l,  2005; Moritz et 
al., 2005; Tang et a l,  2005; Yang et al., 2005; Zolotarjova et al., 2005).
This thesis in chapter 2 presents a relatively inexpensive method of removing 
abundant proteins from human serum that increases the number of protein spots 
resolved, making it suitable for down-stream analysis by 2D DIGE. The alteration of 
the provided protocol for depletion of human serum by IgY Spin Column technology 
proved a suitable method of producing depleted serum. Whilst liquid 
chromatography mass spectrometry (LC-MS) revealed a number of proteins non- 
specifically removed in the fraction bound by the IgY 14 columns utilised for the 
subsequent 2D DIGE study, the quantity removed was small relative to the total
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bound fraction. The removal of non-specific proteins in the bound fraction is of some 
concern, however, the findings outlined of low-non specific binding are in line with 
a previous study and more favourable than the equivalent IgG based depletion 
technology (Huang et al., 2005). However, it could be the case that the abundant 
portion of the serum samples utilised in the 2D DIGE study may be of interest, and 
so all bound protein portions from the 36 serum samples were stored at -80°C thus 
enabling further study in the future if desired. This compares favourably to similarly 
priced single use columns where the bound portion cannot be retrieved.
The serum depletion protocol presented in this thesis is relatively inexpensive when 
compared with the higher capacity HPLC version of the IgY14 column. However, 
due to its lower capacity, multiple aliquots of each sample were required to be 
processed. This dramatically increased the labour intensity of the sample preparation 
process. This is an important consideration in selecting a serum depletion strategy.
While software used to analyze 2DE images have improved over time, and this 
technology is widely utilized, the intelligence has not been perfected. For example, 
while PDQuest™ (BioRad) and Progenesis, used in this thesis, tend to agree on the 
quantification and analysis of well-defined well-separated protein spots, they deliver 
different results and analysis tendencies with less-defined, less-separated spots. 
Discrepancies such as these are of concern to researchers utilizing 2DE. Further, 
automatic software-based analysis faces additional challenges such as incompletely 
separated spots, distinguishing weak spots from background, unmatched or 
undetected spots leading to missing values all of which confound analysis (Pedreschi 
et al., 2008; Miecznikowski et al., 2010). However, Progenesis SameSpots software 
package used in this study goes some way towards overcoming these issues.
While 2D DIGE analysis of depleted human serum in chapter 3 provided an insight 
into medium abundance proteins in the serum of postmenopausal women, the 
antibody array study carried out in Chapter 4 provided insight into low abundance 
proteins such as cytokines, some of which are beyond the detection limit of 2D 
DIGE. Therefore, the analysis carried out in this thesis provides a comprehensive 
proteomic analysis of circulating serum of postmenopausal women with osteopenia 
and osteoporosis.
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5.2 Differential protein expression in postmenopausal women with 
osteopenia and osteoporosis
The proteomic analyses carried out in this thesis utilising 2D DIGE and antibody 
array platforms provides a novel insight into the pathogenesis of bone loss. To date 
there are no published studies that use these approaches to investigate the serum 
profile of postmenopausal women with osteopenia and osteoporosis.
The analysis of serum from postmenopausal women depleted of major abundant 
proteins by 2D DIGE revealed a set of proteins significantly differentially expressed 
none of which have previously associated with osteopenia or osteoporosis. 
Admittedly, as mentioned, no 2D DIGE study has been carried out on samples such 
as these, nonetheless, this finding underlines the ability of 2D DIGE to generate 
novel data.
Having been in existence for thirty years in its current format, the inherent 
limitations of 2DE are well understood. However, the issues of gel-to-gel variation, 
accurate quantitation and accurate spot matching across a gel set were overcome by 
using 2D DIGE used in Chapter 3. Similarly, since its commercialisation the 
limitations of 2D DIGE have been identified. In a three way Cy dye study that labels 
the internal pooled standard with Cy2 and the study samples with Cy3 and Cy5, Cy2 
is used as a denominator in generating a spot volume value for a given spot, with the 
numerator being the Cy3 value for that particular spot in the control sample, for 
instance, and Cy5 for the experimental sample. However, this approach violates the 
basic assumption of a statistical test such as Student’s t test and ANOVA, that the 
pieces of data being compared are independent of each other. In this case, a common 
value, the Cy2 generated spot value, is used to generate the two data points (Karp 
and Lilley, 2005; Karp et al., 2007). The work presented in Chapter 3 overcomes this 
shortfall by using only Cy3 and Cy5, where the internal standard was labelled with 
Cy5 and used for the purpose of normalisation and accurate spot volume assessment 
across the gel set. The approach is one that is becoming increasingly prevalent in the 
literature (Grassl et al., 2010; Scaife et al., 2010).
An interesting finding of the 2D DIGE study in Chapter 3 was that, of the three 
comparisons made, the largest number of differentially expressed spots were 
identified in the osteoporosis group compared with the osteopenia group (N=48
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proteins). There was also a very notable separation of protein expression profiles 
between osteopenia and osteoporosis as determined by principal component analysis. 
The reason for this is unclear, but may be reflective of the progression and 
pathogenesis of advancing bone loss. However, no firm conclusions can be reached 
without further investigation in the form of identification of the protein spots not 
already identified in Chapter 3 and validation by methods such as ELISA used in this 
thesis or Western Blot analysis. This analysis was beyond the scope of this thesis but 
warrants further investigation as in vitro and in vivo analyses tend to focus on the 
early stages of high bone turnover and subsequent bone loss. The analysis of later 
stages of bone loss by proteomics will contribute significantly to knowledge of the 
molecular changes of advancing bone loss
The antibody array analysis carried out in Chapter 4 revealed a significant number of 
proteins (N=60 proteins) differentially expressed with roles in immunity and 
defence. This finding is of note in the light of the emerging field of 
osteoimmunology; the crosstalk between bone and the immune system. At the fore 
of this field is the RANK-RANKL-OPG signalling axis. RANK and OPG were 
significantly differentially expressed across the three clinical cohorts by antibody 
array analysis. It is difficult to assess where the data generated from the array study 
stand in the literature as while much data have been gathered from in vitro and in 
vivo studies in relation to this signalling axis, consensus has yet to be reached 
regarding circulating levels of these proteins in individuals experiencing bone loss. 
This issue would benefit greatly from further study to fully elucidate the correlation 
between circulating serum levels of RANK, RANKL and OPG. In the case of OPG, 
being secreted by osteoblasts, it may be the case that as bone mass decreases, the 
number of osteoblasts decrease, thereby decreasing the number of cells that can 
produce OPG.
The emerging role of osteocalcin as a hormone with a role in energy metabolism 
firmly links the skeleton to fat and glucose homeostasis. In this context it is 
interesting to note that antibody array analysis detected four proteins with roles in 
energy metabolism as being differentially expressed across the three cohorts of 
postmenopausal women; glucagon, insulin receptor, leptin receptor and adiponectin. 
This observation is similar to that made in an ovariectomised mouse model that 
subjected protein extracted from the humerus to 2DE and identified a number of
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differentially expressed proteins with roles in energy metabolism such as pyruvate 
kinase, aconitase 2, enolase(3 and transaldolase (Pastorelli et al., 2005). Whilst it is 
difficult to make comparisons between tissue analysis from an animal model study 
and serum analysis from a clinical study, not least those that have been analysed in 
different manner, it is nonetheless interesting to observe this similarity. There is no 
overlap in identities of the individual proteins; none of the oestrogen regulated 
proteins identified by Pastorelli et al. were included in the antibody array carried out 
in Chapter 4 and as serum and not whole bone extract was analysed by 2D DIGE in 
Chapter 3 it may be the case that these proteins were outside the limits of detection 
of 2D DIGE.
A large number of cytokines were identified as being differentially expressed by 
antibody array analysis in Chapter 3. Cytokines are of particular relevance to 
osteoclasts, being critical for their formation and function. Cytokines macrophage 
colony stimulating factor (MCSF), TNFp, and IL-10 were identified as differentially 
expressed by antibody array analysis all of which have roles in relation to 
osteoclasts. Cytokines are outside the range of detection in serum when analysed by 
2DE. In this manner the two proteomic studies presented in this thesis complement 
and enhance each other.
The two proteomic analyses produced two distinct outputs, with no overlap of 
proteins identified as being differentially expressed between the two studies. This 
underlines the point that utilising two proteomic platforms functioning on two 
different bases will produce two different outcomes. However, while the identities 
of the individual proteins differ between the two studies, there is some common 
ground between the Gene Ontology analyses. Both studies identified significantly 
differentially expressed proteins with roles in immunity and defence; 2D DIGE 
identified 5 including proteins involved in antibacterial response and antibody array 
analysis identified 60 proteins.
The assessment of functionality of a given protein identified by the analyses in 
Chapters 3 and 4 in relation to postmenopausal osteoporosis would most likely entail 
the generation of an animal knock-out model and subsequent ovariectomy as the 
multicellular nature of the disorder is such that in vitro analysis may be insufficient.
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The generation of animal knock-out models involves significant resources that were 
beyond the scope of this particular project.
Any given proteomic technique has its inherent limitations, no single proteomic 
technique can resolve or detect all the proteins in a given proteinaceous sample, 
particularly one as complex as serum. By utilising two different approaches to a 
singular issue, the work presented in this thesis represents a comprehensive 
proteomic analysis of postmenopausal women with bone loss.
It is important to note that studies such as the 2D DIGE study and antibody array 
study presented in this thesis in addition to putting forth candidate serological 
markers of a reduction in BMD shed new light into the pathogenesis of osteoporosis 
in a manner not previously published before.
5.3 Clinical implications
The number of studies published putting forward candidate markers of various 
diseases continues to rise. However, the number of proteins receiving FDA approval 
for use in a clinical setting remains low. The reason for this discrepancy may be due 
to the fact that, unlike the drug-discovery process where a lead compound progresses 
through well-defined stages in a step-wise manner, often within the confines of a 
single company, the biomarker discovery process has yet to become as well 
established. Therefore, promising candidate markers may never progress beyond the 
initial discovery phase.
The finding in Chapter 3 that GFAP is significantly up-regulated in postmenopausal 
women with osteopenia and osteoporosis compared with Normal postmenopausal 
women and significantly inversely correlated with bone density parameters lumbar 
BMD and lumbar T score is of interest clinically as it represents the potential for a 
very specific serological marker as it is expressed in the cytosol of osteocytes.
It has been reported that the serum level of GFAP rises after traumatic brain injury 
and in the case of hepatic stellate cell activation in hepatitis C (Carotti et al., 2008; 
Honda et al., 2010). Whilst they represent very specific circumstances that can be 
easily ruled out, nonetheless they would need to be taken into consideration if GFAP 
were to be utilised in the context of a serum marker of bone density parameters.
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It should be noted that vitronectin was recently identified as a candidate biomarker 
of breast cancer, therefore there may be issues with specificity in relation to this 
particular protein (Kadowaki et al., 2011). This would need to be considered if this 
particular marker were to be used clinically in relation to osteoporosis. It is also 
interesting to observe that in addition to its role in osteoclastogenesis, vitronectin 
also appears to have a role in the osteogenic differentiation of mesenchymal stem 
cells (MSCs) (Salasznyk et al., 2004; Kundu and Putnam, 2006). Clearly, further 
study is required in order to fully ascertain the functional relevance of vitronectin in 
postmenopausal osteoporosis.
The importance of specificity and sensitivity of a diagnostic marker in the early 
validation stage cannot be overstated, as these characteristics assess the likelihood of 
generating a false positive and false negative respectively. Area under the curve 
(AUC) analysis for GFAP and vitronectin showed that assaying circulating levels of 
these two proteins in combination produces specificity and sensitivity levels superior 
to those produced by either protein alone when attempting to identify individuals 
with either osteopenia or osteoporosis compared with individuals who don’t (Figure 
3.19). This finding supports the concept that a panel of proteins may provide 
superior diagnostic utility and may support a move away from the reliance on single 
biomarkers in clinical diagnosis.
The Wnt signalling cascade is an important trigger of osteoblast differentiation 
(Baron and Rawadi, 2007). A Wnt protein binds to the LRP 5/6 receptor, allowing it 
to translocate and complex with the receptor frizzled. The intracellular protein 
Dishevelled is recruited to the complex and at this point, depending on which Wnt 
protein has bound the receptor complex, one of the three Wnt signalling pathways 
will be initiated: canonical, non-canonical and calcium dependant. The canonical 
Wnt signalling pathway is the best studied and understood in relation to bone. This 
form of Wnt signalling relies on the stabilization of P-catenin in the cytoplasm, 
resulting in its accumulation and subsequent translocation to the nucleus, where it 
induces transcription of target genes. In the absence of the binding of Wnt proteins, 
P-catenin does not accumulate and therefore canonical Wnt signalling will not occur. 
Dkkl inhibits Wnt signalling by binding the receptor kremen, which then complexes
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with LRP 5/6, thus preventing Wnt proteins from binding (Mao et al., 2002). Wnt 
signalling can also be inhibited by Sclerostin, which binds LRP 5/6 directly, thus 
preventing Wnt proteins binding (Li et al., 2005). Further, Wnt inhibitory factor 1 
(WIFI) binds Wnt proteins directly, suppressing Wnt signalling (Hsieh et al., 1999).
The finding that serum levels of Dkkl are significantly correlated with bone density 
parameters in Chapter 4 is of particular interest. Dkkl is produced by osteoblasts and 
osteocytes and therefore has the potential to be a specific marker of bone loss and 
not just an indication of systemic changes in the body in response to a fall in the 
level of oestrogen after menopause. Indeed, Butler et al. observed similar 
correlations between serum Dkkl and BMD parameters. It is interesting to note that 
while results in Chapter 4 noted a significant inverse correlation between serum 
Dkkl and hip and spine BMD, Butler et al. did not. The reason for this discrepancy 
is unclear; it may be a result of Butler et al. recruiting both male and female 
participants, whereas the work presented in this thesis involved only postmenopausal 
women. WIFI was also highlighted as significantly differentially expressed by 
antibody array analysis and subsequent ELISA analysis, albeit displaying different 
expression patterns.
AUC analysis for Dkkl and WIFI revealed interesting results; for distinguishing 
postmenopausal women with osteopenia or osteoporosis from those without WIFI 
displayed an AUC value superior to that of Dkkl or the two proteins combined. In 
contrast, when utilised to attempt to distinguish individuals with osteopenia from 
those with osteoporosis the combination of the measurement of Dkkl and WIFI 
provided the best AUC values indicative of enhanced specificity and sensitivity. 
These results mirror those of Chapter 3 in that they again are supportive of the 
concept that the combination of measurements of circulating protein levels may be of 
greater clinical utility compared with assaying a single protein in isolation.
ROC analysis to generate AUC values for the individuals for whom circulating 
levels of GFAP, vitronectin, Dkk 1 and WIF1 were assayed was carried out. AUC 
values generated were below 0.5, indicative of a diagnostic of no value (data not
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shown), this was most likely attributable to the low number of individuals for which 
all ELISA levels were measured (N=10). This was due to only a small overlap of 
study participants existing between the 2D DIGE study and the antibody array 
analysis. Assessment of the utility of the combination of all four proteins would 
benefit greatly from further study with larger study participant numbers.
5.4 Future work
The work in this thesis successfully validated proteins GFAP, vitronectin, Gremlin, 
WIFI and Dkkl by ELISA identified by 2D DIGE and antibody array analysis as 
being differentially expressed. AUC analysis suggested that assaying circulating 
levels of GFAP and vitronectin combined and Dkkl and WIFI combined have 
clinical utility in identifying individuals with a reduction in BMD. However, many 
more proteins identified by both proteomic platforms would benefit greatly from 
additional study and would significantly add to the published literature. Analysis 
could be in the form of ELISA carried out in this thesis, or Western blot analysis.
The finding in this thesis that serum levels of Dkkl are significantly inversely 
correlated with BMD in postmenopausal women is one that poses much promise for 
Dkkl as a blood marker of BMD, but also poses a number of questions. Being 
predominantly expressed postnatally by osteoblasts and osteocytes, Dkk 1 would 
appear to be a tissue specific marker rather than a marker of a systemic response to 
bone loss. However, in order to ascertain disease specificity, further studies 
analysing Dkkl would benefit greatly from the inclusion of cohorts of individuals 
with other bone disorders, particularly those that experience bone destruction. These 
cohorts might include osteoarthritis and rheumatoid arthritis patients and would 
assess whether the inverse correlation seen in this thesis are specific to osteopenia 
and osteoporosis. A further study of Dkkl and individuals with bone loss with 
larger participant numbers will be necessary to further consolidate Dkkl as a 
serological marker of BMD. In the course of collecting samples for the work in this 
thesis, additional serum samples have been acquired (total N=150). It was not 
financially feasible in the context of this particular project to analyse any samples 
additional to those presented in this work. The analysis of a much larger number of
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individuals will be required in order to further add to observations presented in this 
thesis.
The issue of tissue specificity is important in biomarker discovery; that is, 
ascertaining whether the candidate marker is produced by the affected tissue in 
question, or whether the marker represents a systemic response to disease. In the 
case of Dkkl, there is tissue specificity as it has been established in the literature that 
postnatally it is secreted by osteoblasts and osteocytes.
The Wnt signalling pathway is emerging as a target for therapeutic intervention in 
the treatment of osteoporosis. Sclerostin is secreted by osteocytes and inhibits Wnt 
signalling by binding LRP5/6, this prevents any Wnt protein binding receptor 
LRP5/6. Two rare genetic disorders; Van Buchem’s disease and sclerosteosis exhibit 
high bone mass and display inactivating mutations in the gene coding for sclerostin 
(Balemans et ah, 2001; Loots et al., 2005). A monoclonal antibody against 
sclerostin, AMG 785, is currently in a Phase 2 clinical trial with postmenopausal 
women with low BMD compared with the anti-resorptive alendronate and the 
anabolic agent teriparatide. This follows promising pre-clinical data where 
subcutaneous injections of AMG 785 increased bone mass at the femoral neck, 
radius and tibia of cynomolgus monkeys and no reported adverse events in the phase
1 clinical trial (Ominsky et al., 2010; Padhi et al., 2010). Inhibiting Dkkl has been 
investigated only pre-clinically to date, and only recently with a view to treating 
postmenopausal osteoporosis in mouse and primate models of osteoporosis 
(Glantschnig et al., 2011). Further, the anti-Dkkl antibody BHQ 880 has been 
investigated as an agent to prevent osteolysis associated with multiple myeloma 
(Heath et al., 2009). It is also interesting to note that a recent study that analysed 
the gene expression profile of iliac crest biopsies taken from postmenopausal women 
and found that gene expression levels of DKK1 were significantly decreased in 
women with osteoporosis compared with those who did not (Jemtland et al., 2011). 
The reason for the observed inverse correlation between gene expression levels and 
serum levels of Dkkl is unclear; it may be as a result of some as of yet understood 
mechanism to compensate for a decline in BMD. Further study is required to fully 
elucidate the role Dkkl may play in the pathogenesis of osteoporosis.
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It was beyond the scope of the work in this thesis to investigate if there is a 
correlation between serum levels of sclerostin and BMD. Recent studies found a 
positive correlation between serum levels of sclerostin and BMD in postmenopausal 
women and haemodialysis patients (Cejka et a l,  2011; Polyzos et al., 2011). A study 
assaying serum sclerostin levels in children has suggested that sclerostin levels are 
associated with cortical porosity (Kirmani et al., 2011). Further, a study interested in 
the response of cytokines and osteoprogenitor cells to oestrogen found that 
postmenopausal women receiving oestrogen have significantly lower levels of 
sclerostin compared with postmenopausal women not receiving oestrogen, indicating 
that oestrogen may have a role in the regulation of sclerostin expression (Modder et 
ah, 2011). As mentioned, 150 individual samples from postmenopausal women with 
varying degrees of bone loss have now been collected from our collaborators at St 
James’ Hospital and are in storage at -80°C. Levels of sclerostin could be assayed in 
these samples in order to add to the accumulating published data and establish a 
consensus.
GFAP was identified as significantly differentially expressed by 2D D1GE and 
subsequently validated by ELISA. It is possible that the observed rise in GFAP 
serum levels by ELISA in postmenopausal women with osteopenia and osteoporosis 
is as a result of GFAP being released from the cytosol of osteocytes as their cell 
processes are ruptured as microcracks appear in bone. Further study will be required 
in order to ascertain if this is the case. In vitro analysis of microdamage in an 
osteocytes-like cell line MLO-Y4 has been carried out within this research group. 
Osteocyte networks are cultivated in a collagen gel and microdamage simulated 
using acupuncture needles in order to investigate RANKL and OPG response to 
microdamage (Mulcahy et a l,  2011). This in vitro system could be utilised to 
ascertain if GFAP is in fact released as a result of microdamage. Additional further 
study of GFAP levels in serum samples would benefit significantly from the 
inclusion of other patient groups that experience bone destruction in a manner 
similar to that of Dkkl.
While GFAP has the potential to be a very specific marker, it is unclear as to 
whether vitronectin presents the same opportunity as it is expressed predominantly 
by the liver. However, as a matrix protein it is possible that the observed increase in 
serum levels of vitronectin by both 2D DIGE and ELISA is a consequence of
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vitronectin release from bone matrix as bone density declines. A recent study 
identified a vitronectin fragment as a candidate marker of osteoarthritis (OA), noting 
an increase in the level of V65 vitronectin fragment in the serum and synovial fluid 
of individuals with OA, speculating that the increase may be attributable to matrix 
degradation (de Seny et al., 2011). It is possible that this may also be the case with 
declining bone density. Clearly, additional study is required to establish if this is the 
case. The inclusion of an animal model of osteoporosis, such as ovariectomised mice 
or sheep would be useful in order to establish if vitronectin continues to increase as 
bone density declines.
Given the value of the current immunodiagnostic market is estimated to be US$12 
billion annually, there is much interest in the development of biomarker diagnostic 
tests. As mentioned, any biomarker used in a clinical setting in diagnosis would 
require FDA approval. This would involve much larger participant numbers than 
those involved in this thesis and, if required, the development of a specific biomarker 
assay. Diagnostics are classified by the FDA as being either class I, II or III 
(Kingsmore, 2006). Figure 5.1 summarised the subsequent steps required to take a 
validated biomarker assay to an assay that can be performed in a clinical laboratory. 
The work presented in this thesis represents the first stages of developing a validated 
biomarker assay.
While GFAP, vitronectin, WIFI and in particular Dkkl appear to be promising 
blood based markers of BMD status, they may not necessarily have the required 
specificity and sensitivity to be used in isolation for diagnosis, despite promising 
AUC analyses. Further, it is unlikely that a single blood based marker alone will 
replace diagnostics currently in clinical practice for osteoporosis. Further analysis of 
candidates identified by the proteomic techniques in this thesis may add to a panel of 
biomarkers which when analysed in combination provide a more robust tool for 
diagnosing osteoporosis and the efficacy of its treatment. It is more likely that the 
future of diagnostics in osteoporosis will lie in the use of markers new and old in 
conjunction with DXA, FRAX® and other clinical tests.
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Figure 5.1: Schematic of the steps for the development of validated biomarkers into a clinical 
diagnostic test.
(Kingsmore, 2006)
Optimized, multiplexed assays are developed for validated biomarkers and 
transferred to an immunodiagnostic platform. Then specifications are determined 
regarding analytical and clinical performance. Finally, in vitro diagnostic 
development is driven by regulatory, manufacturing and marketing considerations. 
CLIA, Clinical Laboratory Improvement Amendment (the US law to ensure quality 
laboratory testing); GMP, good manufacturing practice.
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• The manufacturer’s protocol for removal of abundant serum proteins using 
IgY Spin Columns failed to produce serum depleted to a satisfactory level. 
However, with some modification to the manufacturer’s protocol shown in 
this study abundant proteins were removed from human serum to a 
satisfactory level.
• IgY Spin Column technology, utilising a modified protocol, is an effective 
method of producing depleted serum suitable for subsequent proteomic 
analysis by 2D DIGE in the context of biomarker discovery in 
postmenopausal osteoporosis.
• 2D DIGE successfully isolated 21 significantly differentially expressed 
protein spots in the depleted serum of postmenopausal women with 
osteopenia and osteoporosis, of which 18 were positively identified by mass 
spectrometry.
• Of the 18 proteins, none have previously been associated with 
postmenopausal osteoporosis, underlining the ability of 2D DIGE to provide 
a new insight into a systemic disorder on a whole body basis.
• Measuring circulating levels of GFAP and vitronectin combined is a 
promising method of identifying postmenopausal women with osteopenia 
and osteoporosis compared with women with normal BMD.
• Antibody array analysis provides an additional novel insight into the 
molecular mechanism of disease successfully identifying 156 significantly 
differentially expressed proteins of which 75 have no previous associations 
with bone, bone turnover or bone loss.
• There was no overlap in the identities of the differentially expressed proteins 
highlighted in both studies, vindicating the approach of utilising two 
different proteomic platforms in this thesis.
5.5 F in al conclusions
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WIFI and Dkkl are promising serological markers of BMD ' 
postmenopausal women.
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1001 Normal 55 160.0 80.0 31.2 -0.3 -0.9 0.939 1.068 none 92 18.9 0.218 34.1 21.1 45
1020 Normal 57 159.0 69.6 27.5 -0.2 0.7 1.039 1.265 none 48 21.1 0.374 41.6 50.8 43
1056 Normal 69 151.7 61.1 26.6 -0.6 -0.8 0.910 1.087 none 52 22.1 0.398 41.7 36.8 44
1059 Normal 57 164.0 71.3 26.5 -0.3 -0.6 0.938 1.112 none 19 23.4 0.452 48.1 36.1 44
1075 Normal 57 163.0 65.8 24.8 0.2 -0.7 1.018 1.089 none 96 37.2 0.502 64.4 31.6 42
1076 Normal 61 167.8 76.7 27.2 -0.6 -0.2 0.924 1.153 none 23 9.9 0.233 18.2 67.5 44
1082 Normal 61 158.0 71.5 28.6 -0.7 0.2 0.898 1.200 none 73 13.7 0.226 29.4 30.2 43
1092 Normal 70 157.0 79.6 32.3 -0.9 -0.7 0.869 1.097 none 76 23.7 0.404 61.9 19.1 43
1111 Normal 60 158.5 64.2 25.6 -0.6 -0.7 0.903 1.099 none 41 14.9 0.134 24.7 40.7 43
1123 Normal 61 160.5 97.7 37.9 -0.4 -0.2 0.850 1.151 none 41 24.1 0.221 61.3 43.7 45
1155 Normal 64 165.0 62.9 23.1 0.3 -0.5 1.021 1.125 none 50 19.2 0.140 34.3 23.5 45
1187 Norm al 69 168.0 78.2 27.7 -0.7 0.4 0.914 1.229 none 61 30.3 0.390 83.0 24.4 43
1018 Osteopenia 57 165.0 66.0 24.2 -0.5 -2.4 0.924 0.894 none 72 23.0 0.109 34.2 40.8 46
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1024 Osteopenia 76 172.0 94.0 31.8 -1.2 -1.1 0.859 1.051 none 19 16.9 0.182 32.2 47.7 44
1027 Osteopenia 61 153.0 66.0 28.2 -0.4 -1.3 0.937 1.020 none 18 20.8 0.305 29.9 50.9 39
1029 Osteopenia 57 168.5 87.0 30.6 -0.5 -1.4 0.942 1.004 none 24 24.9 0.306 50.9 31.1 45
1031 Osteopenia 56 171.3 95.8 32.6 0.8 -1.9 1.079 0.956 none 26 16.9 0.281 32.7 42.6 47
1035 Osteopenia 65 167.5 74.5 26.6 -1.1 -1.6 0.846 0.991 none 41 30.8 0.646 77.1 54.6 40
1049 Osteopenia 76 166.0 79.7 28.9 -2.4 -0.3 0.687 1.148 none 13 30.4 0.226 63.5 37.3 42
1062 Osteopenia 72 162.0 64.1 24.4 -1.1 -1.6 0.852 0.977 none 24 29.3 0.652 76.8 29.2 42
1077 Osteopenia 58 168.5 76.7 27.0 -0.7 -1.3 0.898 1.011 none 77 35.2 0.581 71.7 32.4 45
1124 Osteopenia 63 158.0 59.0 23.6 -1.9 -2.1 0.747 0.928 none 30 19.8 0.327 61.6 31.9 45
1128 Osteopenia 63 160.0 69.2 24.5 -1.7 -1.4 0.798 1.014 none 65 24.4 0.334 48.5 24.5 45
1138 Osteopenia 58 159.0 89.9 35.9 0.9 -1.2 1.109 1.037 none 10 15.6 0.254 39.4 71.7 47
1003 Osteoporosis 56 164.5 68.0 21.5 -1.3 -2.4 0.824 0.894 none 27 35.1 0.351 78.8 25.0 48
1023 Osteoporosis 75 154.0 59.1 24.9 -2.6 -4.4 0.670 0.656 none 70 11.2 0.164 31.3 15.2 44
1033 Osteoporosis 62 165.0 65.0 23.9 -1.4 -2.6 0.810 0.865 none 10 30.9 0.616 69.6 33.6 44
1088 Osteoporosis 61 162.2 57.3 21.8 -2.5 -4.0 0.679 0.701 none 51 14.0 0.145 24.0 26.2 43
1101 Osteoporosis 58 160.5 65.4 25.4 -2.6 -4.5 0.683 0.641 none 40 40.2 0.277 60.4 47.4 43
1104 Osteoporosis 75 142.5 62.5 30.8 -2.9 -3.8 0.629 0.726 none 85 17.5 0.222 32.1 26.4 45
1105 Osteoporosis 74 151.5 69.7 30.4 -2.5 -3.4 0.705 0.769 none 96 55.8 0.737 99.1 97.0 48
1127 Osteoporosis 74 168.0 68.7 24.3 -2.8 -2.6 0.662 0.866 none 52 39.0 0.484 51.1 67.7 41
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1137 Osteoporosis 79 160.0 66.2 25.9 -2.6 -2.6 0.688 0.883 none 10 27.3 0.259 37.6 69.0 44
1152 Osteoporosis 66 154.8 61.5 25.7 -0.6 -3.7 0.912 0.735 none 48 27.6 0.287 55.8 30.8 44
1185 Osteoporosis 76 159.0 70.0 27.7 -2.8 -2.3 0.646 0.905 none 40 13.2 0.269 28.4 55.7 41
1186 Osteoporosis 61 146.7 45.7 21.2 -2.0 -3.1 0.745 0.811 none 61 40.1 0.432 59.7 46.0 44
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Fifty micrograms of serum depleted of abundant proteins using the IgY14 Spin 
Column as described in Chapter 2, was labelled with CyDye and subject to 
separation by 2DE. Images of the gels were acquired using a Typhoon scanner 
and imported into Progenesis SameSpots. Following manual alignment, 
automatic spot detection, spot normalisation and quantitification were carried 
out. Twenty one spots were identified as being significantly differentially
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expressed across the 3 clinical cohorts (ANOVA p<0.05). These spots are 
magnified in Figure 3.7 above and are representative images of the twelve 
samples included in each of the three groups. Normal N=12, osteopenia N~12, 
osteoporosis N=12. The data for these spots are shown in Table 3.3.
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1001 Normal 55.4 160.0 80.0 31.2 -0.3 -0.9 1.068 0.939 N 92 18.9 0.218 34.1 21.1
1004 Normal 55.1 164.5 68.0 25.1 -0.3 -0.8 1.089 0.939 N 92 18.9 0.218 34.1 21.1
1016 Normal 53.7 177.1 66.3 21.1 -0.3 1.1 1.307 0.944 N 45 18.3 0.317 27.7 30.2
1020 Normal 56.5 159.0 69.6 27.5 -0.2 0.7 1.265 1.039 N 48 21.1 0.374 41.6 50.8
1021 Normal 49.6 150.0 61.4 27.3 -0.2 -0.6 1.109 0.951 N 81 26.4 0.346 67.7 43.2
1022 Normal 56.7 153.0 71.0 30.3 0.6 0.8 1.277 1.049 N 36 26.0 0.226 55.5 39.4
1034 Normal 67.7 157.3 80.8 32.7 -0.7 0.1 1.181 0.898 N 35 26.5 0.539 68.9 39.4
1036 Normal 62.9 165.5 85.2 31.1 0.2 1.2 1.321 1.028 N 22 19.9 0.192 37.6 34.2
1039 Normal 56.8 168.8 75.0 26.3 1.0 2.2 1.444 1.106 N 31 22.2 0.384 39.2 44.5
1040 Normal 55.6 163.0 66.2 24.9 0.2 0.5 1.201 1.057 N 86 34.8 0.468 94.4 35.8
1047 Normal 56.0 169.3 73.7 25.7 0.7 -0.4 1.131 1.083 N 35 16.7 0.147 30.2 24.6
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1055 Norm al 55.1 168.0 74.1 26.3 -0.4 2.1 1.430 0.930 N 59 23.0 0.304 52.7 47.8
1056 Norm al 68.9 151.7 61.1 26.6 -0.6 -0.8 1.087 0.910 N 52 22.1 0.398 41.7 36.8
1059 Normal 56.6 164.0 71.3 26.5 -0.3 -0.6 1.112 0.938 N 19 23.4 0.452 48.1 36.1
1066 Normal 56.9 163.3 62.9 62.9 0 -0.5 1.124 0.994 N 79 13.6 0.175 23.2 31.5
1072 Normal 53.3 164.3 83.2 30.8 0 0.3 1.212 0.999 N 11 22.5 0.333 31.3 37.5
1075 Normal 56.6 163.0 65.8 24.8 0.2 -0.7 1.089 1.018 N 96 37.2 0.502 64.4 31.6
1076 Normal 60.8 167.8 76.7 27.2 -0.6 -0.2 1.153 0.924 N 23 9.9 0.233 18.2 67.5
1081 Normal 48.5 172.0 75.3 25.5 0.5 0.7 1.260 1.044 N 44 10.9 0.12 20.9 27.5
1082 Normal 60.6 158.0 71.5 28.6 -0.7 0.2 1.200 0.898 N 73 13.7 0.226 29.4 30.2
1089 Normal 54.7 154.0 59.9 25.3 -0.6 -0.6 1.114 0.905 N 57 15.9 0.268 48.7 24.8
1090 Normal 58.4 167.5 71.5 25.5 -0.2 -0.5 1.117 1.020 N 43 15.4 0.150 48.9 26.4
1092 Normal 69.8 157.0 79.6 32.3 -0.9 -0.7 1.097 0.869 N 76 23.7 0.404 61.9 19.1
1094 Normal 60.2 158.0 79.2 31.7 1.4 1.3 1.335 1.152 N 19 32.7 0.271 66.5 35.3
1111 Normal 59.5 158.5 64.2 25.6 -0.6 -0.7 1.099 0.903 N 41 14.9 0.134 24.7 40.7
1112 Normal 51.8 164.8 80.6 29.7 -0.1 0.8 1.277 0.963 N 64 19.6 0.211 48.5 31.6
1118 Normal 53.8 166.5 91.6 33.0 2.0 0.2 1.210 1.235 N 53 24.3 0.586 59.1 38.4
1119 Normal 57.0 175.2 75.9 24.7 -0.1 1.4 1.343 0.986 N 40 22.8 0.443 46.2 28.9
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1122 Normal 51.2 166.5 55.9 20.2 -0.5 -0.7 1.099 0.941 N 57 13.7 0.361 28.6 33.9
1123 Normal 61.0 160.5 97.7 37.9 -0.4 -0.2 1.151 0.850 N 41 24.1 0.221 61.3 43.7
1129 Normal 51.3 157.3 61.6 24.9 1.3 1.4 0.801 0.811 N 38 13.5 0.245 31.0 40.2
1131 Norm al 50.1 164.5 92.8 34.3 -0.9 0.3 1.210 0.870 N 39 11.5 0.221 19.0 35.8
1132 Normal 50.4 161.4 70.3 27.0 -0.8 -1.0 1.063 0.907 N 58 15.7 0.221 26.2 29.7
1133 Normal 54.4 162.5 88.3 33.4 0.3 -0.5 1.119 1.021 N 28 12.9 0.272 45.3 29.0
1135 Normal 56.8 155.0 81.9 34.1 -0.6 -0.4 1.133 0.927 N 71 13.1 0.165 39.9 42.5
1136 Normal 55.6 170.5 77.4 26.6 -0.6 -0.7 1.091 0.908 N 25 31.6 0.401 66.5 59.4
1011 Osteopenia 53.5 178.0 78.4 24.7 -1.3 -0.7 1.097 0.841 N 22 22.1 0.280 42.5 48.1
1015 Osteopenia 54.3 154.0 57.1 24.1 -1.1 -2.0 0.938 0.850 N 32 26.8 0.380 54.1 31.1
1018 Osteopenia 56.5 165.0 66.0 24.2 -0.5 -2.4 0.894 0.924 N 72 23.0 0.109 34.2 40.8
1024 Osteopenia 75.5 172.0 94.0 31.8 -1.2 -1.1 1.051 0.859 N 19 16.9 0.182 32.2 47.7
1027 Osteopenia 60.5 153.0 66.0 28.2 -0.4 -1.3 1.020 0.937 N 18 20.8 0.305 29.9 50.9
1028 Osteopenia 65.0 159.0 83.3 32.9 -1.0 -1.3 1.020 0.854 N 65 29.6 0.392 47.1 19.5
1029 Osteopenia 56.5 168.5 87.0 30.6 -0.5 -1.4 1.004 0.942 N 24 24.9 0.306 50.9 31.1
1031 Osteopenia 55.8 171.3 95.8 32.6 0.8 -1.9 0.956 1.079 N 26 16.9 0.281 32.7 42.6
1035 Osteopenia 65.2 167.5 74.5 26.6 -1.1 -1.6 0.991 0.846 N 41 30.8 0.646 77.1 54.6
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1044 Osteopenia 61.8 161.0 68.0 26.2 -0.9 -1.5 1.081 0.923 N 40 53.0 0.445 106.9 30.4
1045 Osteopenia 55.6 167.0 66.7 23.9 -0.9 -2.2 0.918 0.899 N 35 20.7 0.377 52.7 38.8
1048 Osteopenia 53.0 165.0 76.0 27.9 -1.3 -0.5 1.120 0.847 N 50 21.5 0.397 46.5 41.9
1049 Osteopenia 76.0 166.0 79.7 28.9 -2.4 -0.3 1.148 0.687 N 13 30.4 0.226 63.5 37.3
1057 Osteopenia 51.7 158.5 64.1 25.5 -1.5 -0.6 1.107 0.798 N 15 25.4 0.427 81.8 28.3
1058 Osteopenia 55.5 165.0 74.7 27.4 -1.7 -0.4 1.129 0.774 N 56 22.2 0.186 39.3 18.5
1060 Osteopenia 52.4 161.2 80.9 31.1 -0.6 -1.8 0.949 0.910 N 30 22.6 0.348 43.4 46.7
1062 Osteopenia 71.9 162.0 64.1 24.4 -1.1 -1.6 0.977 0.852 N 24 29.3 0.652 76.8 29.2
1064 Osteopenia 58.7 156.0 62.8 25.8 -1.1 -1.3 1.019 0.844 N 58 28.6 0.324 49.4 40.0
1077 Osteopenia 57.5 168.5 76.7 27.0 -0.7 -1.3 1.011 0.898 N 77 35.2 0.581 71.7 32.4
1079 Osteopenia 62.3 163.0 85.9 32.3 -1.8 -1.8 0.960 0.764 N 81 11.2 0.274 25.6 41.6
1084 Osteopenia 56.3 159.0 71.6 28.3 -0.1 -1.2 1.038 0.983 N 59 22.1 0.085 38.0 28.7
1086 Osteopenia 55.4 147.8 49.3 22.6 -0.9 -1.7 0.980 0.874 N 62 15.1 0.167 24.2 26.4
1097 Osteopenia 55.3 158.0 62.5 25.0 -2.4 -2.3 0.890 0.704 N 69 34.0 0.522 79.6 36.2
1098 Osteopenia 58.9 156.0 71.3 29.3 -1.2 -1.4 1.013 0.855 N 68 64.0 0.768 163.4 31.6
1100 Osteopenia 58.1 173.0 65.1 21.8 -1.8 -2.2 0.915 0.789 N 42 25.9 0.393 62.6 38.7
1114 Osteopenia 66.4 157.5 70.2 28.3 -0.2 -1.2 1.035 0.975 N 93 32.2 0.634 71.0 30.4
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1116 Osteopenia 66.6 161.0 61.1 23.6 -0.7 -1.9 0.951 0.916 N 75 19.6 0.240 29.3 27.0
1121 Osteopenia 61.2 161.5 72.8 27.9 -1.5 -1.6 0.994 0.802 N 38 21.3 0.308 41.0 30.0
1124 Osteopenia 62.5 158.0 59.0 23.6 -1.9 -2.1 0.928 0.747 N 30 19.8 0.327 61.6 31.9
1125 Osteopenia 53.4 164.0 59.8 22.2 0.4 -1.4 0.996 1.052 N 68 18.0 0.313 32.5 29.4
1128 Osteopenia 63.4 160.0 69.2 27.0 -1.7 -1.4 1.014 0.798 N 65 24.4 0.334 48.5 24.5
1134 Osteopenia 50.6 158.0 60.2 24.1 -1.4 -1.4 1.007 0.809 N 18 22.7 0.171 44.2 22.0
1138 Osteopenia 58.1 159.0 89.9 35.6 0.9 -1.2 1.037 1.109 N <10 15.6 0.254 39.4 71.7
1003 Osteoporosis 56.0 164.5 68.0 25.1 -1.3 -2.4 0.894 0.824 N 27 35.1 0.351 78.8 25.0
1005 Osteoporosis 74.4 152.0 76.9 33.3 -1.6 -3.2 0.793 0.792 N 85 30.0 0.439 70.9 20.9
1006 Osteoporosis 60.9 148.5 53.3 24.2 -1.9 -3.1 0.812 0.756 N 12 23.9 0.473 36.4 25.0
1008 Osteoporosis 57.0 168.0 66.5 23.6 -1.0 -3.0 0.823 0.886 N 31 29.3 0.653 61.6 39.1
1009 Osteoporosis 71.2
159.0 64.4 25.5
-2.8 -4.2 0.698 0.664
T i l ,  L I  Severe 
biconcavity 39 27.3 0.657 86.1 42.4
1023 Osteoporosis 74.8 154.0 59.1 24.9 -2.6 -4.4 0.656 0.670 N 70 11.2 0.164 31.3 15.2
1025 Osteoporosis 72.4 150.0 58.0 25.8 -2.0 -4.2 0.673 0.756 N 52 38.2 0.524 96.6 29.8
1033 Osteoporosis 62.0 165.0 65.0 23.9 -1.4 -2.6 0.865 0.810 N 10 30.9 0.616 69.6 33.6
1037 Osteoporosis 55.7 163.5 66.9 25.0 -0.8 -2.6 0.873 0.910 N 36 31.1 0.227 54 30.3
1042 Osteoporosis 79.3 157.0 68.0 27.6 -3.2 -1.8 0.966 0.601 N 26 28.0 0.422 66.6 38.6
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1046 Osteoporosis 52.6 162.8 71.6 27.0 -2.0 -2.5 0.880 0.736 N 63 42.0 0.665 75.5 32.9
1054 Osteoporosis 58.2 149.5 62.2 27.8 -2.7 -3.8 0.726 0.682 N 30 18.1 0.181 38.3 54.2
1067 Osteoporosis 58.0
162.0 62.8 23.9
-2.7 -4.5 0.633 0.656
T l l  Moderate 
wedge 43 25.5 0.248 55.3 27.4
1070 Osteoporosis 61.0 161.5 60.5 23.2 -0.7 -2.9 0.837 0.919 N 67 27.8 0.744 95.5 23.9
1074 Osteoporosis 66.0 148.5 67.5 30.6 -2.5 -4.9 0.580 0.677 N 73 27.9 0.520 50.5 38.4
1087 Osteoporosis 72.6 152.0 51.8 22.4 -2.4 -2.8 0.839 0.679 N 93 30.2 0.295 52.8 27.8
1088 Osteoporosis 61.1 162.2 57.3 21.8 -2.5 -4.0 0.701 0.679 N 51 14.0 0.145 24.0 26.2
1095 Osteoporosis 55.9 160.0 61.9 24.2 -0.9 -2.8 0.840 0.897 N 44 36.3 0.567 60.8 38.6
1099 Osteoporosis 58.8 167.5 70.8 25.2 -1.6 -3.3 0.771 0.811 N 60 21.9 0.271 37.7 25.5
1101 Osteoporosis 58.1 160.5 65.4 25.4 -2.6 -4.5 0.641 0.683 N 40 40.2 0.277 60.4 47.4
1102 Osteoporosis 58.5 154.7 50.5 21.1 -2.6 -0.4 1.123 0.693 N 74 78.3 0.686 85.5 86.5
1106 Osteoporosis 55.8 170.0 61.5 21.3 -0.7 -3.2 0.819 0.897 N 35 31.1 0.429 62.1 36.6
1107 Osteoporosis 58.7
163.0 61.6 23.2
-1.6 -3.6 0.919 0.881
L I  Moderate 
biconcavi ty 41 21.1 0.198 28.6 28.0
1113 Osteoporosis 59.9 156.0 58.6 24.1 -1.4 -2.8 0.839 0.811 N 40 28.8 0.22 40.9 38.5
1117 Osteoporosis 72.6
153.5 68.8 29.2
-2.9 0.1 1.182 0.631
T9, T10 Moderate 
wedge 43 98.9 1.03 129.7 121.7
1126 Osteoporosis 53.6 164.0 55.5 20.6 -1.6 -3.2 0.801 0.811 N 43 36.3 0.337 69.0 24.3
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1127 Osteoporosis 74.4 168.0 68.7 24.3 -2.8 -2.6 0.866 0.662 N 52 39.0 0.484 51.1 67.7
1130 Osteoporosis 56.3 162.0 47.6 18.1 -2.2 -3.5 0.765 0.718 N 12 27.3 0.77 57.6 35.8
1137 Osteoporosis 79.0 160.0 66.2 25.9 -2.6 -2.6 0.883 0.688 N 10 27.3 0.259 37.6 69.0
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A p p e n d ix  5: R a y B io  h u m a n  b io tin  la b e l-b a se d  a n tib o d y
a r r a y  n a m es a n d  lo ca tio n s  ta b le
> Htg 32 btfKAcin 62 C814 82 ua sw jt- i
6Cton» 33 bita-Ottmail 63 CD27 'THFPSF7 »3 CXCIK
AdnviA 34 fc&NGF H CMOITfflOB »4 0«
Attnwi 35 IK 65 CDMLigndi'TNFSfl 95 QAN
ActMiC 34 tic /icA -iitita ti » cw o im sR » DANCE
Acti¥inRlAiALK*2 3? HM 67 CWOUjmditHFSFStDIH 97 worniFiisFte
AitiwiRiaiAlW 31 U N <8 CDK3 96 Dtosim
AtUwiRIIM 39 WP-3b/GOF-IO 69 C*rt»iu$1 99 ttk-1
AeHAiMA «1 HIM 70 OMim 100 M-3
AdpowciVAajM 41 MP4 71 CtardWJbl 101 0 *4
AjRP 42 MM 72 CtwrdlMJMl 102 m n » m n
ALCAM 43 MM 73 Csl 103 0R6/THFMF21
An^tgm 44 MM 74 ac 104 M
Anp0|)0Ktm-1 43 BMP-15 75 CKTF 105 EW-A2
A>0«pMv3 44 MW4AIAU4 75 CHTFR riFtu
Cospbdon Fitter VII Ttasu«
106 EDAR
An 47 ■nWBfALM 7T Fug 107 tow
AnpopciafoBvl 41 m 73 CMI1 10« EtF
19 An^op«tivB«2 49 BTC 7» Cnplo-1 ID« EGFRI&bll
20 Angopoi«inflwFKt«r » CMN«|M-1ICT-1 BO CHH4 110 ■ /' VE(f)M(1
21 Anvomtn 51 eaillHCM.HCC-1 61 Ct«* 111 HUM
22 AN 92 (XUtiVK 82 CTACK/CCU7 112 HA-71
23 U|Anvhlr«9Uln| S3 ecu S3 CTtf ICCH2 113 Mean
24 APRIL 54 ocn 64 CTU4«DI52 1M MgtfhftDIOS
25 Aitmr 55 CCM 65 CV-)'CrKS»rim-2 115 EixtMan
28 M se ce*4 U cxa u itu K 1« BHAiE
27 87-1 /:dm 57 CCK O' CKCLK 117 Cotuln/cail
28 B w rm iN ntrac 51 can 8i CXCM/L-HA tie Eotol&*2/W H
2» BCNAiTMFR$f17 5» CCi? 99 CXCD2fL4U 110 £««»|-31CCUS
30 KM 60 Odd 90 CXCD3 120 3* 10*1
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A p p e n d ix  5 co n tin u ed : R a y B io  h u m a n  b io t in  la b e l-b a se d
a n tib o d y  a r r a y  n a m es a n d  lo c a t io n s  ta b le
122 BbB3 152 FGM
121 EibB4 153 FUG
124 Bytinpoiahi 15) IMUgad
125 E-Madin 1S5 FiWMin
126 BxUMh 156 FofenMbl
127 FADE) 157 facrtna
121 FAM3I 151 FKzM-1
129 Fu/TNFRSFS 159 FfizzM-3
130 FttUfpnd teg FiizM4
131 FGF Basic 151 Ffahd-5
132 FGF4P 162 ftOtH
133 FOfRJ 163 FitnWJ
134 FGFR4 164 9MU
135 FOFRJ I65 GUM/WIKMiRP
136 FCF4 166 MBH/HBHMI
137 FSF-5 IP SCF-I/CKCL6
13» MM 1« SC*
139 F8F-7IKSF 169 4CJFI1C0H4
140 KH 179 on
141 FAM 171 SCF1
142 FSF-ttf KGf-2 17! am
143 FGf-11 173 GCB
144 HF-tt 174 am
146 FGF-13II 175 com
14ft FGF-tt m ttf-B
147 FGF-17 ITT awF
146 FGF-11 171
149 FGF-19 179
150 FGF-a 160 R4M
112 omi t vii 212 ICMH|CD50)
193 THF3F19 213 ICAM-5
164 amgn 214 IRUMBftMlRI
185 EU1 215 IFm**aita(alt2
1K M2 2M IFN*at
187 SMI 217 IFH^inraa
188 GUS 211 iFU-gmltl
ISP StypcanS 219 ISf 1
190 2» ISFIF-2
191 GM4SF 221 IG^BP-3
192 222 IS 4
193 OnrijmeA 223 BFBP-6
m ERBftJR 224 IGFBP-fpl i1 KSF6P-7
195 no 225 K5H
196 «0« 226 KF48K
197 &o«1hHn»»n«(6H| 227 ISFJI
IM QmAHonMMl (fit*) 226 BHR
19» H0-SOF 22* IL-Hphj
200 HCWfC«,* 230 HbaU
201 HCI/CIAWV1 ¡31 IL-1 F5 f FLIMa
202 Hapatsoan 232 l-1F*/fll1 apaton
203 H«ra»*n' HOF f OGF1 Ntu*fli4ln 233 1-1F7'Fill »tt
204 HOF 234 HF8IBL1«a
206 HO* 235 IL-1 »1 IL-1 HI
206 Kftfefeh» 2» R.-1F10/H.-W2
207 HRtb*Q1 237 IL-1 R3.( IL-1 RAcF
20« HVBKTWRSFW 2» IL-1M/ST2
2K UW 230 IL-1 R6/IL-1 fcp2
210 KN6-1 240 HR9
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A p p e n d ix  5 co n tin u ed : R a y B io  h u m a n  b io tin  la b e l-b a se d
a n tib o d y  a r r a y  n a m es a n d  lo c a tio n s  ta b le
242 IH r* 272 IMS 302 IL-2M 132 LwfttKftVIXCU
2*3 IW jM 213 B.-15R**» 303 IL-2» 133 Lyirohotgiiinbala/TNFJfJ
244 «.•urn 274 H.-1I 3H 1-31 114 LynphmxInbaliXniFSSH
245 11-2 275 IL-17 3« 0.-31 RA 135 HU-1
24« IL-2«alplia 276 11-171 3M HMnA 136 MCP-1
247 IL-ZR ta t ,0)122 277 11-171« 307 H*inB 137 HCf-2
24 B 1.-2« (pnm 27» IM7C 301 knJn na HC?-!
249 IL-3 276 IL-17« 3GS kminR lit MCP-4ICCL13
250 IL-3Kdpha 220 1.-17I 310 InnJpfaflDE 3M IK »
251 IW »1 1-ffF 311 IP-10 141 IK4TR
252 14R 2S2 MTU 312 i-r«crcxcLit 142 woe
253 IL-5 243 M7HC 311 Kirwoflaiiiii'ldnmoflei M3 ■FG-EB
254 lUSRalph* TU IL-17RD 314 KianH-1 144 ■n v
255 IW 215 MIBPl 316 Kian«h2 145 IIIF
256 1 « 216 IL-U«4taJL>1«5 316 l i t 146 IK
251 IW 247 IL-IBKMaUen. 317 U«tTSF**( bq1 147 MP-la
259 IL-? R' *- "h. 241 IL-19 316 LV 141 HMk
259 in as IL-20 31« LECT2 149 MP-td
200 IW ¡so U 9 l« a 320 la*»-« 156 UP 2
261 IL-10 2S1 uonbau 321 lapn« 151 W?0#ha
M2 11-1«« alpha 292 11-21 322 L*m>(C 152 V -IbM
2(3 IL-1Mba)a 2W IL-21K 323 LFA-1*te 153 M M
»4 M l 2M IL-iJ 324 ur »4 mp-2
265 IL-12p40 296 IL-22* 32f Ltf Rafpta 155 MP-3
2« 11-129» m 1-22« 326 USHT'TW»14 154 MP-7
267 IL-12R6anl 297 IL-2) 327 Upoc^ h-1 157 IHP4
261 11-12« bate! 296 U l 326 LKP-1 151 H IM
269 IU13 29« IL-24 326 LAN 159 ■TP-10
270 IL-1JR. -B l 300 IL-K 330 l^ dtOnlCOCU 366 M P.1l/anm lyM
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A p p e n d ix  5 c o n tin u ed : R a y B io  h u m a n  b io t in  la b e l-b a se d
a n tib o d y  a r r a y  n a m es a n d  lo c a tio n s  ta b le
JGS VO H2 DM o (U «2 TSMai 412 TUL/nvti
K ■Ml 383 *3 SCf 4» 134« S 4» nuinMiDMinnffttt
W ■MS W 0W(«nJllW» «24 m o w 4)4 KFtarillMM 444 nuftnioHjnmm
i£ MMURMIff » m  ctii 43 41! TtfMiW 4« wm9,nnsnx
S ■M * (MWF «1 »»•1 4» TtTMal» 4» tmim/wwh»
» Wt BT PWF»Hh] « lf»4 41? r«MmM 44" mua
a JB rWRM 431 IFIV4 451 48 TW1
» V tfW BJ fMMA 12! <gm in n<miapnk\ng\ 4» M0HIMSf1l
m fca «0 IN a in 4« HBtfttptndM 4« TIM
j*t up^ nm «1 non Cl tyc4CDH 41 Thw*«pnM 461 rnp
nj WCMMn «2 FWC e 412 IfttafeapnM 462 1Y*MiTI«fl2
m HIM 40i TOM a nn 41) ThawaaMa 4B TWUP'W»9ftt
JT4 itwm 4)1 HCMMUM a Ml 4U IM 4t4 HMM
ire «t* « PwnanJTH.il « M4 44! Tiaj 1% M
IK Man 4» hnaftai a MS 4H IBM 416 ten
Ji7 air miCKU *5.T Mr 4T TOM 4ff Van
m MMl «a rw a haM 4U TIN «e ucm^eimb





Ml M 420 TLiA/nnn> HO m
fnyatMt 141 SMtM)A^(SHill4ra4 «1 run »1 rtffitnw*!
E MlatWHIftQta
■KlfcoUHKttaM
411 Midi W MR 472 nu SC IBD
& 413 Manti U! tyra« 4,') TUI 503 awnTOM
N IH 414 UK H4 uanrnrm 4?4 1U4 504 IBK
H we 41S MKilNflttflU <4! fjTC 4» WSM'TawajA-1 5(6 IBM
s KM 416 wn 4* ihiwh 4» h k 806 rtBilNWll
KM 417 nihn *4J TB'ttUS 477 mm- 50?
1« (Ml* 411 niimra W im 471 nu« 6» WMICCM
HE (hail 419 mot <41 43 mmnniiFtt VS «DM
» M 4» MMUI « rcuai 416 wmnrara SID I I
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i B 7 1
] 0 0 4 0
□  IL1  ra  
I IL 2 7
□  L E C T 2  
I L y m p h o to x in b e ta R
□  M IR Ia
□  T N F  b e ta
O s te o p e n ia O s t e o p o r o s is
D X A
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis (N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. Graphs show pixel density normalised to a positive control on the array. Error bars show standard deviation. Experiment performed in triplicate (ANOVA p<0.0001). The Gene Ontology analysis using the web-based bioinformatic tool DAVID http: //da v id. abcc. nc i fcri. gov /home. i sp revealed that 8 proteins have a role in T-cell mediated immunity.
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A p p e n d ix  7: D iffe r e n tia lly  e x p r esse d  p r o te in s  id e n tif ie d  b y  a n tib o d y  a rr a y  a n a ly s is







■ i o -
B i  C D 4 0  
C 3  C X O R 1□  I C A M 2  
^  ll_ 1  r a□  I L 3 R a l p h a  
L_J TTsIF b e t a
O s t e o p e n i a O s t e o p o r o s i s
D X A
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis (N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. Graphs show pixel density normalised to a positive control on the array. Error bars show standard 
deviation. Experiment performed in triplicate (ANOVA p<0.000l). The Gene Ontology analysis using the web-based bioinformatic tool DAVID http://david.abcc.ncifcrf.gov/home.isp revealed that 6 proteins have a role in B-cell and antibody mediated immunity.
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A p p e n d ix  8: D iffe r e n tia lly  ex p r esse d  p r o te in s  id e n tif ie d  b y  a n tib o d y  a rr a y  a n a ly s is
w ith  ro le s  in  m a cr o p h a g e - m ed ia ted  im m u n ity
■
I EISIRAGE. 
3 ll_1 O U 3  IL1 9  I  M C S F  
□□ IVIIR 1 TTsIF-
O s t e o p e n i a O s t e o p o r o s i s
D X A
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis (N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. Graphs show pixel density normalised to a positive control on the array. Error bars show standard deviation. Experiment performed in triplicate (ANOVA p<0.0001). The Gene Ontology analysis using the web-based bioinformatic tool DAVID http://david.abcc.ncifcrf.iiov/home.isp revealed that 6 proteins have a role in B-cell and 
antibody mediated immunity.
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■ C C R 4□  C X C R 2
□  C .C P 2  
B  I L 1 7
□  I L 3 R a l p h aO  M C S F
□  M IF * 1 a
O s t e o p e n i a O s t e o p o r o s i s
D X A
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis (N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to 
assay 507 proteins. Graphs show pixel density normalised to a positive control on the array. Error bars show standard deviation. Experiment performed in triplicate (ANOVA p<0.0001). The Gene Ontology analysis using the web-based
bioinformatic tool DAVID http://david.abcc.ncifcrr.gov/home.isp revealed that 7 proteins have a role in granulocyte mediated immunity.
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A p p e n d ix  10: A d d it io n a l d iffe r e n tia lly  ex p r esse d  p r o te in s  id e n tif ie d  b y  a n tib o d y  a r r a y




O s t e o p e n i a
D X A
i
l A g R P
]  A n g io p o ie t in lik e l
□  A x l 
I  O S k i n e□  C D 2 7  
3 C o a g u l a t i o n f a c t o r  I C r y p t i c
cm c v 2
]  D A N C E
I E D A R
O s t e o p o r o s i s
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis (N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. Graphs show pixel density normalised to a positive control on the array. Error bars show standard 
deviation. Experiment performed in triplicate (ANOVA pO.OOOl).
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A p p e n d ix  10 co n tin u ed : A d d it io n a l d iffe r e n tia lly  e x p r esse d  p r o te in s  id e n tif ie d  b y
a n tib o d y  a rra y  a n a ly sis
H  E G V E G F
LZJ
I _J E o t a x i n  B B  E o t a x i n 2I I  E o t a x i n 3  » 1  F a s□  F G F 1  1 IH3 F G F 1  2  
CZD F G F 1  9  MM F C 3 F 2 0
O s t e o p e  n i a O s t e o p o r o s i s
D X A
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis (N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to 
assay 507 proteins. Graphs show pixel density normalised to a positive control on the array. Error bars show standard deviation. Experiment performed in triplicate (ANOVA p<0.000l).
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D X A
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis (N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. Graphs show pixel density normalised to a positive control on the array. Error bars show standard 
deviation. Experiment performed in triplicate (ANOVA p<0.0001).
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D X A
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show pixel density normalised to a positive control on the array. Error bars show standard deviation. Experiment performed in 
triplicate (ANOVA p<0.000l).
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D X A
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show pixel density normalised to a positive control on the array. Error bars show standard deviation. Experiment performed in 
triplicate (ANOVA p<0.000l).
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Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show pixel density normalised to a positive control on the array. Error bars show standard deviation. Experiment performed in 
triplicate (ANOVA p<0.0001).
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D X A
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show pixel density normalised to a positive control on the array. Error bars show standard deviation. Experiment performed in 
triplicate (ANOVA p<0.000l).
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D X A
Whole, undepleted serum was taken from postmenopausal women classified as normal (N=36), osteopenia (N=33) and osteoporosis 
(N=32) by DXA, an equal volume of each sample pooled and subject to analysis by RayBio antibody array to assay 507 proteins. 
Graphs show pixel density normalised to a positive control on the array. Error bars show standard deviation. Experiment performed in 
triplicate (ANOVA p<0.0001).
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